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Amyotrophic lateral sclerosis (ALS) is an incurable lethal disease that affects motor 
neurons and its heterogeneity is reflected in various mutations among the sporadic ALS 
(sALS) and familial ALS (fALS) disease types. Superoxide dismutase-1 (SOD1), as a 
cell guardian, is an essential protein needed for the antioxidative cellular homeostasis but 
is many times a silent traitor in both types of ALS. The exact mechanisms by which SOD1 
mutations contribute to ALS are still not fully understood, but structural investigations 
have interestingly revealed that the protein is a homodimer. It is suggested that the most 
severe mutations disrupt the dimer interface, causing dissociation, misfolding, and protein 
aggregation, which are the main sources of toxicity. Additionally, the aggregation 
processes trigger many other mechanisms, and correlation between the mutants’ 
structural damage and aggregation pathways remains a puzzle. 
In this thesis, in silico docking studies are done to design multifunctional ligands, whose 
biphenyl core structures mitigate the aggregation of a severe dimer interface mutant. A 
modular synthetic approach is developed, and different ligands are synthesized to anchor 
the protein dimer while preventing protein dissociation. Protein-ligand interactions, 
affinity, and their behaviour are then investigated via microscale thermophoresis, 
isothermal calorimetry, and aggregation assays. It is shown that synthesized ligands with 
aromatic substituents have a higher binding affinity toward the protein, and that they 
could reduce the aggregation of the SOD1 mutant. Additionally, the principle that the 
ligands can mediate a transfer of a fluorescent dye onto a target amino acid shows their 
multifunctionality. The design of affinity-based fluorogenic probes is envisaged as an 
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Communication between nerve cells in the human brain and muscle nerves is a crucial 
step needed for voluntary muscle movements. Despite the high number of neurons and 
their continuous impressive performance and signalling in the brain, damage of motor 
neurons can be fatal very quickly. These fatalities are seen in many neurodegenerative 
diseases, and among them, the deterioration and loss of upper and lower motor neurons 
is still the main characteristic of Amyotrophic lateral sclerosis (ALS).[1,2] When the motor 
neurons stop sending a signal, the muscles are weakened, which leads to paralysis. And, 
when the skeletal muscles of the diaphragm are affected, the outcome becomes mortal 
very fast. Now, there are only two approved drugs for the treatment of ALS, and while 
the cause remains unknown, there is no cure for this disease. It was initially thought that 
ALS is an only sporadic disease (sALS), however, it is shown that some people inherited 
the disease from their parents, also known as familial ALS (fALS).[3] The research 
identified different processes in the neurons by studying the modified genes from those 
patients, that might cause the disease. It is not clear which processes are the result of the 
disease and which could be causing it. Also, different epidemiology and heterogeneity 
involved do not go hand in hand with fast revelation in curing the diseases.[4] However, 
since that time, many breakthroughs in different areas of science have also contributed to 
the knowledge of the ALS disease.  
The most impact on ALS development was the discovery of the first gene sod1, related 
to this pathogenic disease. Since then, more than 50 years ago, different genes were 
discovered.[5] However, research has shown that SOD1 is still the second most present 
protein involved in many processes related to the ALS as well as other neurodegenerative 
1 Introduction 
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diseases. Moreover, up until now, there are no treatments for SOD1-ALS related disease. 
With the resolution of the crystal structure of the SOD1 protein, research has focused on 
the structural investigation of the protein and its mutations that occur in fALS and sALS 
patients. Multiple mechanisms were indicated into the toxicity of the SOD1, and as a 
protein involved in antioxidative regulation, initially, it was assumed that the main 
problem is a functional loss of the protein. However, now it is generally accepted that the 
main pathogenicity of the SOD1-mutant proteins is rather causing toxic gain of function, 
either in single or dependent processes, maturation, misfolding, stability and 
aggregation.[6] Lack of stability has been discussed as a reason for SOD1 malfunction, 
and so far, groups proposed that it is possible to stabilize the protein itself. Our approach 
toward potential therapeutically interesting targets is presented in the following chapters, 
firstly, through an in silico design approach to structurally understand the SOD1 protein 
and to identify potential sites for protein stabilization by small-molecule binding, 
secondly, through a synthesis of potential lead structures and lead structure libraries, and 
thirdly through testing of synthesized ligands for their affinity to the protein and their 





 STATE OF THE ART 
 Amyotrophic Lateral Sclerosis 
2.1.1 Disease patterns and epidemiology 
In the early 19th century neurologist Jean-Martin Charcot reported to his medical 
colleagues, after reassuring his patient of recovery, “…we can and must speak amongst 
ourselves in total frankness. The prognosis is deplorable; alas, he is a lost soul…”[7] This 
followed from their earlier studies, in which life of other ALS patients from first 
indications until the end was not more than three years. Furthermore, they found that 
lesions in different parts of the spinal cord, lateral and frontal horn, have distinct 
manifestation, chronic progressive paralysis, muscle contractures and spasticity without 
atrophy, whereas in the latter one paralysis with muscle atrophy.[7] Until today, 
fundamental description in the clinical picture of the amyotrophic lateral sclerosis (ALS), 
also known as Charcot, Lou Gehrig’s or motor neuron disease (MND) did not change 
much.[7][8][9] However, crucial patterns and characteristics evolved throughout the years, 
like weakness, muscle wasting, fasciculations, weakness in anti-gravity muscle or 
spasticity, which could be attributed to the upper motor neurons.[1] Even though that only 
approximately 27-28% of disease onsets show bulbar symptoms, which combine 
difficulty of speaking and swallowing (dysarthria and dysphagia), while 58-80% is 
usually manifested in the limb-onset, and the remaining 8-23% is a combined onset, the 
effect on bulbar functions usually have more detrimental consequences.[2,7,9,10] 
Additionally, patients with bulbar onset are usually diagnosed earlier than the others. 
However, because of nonspecific early symptoms, delay in ALS diagnosis still ranges 
2 State of the art 
4 
from 9 to 24 months.[10] Usual disease onset is between 51 and 66 years, and only 10% of 
diagnosed patients live 10 years or longer, while the majority has only 24 - 50 months to 
live after diagnosis.[10] A yearly incidence of 0.6 to 3.8 per 100 000 individuals worldwide 
is reported; however only in Europe, the initial range rate is two times higher. Even 
though the incidence and prevalence numbers vary significantly between the continents 
and countries, mostly because there are not enough real population studies outside of  
Europe, the number of diagnosed patients is increasing, and risks emerge also from 
different environmental factors that are still poorly understood.[1,10,11] ALS disease is 
divided into two major groups, sporadic ALS (sALS) that covers 90% of all the cases, 
and familial ALS (fALS) with 10% of all cases. While sALS occurs with no familial 
history, in fALS at least one additional family member has inherited disease either in an 
autosomal dominant or recessive manner.[3,12][13] So far, clinically it is not possible to 
distinguish between these two types; however, advanced research in molecular genetics, 
ensures a better understanding of familial ALS, which on its own provides also a little 
more insight into cases with sALS.[14] Today, with more than 50 genes classified as 
potentially causative, 40-55% of all fALS cases are attributed to four genes and their 
pathogen variants sod1, c9orf72, fus and tardbp.[4,12,14] Additionally, as shown in Figure 
2.1, meta-analysis among diverse studies shows that in European population almost 34% 
of fALS cases are linked to c9orf72 gene, 3-4% to fus and tardbp, respectively, and 15% 
to sod1, while the rest is still unknown. However, the numbers for the two most 
represented genes linked to fALS are quite different for the Asian population, 30% are 
attributed to the sod1 gene, and only 2.3% to the c9orf72 gene.[4] The anatomy of sALS 
remains unknown, as only 11% can be attributed to the most common genes classified in 
fALS. Therefore the difference across populations is negligible.[4,12]  
Up to date research was conducted toward understanding and correlation of genetic risks 
for sALS, yet a huge part remains undiscovered, beside complexity of the disease itself, 
lack in more advanced technologies and some environmental factors also play a role that 
is not easily correlated.[12,15]  
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Figure 2.1 Distribution of fALS with most common genetic variation in European (left) 
and Asian (right) population. Adapted from [12], Copyright © 2019 with permission from 
Mejzini, Flynn, Pitout, Fletcher, Wilton and Akkari. 
2.1.2 Pathophysiology and neuro mechanisms 
The complexity of all pathophysiological mechanisms, genetic findings and symptoms 
related to the ALS disease is vast, even so, that is preferably named, neurodegenerative 
syndrome, rather than disease.[16] Generally, genetic mutations are associated into mostly 
three pathophysiological processes: disturbance in RNA mechanisms, protein 
degradation pathways and impaired axonal function and transport.[12,17] Yet, these are just 
part of the mechanisms proposed to influence ALS. How exactly they are correlated, and 
what is more causative, remains an unsolved puzzle. Here, some mechanisms are 
described, and shown in Figure 2.2.[18] A gain of toxic RNA species, intracellular 
aggregates and nuclear transport defect is usually caused by mutations and depletions of 
c9orf72, tardbp and fus genes, which alter transcription and translation processes.[12,13,16] 
Williamson and Cleveland[19] showed axonal impaired function of SOD1 mutants, early, 
before the onset of symptoms. Now it is known that accumulation of neurofilaments, as 
well as loss or gain of function in glial cells, disrupt cytoskeletal architecture and impair 
axonal function.[12,17] Mutations in SOD1 and other genes have interference with protein 
degradation pathways, and destruction of proteostasis, mostly due to aggregate 
accumulation and disruption of the protein clearance mechanisms.[11,12,18] The processes 
related to SOD1 will be discussed further in Section 2.2. Glutamate excitotoxicity is a 
pathological response onto the impaired function of EEAT2 receptor and reduced 
clearance of glutamate from the synaptic cleft, which leads to an increased damage of 
AMPA and NMDA glutamate receptors and induces neurodegeneration through an 
increased flow of Ca2+.[12,18] This process triggers mitochondrial dysfunction and 
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oxidative stress, by the accumulation of Ca2+ in mitochondria, which results in generating 
neuronal toxic hydroxyl and free radicals, yet the effects of SOD1 mutants on 
mitochondrial dysfunction seem to result from misfolded proteins rather than impaired 
enzymatic activity.[18,20] Other mechanisms such as oligodendrocyte dysfunction and 
neuroinflammation have also been implicated in ALS pathophysiology, contributing 
axonal impairment, and neuronal loss by microglia and astrocytes inflammatory 
response.[12,17,18,21] 
 
Figure 2.2 Some pathophysiological mechanisms involved in Amyotrophic Lateral 
Sclerosis neurodegeneration. Adapted from[18], Copyright © 2016, Springer Nature 
2.1.3 Therapeutic approaches and ALS treatments 
Currently, there are only two drugs, which are approved as a treatment for ALS, and only 
Riluzole[22] reached the market worldwide (see Scheme 2.1). It was approved in 1995 as 
a first drug for ALS, and, in the first trial, showed improvement of limb function in 
comparison with the placebo group; however, it only prolongs patients survival about 
three months.[12,22,23] Riluzole influences glutamate excitotoxicity pathways. Nowadays, 
the theory of blocking mechanisms on the glutamate receptors[24] is not accepted anymore, 
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yet it is proposed that the effect is mostly obtained by stimulating glutamate uptake from 
the synapse.[25,26] Edaravone[27], is a drug, which has been approved as a free radical 
scavenger and antioxidative agent in 2017 for the US and Japan market.[12,28] One of the 
reasons, why the drug still did not reach EU market is due to the failure in a first clinical 
phase 3 trial. Two additional trials showed impact in treated patients compared to the 
placebo control. However, the trials were completed only on Japanese population, which, 
epidemiologically, differs from European countries.[26] In the 25 years from first drug 
approval more than sixty compounds have been researched, and mostly tested for anti-
inflammatory, anti-oxidative or neuroprotective treatment, however, the most common 
failure of efficiency was in human clinical trials, which is another indication for the 
complexity of the disease and its heterogeneity.[26] Masitinib is potentially next in line to 
be approved as a drug for ALS treatment. It is known as a selective tyrosine kinase 
inhibitor, and, in preclinical studies showed an impact on neuroinflammation 
mechanisms, as well as prolonged survival in mutated sod1 mice, even if delivered after 
the disease onset.[26] The second larger phase 3 clinical trial for Masitinib was approved 
and started this year (2020) with an estimated duration of two years.[29] 
 
Scheme 2.1 Drugs approved for treatment in ALS, Riluzole (left), Edaravone (centre) and 
drug in phase 3 of clinical trials Masitinib (right). 
New approaches for ALS treatment evolved particularly in RNA therapeutics, with 
antisense oligonucleotide drugs, in which the first drug for the treatment of ALS is already 
in clinical trials with estimated primary results in summer 2021.[12,30] So far, there are still 
many pathophysiological mechanisms unexplored in terms of treatments of ALS, and 
because of the heterogeneity and complexity involved, it might be required to act 
simultaneously on different mechanisms and pathways to achieve notable results. 
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 Superoxide Dismutase-1 (SOD1) 
2.2.1 Structure and function 
In the late 1960s McCord and Fridovich discovered the enzyme, superoxide dismutase. 
The main breakthrough was the attribution of the function to the ubiquitous blue-green 
copper protein (erythrocuprein), which, until that time, was assumed to be only a copper 
storage without any enzymatic function.[31,32] By studying the reduction of cytochrome c 
with the enzyme xanthine oxidase (XO), they confirmed that inhibition of the reaction is 
not occurring via the binding site of XO as originally thought, rather a superoxide radical 
is the product of the xanthine oxidase and inhibition occurs in a competing reaction 
between the SOD enzyme and cytochrome c.[31,33] They concluded that the enzyme SOD 
catalyses the dismutation of superoxide to hydrogen peroxide and oxygen.[31] 
Furthermore, the catalytic cycle, in which SOD catalyses the disproportionation of two 
superoxide molecules, was later called “ping-pong mechanism”, Scheme 2.2.[34,35] 
 
Scheme 2.2 Disproportionation of superoxide anion in SOD1 catalysed mechanism 
The importance of the SOD enzyme was recognised very quickly as it could not be found 
in anaerobic organisms, yet in almost all biological aerobic organisms, to serve as a 
bodyguard from reactive oxygen species (ROS) of the oxygen metabolism.[35–37,37] With 
a 104 higher rate than spontaneous dismutation, the SOD1 catalysed reaction is also 
regarded as diffusion-controlled (2 x 109 M-1s-1).[38] SOD enzymes are divided in different 
families according to their metals in the active sites. In humans, there are three different 
forms of SOD: SOD2 (Mn-SOD) is localised in the mitochondria and contains Mn as a 
cofactor in the active site. The Cu and Zn family is subdivided in two forms: EC-SOD is 
found in the extracellular space, and the Cu,Zn-SOD1 protein is located intracellular e.g. 
the cytoplasm and nucleus.[39,40,40] Today, SOD1 is known as a 32 kDa homodimeric 
protein, which consists of 153 amino acids per monomer. From the early crystallographic 
structures of the bovine, later human SOD1 it was found that each monomer unit contains 
an eight-stranded anti-parallel ß-barrel forming the hydrophobic core.[34,41] (see Figure 
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2.3) In the active centre of each monomer, copper and zinc coordinating sites are linked 
by His63 in the oxidized Cu(II) state, Figure 2.3 (bottom). They are balanced among two 
loops, which are both contributing to the active site, the electrostatic loop VII (amino 
acids 122-143) shown in orange-red and the zinc loop IV (amino acids 49-84) in blue. 
Furthermore, the zinc-loop has also a structural role by which the ß-barrel sheet is 
stabilized via a (Cys57-Cys146) disulphide bond, shown in yellow, Figure 2.3 (top). In 
the catalytic process, both loops are involved by forming the active site and enhancing 
the interaction with a substrate via electrostatic forces.  
The mechanism of the reaction starts by water displacement at copper (II) when the 
superoxide enters the cavity, and binds to a copper, stabilized by Arg143. Copper (II) is 
then reduced to copper (I), and oxygen is released simultaneously. Consequently, His63 
is protonated and binds the second superoxide which also forms hydrogen bonds to 
Arg143, due to bond rearrangements and a proton transfer from the water in the active 
site, copper (I) is oxidised and hydrogen peroxide is released, Scheme 2.3.[42,43,43] 
 
Scheme 2.3 SOD1 mechanism cycle in the active site, taken from.[43]  
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Figure 2.3 Human SOD1 homodimer and its active site, top and bottom. Zinc and loop IV 
(blue), Cu and electrostatic loop VII (orange), disulphide bridge between strand 8 of the ß-
barrel and loop IV (yellow). PDB code 2V0A, model visualized via UCSF Chimera[44]. 
The fully metallated SOD1 protein with an intact intra-molecular disulphide bond is a 
very stable homodimer with a melting temperature ranging from 77 °C up to 100 °C, 
which is also likely to be buffer influenced.[34,45,46]. 
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2.2.2 SOD1 in familial ALS 
A new era in ALS disease research began almost 30 years ago with the discovery of the 
21q22.1 chromosomal locus of the sod1 gene. 11 mutations in the primary sod1 sequence 
were associated with familial ALS.[5] Now 187 mutations in sod1 are known to be linked 
to ALS disease, as last accessed from the ALSoD database (October 2020).[47] However, 
it is not confirmed if all of them are also pathogenic. Many groups showed that the 
mutations influence structural integrity of the β-barrel, the dimer interface and the loops 
leading to an overall destabilization of the protein structure, later known as “framework 
destabilization”.[48][49] 
Uniform arguments were observed throughout the years from many experiments that 
mutations indeed influence the unfolding properties, causing dimer destabilisation, and 
the formation of soluble and insoluble oligomers. Aggregation was also correlated to the 
lack of the intramolecular disulphide bridge and/or cofactors in the active site.[49,50,51–53,53] 
Interestingly, the most common mutations Ala4Val (A4V) and Ile113Thr (I113T) are 
located at the dimer interface. The survival of patients with A4V or I113T SOD1 
mutations is very short with 1.2 to 4.3 years after onset. Other mutations such as H46R 
go along with a survival rate of 17.6 years in average.[54] Furthermore, I113T can also 
appear as sporadic phenotype and can have a different onset and variability, where more 
than 90% people that carry the mutation, will have developed the disease after the age of 
seventy. Characteristics among the mutations throughout the protein are different even 
among those in the same region. On the other hand, similarities are shown among the 
mutations at particular sites such as the dimer interface, the metal region, the β-barrel and 
the loops. They all interfere with the structural integrity, and the protein is not possible to 
mature into the wild-type structure. Although, many destabilisation processes are 
involved in structural perturbation, including removal of hydrogen bonding, salt bridges 
or disturbance of hydrophobic interactions, repulsive steric clashes induced by mutations 
are shown among all of them, and it result in varying but relatively short survival times, 
as shown in Figure 2.4.[55] 
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Figure 2.4 ALS mutants at different SOD1 dimer sites. Taken from[55] Copyright © The 
Author(s) 2019  
Hough et al. showed differences in the conformation between wildtype and A4V and 
I113T, respectively, where the opening of the dimer interface is observed for both mutants 
and even more pronounced in the latter one, where the observed conformation of the 
dimer is elongated. Their conformation difference dictates the orientation of the 
monomers.[51]  Both mutations have an influence on the hydrogen bond between Ile151-
Gly114; however, variation in hydrogen-bond distance is more observed in the A4V 
mutation. Another important effect of I113T was that the influence on the nearby residues 
was minimal, yet the major perturbance was observed due to the loss of hydrophobic 
contact at dimer interface between the carbon atoms of Ile113 and Ala4.[51] Different 
findings and crystal structures of the mutants of the zinc-loop dimer interface can have 
significant impact on the destabilization of the dimer and the β-barrel structure, thus 
trigger aggregation processes. A similarity to dimer interface mutants and the importance 
of preserving hydrophobic interactions can be observed in Leu38Val mutation, in which 
the side chain is usually inserted into the hydrophobic core and has a stabilising van-der-
Waals interaction with Val114 and nearby residues at the β-turn. However, those 
interactions are disrupted in the mutated protein.[56] Cardoso et al. observed the same 
effect with the A4V mutation, which resulted in a movement of the subunits, thus, caused 
structural opening on the other side of the β-barrel at Leu106. Depending on the mutation, 
interactions will be reduced or clashes and repulsion inside the β-barrel will interfere with 
the structural integrity and initiate aggregation.[57] Generally, findings indicate that ALS-
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correlated mutations are more likely to occur in the functional parts, such as the interface, 
the metal binding, the β-barrel root and the disulphide region as part of the zinc loop, 
while more solvent-exposed and not protected regions are less likely to be mutated.[55] 
This indicated that SOD1 involvement in ALS is not only through reduced activity and 
loss of function but rather to many correlated processes that could have a gain of toxic 
function. This all correlates well to the earlier findings from the complete knock-out of 
SOD1 in mice that did not show any symptoms of ALS.[58,59] Moreover, it was already 
shown by Bruijin et al. that formation of aggregates in G85R mice increases the progress 
of the disease.[59] All this led to the conclusion that SOD1 toxicity probably results from 
gain of function resulting in misfolded, oligomerised and aggregated species of SOD1. 
Therefore, SOD1 related ALS correlates with aggregation as a hallmark of many 
neurodegenerative diseases. 
2.2.3 ALS and SOD1 aggregation 
To expand and understand the underlying mechanisms of the aggregation observed and 
implicated in SOD1-related disease, many cells and in vitro models were developed. 
Rakhit et al. reported pronounced aggregation of the zinc-deficient wildtype as a 
consequence of oxidation, while in the other mutants the effect was much less 
pronounced. Light scattering of the metal deficient wild-type at 350 nm showed the 
formation of big aggregates, even with the copper present in the active site.[60] 
Furthermore, the lack of oxidants still showed a small amount of aggregation in the zinc-
depleted control, indicating the importance of metal in the aggregation process. Many 
aggregates confirmed in correlation with SOD1-ALS resembled an amyloid fibril 
structure as known from other neurodegenerative diseases.[49,51,61] Interestingly, rather 
amorphous than amyloid-like aggregates have been observed in the spinal cord, 
resembling unfolded and monomeric structures of SOD1.[62] This is also an indication 
that formation of aggregates of SOD1 not necessarily has to be typically fibrillar, as it is 
mostly observed for α-synuclein or other aggregation prone proteins. The structures might 
highly differ depending on the mutations and processes by which they occur. It was shown 
that mutations within different protein sites have generally different influence on the 
overall structure.[63] Additionally, the lack of metals affects aggregation of the SOD1 and 
the formation of soluble oligomers. The protein structure of the apo form is perturbed and 
much more flexible, with the buried Cys6 and Cys111 more likely to be exposed and 
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oxidized to form soluble oligomers, either by disulphide bonds or noncovalent 
interactions between the β-sheets.[64,65,65] Furthermore, similarities between aggregates 
observed in vitro versus in vivo were confirmed in which they share similar fibrillar 
features.[66] Yet, the aggregates, heterogeneity and initiation of fibril formation were also 
shown in self-assembling peptides particularly the segments of the β-strand 8 (147-153), 
and the loop VI (101-107), in which the hydrophobic side chains induced a zippering 
effect.[67] This also suggests that the solvent exposure of the dimer interface can have a 
significant effect on the aggregation of the SOD1 protein. Even more, if the internal 
disulphide bond is broken, flexibility is induced in the loop, and the dimer contacts are 
loosened, which can easily trigger aggregation, as shown for the peptide segments.  
Unfolded monomeric SOD1 was also shown to influence the aggregation gained by either 
oxidative response or dimer dissociation, by which cellular toxicity due to formation of 
soluble low molecular aggregates was confirmed.[46,51,52,68] Monomer formation can result 
in monomer association with a dimeric non-disulphide bonded SOD1 to first form 
trimers, and later higher toxic oligomeric species.[69,70]  
Different mechanisms and pathways, by which the mature proteins aggregate have been 
described, which occur either dependent or independent of each other. As shown in Figure 
2.5 those aggregation processes can be roughly divided into three pathways. 
Demetallation and reduction of the internal disulphide bond effect the stability of the 
protein by leading to solvent exposure of all cysteine residues, and, hence, to oligomer 
assembly. Additionally, the induced structural perturbation aligns β-barrel sheets in an 
ideal position for fibrillation and aggregation. Furthermore, they all affect the dimer 
interface, which leads to destabilization of the intact dimer: reduced disulphide bonds 
induce flexibility into the zinc subloop at the dimer interface causing clashes, while 
demetallation initiates barrel perturbation, and, hence, dissociation into monomers. 
Dissociation of the folded wild-type, on the other hand, is very unlikely on its own, as the 
binding dissociation constant is very low in a range of 10-8 to 10-10 M.[71,72] However, 
mutations on the dimer interface influence dissociation and destabilization of the dimer, 
subsequently causing aggregation.[72,73] Furthermore, demetallated wildtype and mutant 
SOD1 protein have an even higher propensity to dissociate.[74] 
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Figure 2.5 Discussed aggregation pathways of SOD1 protein (from left to right: disulphide 
(Cys57-Cys146) bond reduction, demetallation and destablization of the dimer). 
2.2.4 Insight into current SOD1 therapeutic approaches  
In the last fifty years of SOD1-ALS related research, many structural and functional 
properties have been revealed and knowledge was gained. With the first approved drug 
for the treatment of ALS, therapeutic approaches and investigations on SOD1 were also 
directed toward that area, considering all structural and functional properties as well as 
the ubiquity of the protein in many ALS-related mechanisms. Yet, until now there is no 
drug or therapeutic approved in correlation with the SOD1 protein. On the other hand, 
several approaches have been developed to address critical structural and functional 
properties implicated in ALS. 
Regulation of copper and zinc levels in the metal active site is important for the functional 
protein, yet the mutants usually reveal impaired ability to correctly metalate in the folding 
process. Researchers showed that zinc dose dependency in transgenic G93A mice has to 
be carefully balanced to have a beneficial effect on deficiency, and survival rate, but it 
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should not exceed more than 11 mg per day.[75] Others showed that promoting copper 
increase might have more influence, especially when taken into account the reduced 
ability of mutants to interact with a copper chaperon for SOD1 protein (CCS). Studies 
indicate a scavenging capability of CuATSM (diacetylbis(N(4)-
methylthiosemicarbazonato) copper(II) toward peroxynitrite, a product of the reaction of 
superoxide and nitric acid, that damages cells in the process of protein nitration.[76][77] 
Furthermore, mutated G93A, G37R and G93A mice co-expressing human CCS showed 
an increase in survival upon controlled treatment with CuATSM, which resulted in higher 
copper levels and activity in the majority of mutants.[78][79] In cellular experiments, 
CuATSM resulted in increased cell survival and lower aggregation levels, however, it 
was only specific for mutants with wildtype similarities and not for metal-binding region 
mutants.[80] The mechanisms involved are still not clear and are currently investigated, 
yet treatments with CuATSM are already in phase I and II of clinical trials in Australia.[80] 
Ray et al. showed that instability and dissociation of the A4V mutant SOD1 protein could 
be minimized by harnessing the amino acids at the dimer interface by a disulphide 
bond.[52] While engineering a V148C substitution they were able to retain a dimeric 
structure comparable to the wildtype protein. In the low concentration range the A4V 
mutant was confirmed to be monomeric and in an amyloid pore-like aggregated species. 
Similarly, Auclair et al. showed covalent bridging of monomers by maleimide functional 
groups. They used a small-molecule approach to cross-link two exposed cysteine residues 
(Cys111) and stabilize G93A and G85R mutants by approximately 20 and 45 °C, 
respectively.[81] Additional approaches were shown to target solvent-exposed and 
oxidation-susceptible Cys111 site. In 2012 Banci et al. confirmed the influence of 
cisplatin, a known therapeutic in cancer treatments, has a positive effect on apo SOD1 
proteins. Even though crystallographic data revealed steric clashes at the dimer interface 
and a distortion of the structure between the Cys111 residues, protein thermal stability 
was improved by 8 °C with a binding affinity of approximately 37 µM. Besides dimer 
stabilization and aggregation inhibition, already formed SOD1 aggregates were 
dissolved.[82]  
Two years ago, Capper et al. showed antioxidative ebselen and ebsulphur to act as a 
chaperone in SOD1 folding, by increasing the dimer affinity. The effect of increased 
dimer affinity was most pronounced for the A4V SOD1 variant with an almost 60-fold 
increase in association strength in the presence of ebselen. A slight increase in the 
association strength of the dimer, 1 to 3 fold depending on the compound, was also shown 
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with the zinc-metallated wild-type.[73] Beside balancing dimer stability to suppress 
dissociation and unfolding processes that lead to aggregation, an experiment in living 
human cells indicated intramolecular disulphide bond formation of reduced zinc 
metallated SOD1 mutants when treated with ebselen. This enabled proper folding of 
immature monomers, which were impaired, if the amount of copper chaperone in the 
cytosol was inadequate.[73] So far, all tested small molecules which lead to an increase in 
stability or promote folding and reduce aggregation, are not specific enough and could 
bind to other proteins or are unstable in cellular environment.  
In 2005 Ray and Lansbury, after their earlier disulphide bridging in V148C substitution, 
performed in silico studies and screened a library of 1.5 million small molecules.[83] They 
addressed the cavity of the SOD1 protein at the dimer interface opposite to the earlier 
described cysteine 111 proximity site. From the top 100 hits of the initial library screen, 
they narrowed it down to 15 molecules which appeared adequate in stabilizing and 
lowering aggregation of the A4V dimer under induced unfolding conditions. They 
confirmed the importance of the Val148 site for the binding affinity of the tested 
molecules by mutating Val7 and Val148 residues with Phe, in which aggregation 
inhibition was not observed. From the structural similarity of the tested compounds, an 
aromatic moiety was shown to be important for the binding to the hydrophobic core 
between the valine residues and the stability of the protein.[83] Five years later they 
presented improved molecules with binding specificity toward SOD1 mutants, while 
enlarging the in silico screen of a commercially available database of 2.2 million 
compounds. 
 
Figure 2.6 Binding site Val148  and compounds with aza-uracil like moieties, adapted 
from.[84] 
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Docking was performed iteratively with the flexible target and also with hydrogen bond 
constraint parameters on Val7 and Asn53 residues in the cavity. Fourteen obtained 
compounds showed an increased binding affinity for the A4V and a high efficiency to 
block aggregation. Six of them showed high specificity toward the SOD1 in comparison 
to the blood plasma. Structurally, the compounds were similar to previously reported 
compounds with aromatic moieties, but contained uracil or aza-uracil like moieties that 
could be involved hydrogen bonding with Asn53 and Val7 of the opposing monomer 
units.[84] (Figure 2.6) They also indicated that in silico design could be a potent tool for 
new drug design. However, compared to the previously described cysteine site studies, 
the binding behaviour of the compounds was not structurally confirmed. 
Consequently, these findings were challenged by Antonyuk et al. when they attempted to 
structurally inspect these ligands via cocrystallization experiments with the mutants. They 
obtained 1.7 Å resolution crystal structures of the SOD1 L38V mutant with uridine 5’-
monophosphate (UMP) chosen to compare the similarity of uracil-like structures, 
proposed earlier in ligand screening.[56] The UMP binding site was located farther from 
the dimer interface between the electrostatic and zinc-binding loops. During structural 
investigation, they discovered a “druggable” site in proximity of the Trp32 residue from 
crystal structures of G93A and L38V with 1.55 Å to 1.65 Å resolutions, respectively. 
They were able to provide structural information of binding with SOD1 mutants.[56] Later, 
they showed that isoproterenol and 5-fluorouridine do not have a tremendous effect on 
the guanidine induced unfolding of A4V and I113T SOD1 mutants. Furthermore, the 
crystal structure revealed a binding site in between the β-strands 2, 3 and 6 close to 
Trp32.[69] These compounds were shown to have a high ability to block the aggregation 
of A4V SOD1 and were specific for SOD1 in blood plasma.[84] These experiments clearly 
show the importance of crystal structures for drug design and the need for relevant 
methods to test the binding affinity of small molecules for SOD1. Afterwards, Manjula 
et al. reported different compounds to bind to Trp32 in the low micromolar range and 
inhibit oxidation.[85,86] Pokrishevsky et al. also showed the importance of that site, they 
confirmed that a Trp32Ser mutation diminishes SOD1 aggregation, induced by Trp32 
self-seeded aggregation, despite the generally reduced stability of the mutants and 
wildtype proteins. Additionally, they tested 5-fluorouracil and 5-fluorouridine onto Trp32 
aggregation and confirmed high potency of those chemotherapeutics to reduce 
aggregation in SOD1, and up to now, they seem to be the most prominent candidates for 
SOD1-ALS treatment.[87] 
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As described above, many approaches were developed for the treatment of SOD1 related 
ALS over the years. In Figure 2.7 all cavities and sites reported are visualized that could 
be potential therapeutic targets in SOD1. The metal site is shown in red, the dimer 
interface with two possible cavities, Cys111 (yellow) at the top of the protein, and Val148 
(blue) at the core between two monomers, and the Trp32 site shown in green. 
 
Figure 2.7 Potential therapeutic sites in SOD1 protein: metal (red), Cys111 (yellow), Trp32 
(green), Val148 (blue). PDB code 2V0A, visualization by UCSF Chimera.[44] 
The understanding of SOD1 functional and structural properties has improved extensively 
since its gene discovery. It is now known that the metal-binding site, the dimer interface 
and β-barrel structure influence the SOD1-related ALS disease. Furthermore, CuATSM, 
ebselen and 5-fluorouracil were shown to be potent small molecules in intervening 
aggregation. Although these important findings are milestones in the therapeutic 
development of SOD1, the question of delivery, specificity and affinity to SOD1 is yet to 
be answered in order to develop sensible therapeutic strategies. The revelation of SOD1 
aggregation on ALS might be the main breakthrough. Mutations were found across the 
whole protein, yet not all of them are propagating aggregation. Those at the critical sites 
of the protein are promoting dissociation, unfolding and prevention of folding into stable 
dimers, which will lead to inclusions, as well as fibrillar and amorphous aggregates. The 
actual structure-toxicity relation is still a puzzle and might differ because of different 
initiation points and propagation mechanisms. Additionally, differences in sALS and 
fALS epidemiology of SOD1 are huge, and many mechanisms of aggregate formation 
are still unknown, contradictory and cannot always be correlated. Hence, it can be 
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concluded that there is still much more that we do not yet know, and basic research in 




 AIM OF THE WORK 
Superoxide dismutase-1 (SOD1) is a well-known protein that is involved in fatal ALS 
disease. However, throughout the years of structural and functional discoveries, there are 
still unanswered questions of its pathogenicity in ALS as well as other neurodegenerative 
diseases. 
Early structural investigations of SOD1 proteins indicated the importance of the dimer 
interface between the two monomer units.[88] Initial studies of interfacial SOD1 mutants, 
such as A4V revealed a destabilization and possible dissociation into monomers that 
could propagate the aggregation.[51] Various strategies have been proposed in order to 
prevent undesired dissociation in SOD1 mutants. For instance, the introduction of an 
artificial disulphide-bridge was found to stabilize the A4V mutant (see Section 2.2.4). 
Furthermore, small molecules, which bind to the interfacial cavities showed structure 
stabilizing effects. However, the V148 cavity was not yet successfully addressed by small 
molecules. 
The aim of this work is the development of an affinity-based stabilization as a labelling 
approach for SOD1 A4V. To achieve this, we intended to design multifunctional ligands 
with an affinity for the cavity of interest that could influence protein aggregation. 
Furthermore, the ligands are planned to be tagged with a fluorogenic dye and, thus, be 
transformed into an affinity-based probe (see Figure 3.1). 
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Figure 3.1 Schematic overview of the aim of this work. A small ligand molecule with an 
affinity for the cavity of interest preludes the fluorescence on the lysine residue. 
To achieve this goal, several tasks have to be addressed: 1) structural analysis of the 
protein cavity Val148; 2) in silico design of the ligands; 3) ligand synthesis; and 4) 
assessment of binding properties and aggregation studies. 
Structural analysis of the protein cavity is important as there are no crystal structures of 
small molecules reported to bind to the cavity. Therefore, different protein crystal 
structures are planned to be analysed prior to molecular docking. For in silico design 
studies, molecular docking of AutoDock Vina is used for prediction of ligand binding 
followed by analysis of their bound conformations in the protein cavity. Ligand synthesis 
is planned to be performed in a modular approach so that the ligand library can easily be 
enlarged. Lastly, the obtained ligands are assessed for their binding properties in 
microscale thermophoresis, isothermal calorimetry and thermal shift assays. Aggregation 




 BIOPHYSICAL AND 
COMPUTATIONAL METHODS 
 In silico design 
In the present work, in silico design also known as computer-aided drug design [89] was 
used for the rational design of small molecules.  The capacity of the method has been 
shown in a broad area of drug research and medicinal chemistry. Essentially, the efficacy 
of in silico design is to shorten the time needed for the identification of lead structures by 
using computational tools if compared to the traditional laboratory experiments and high-
throughput screening (HTS).[90] Through virtual screening, an important technique of in 
silico drug design, methodical docking of a broad range of the drug candidates is 
performed for the identification of potential ligands. [89,90]  
There are mainly two categorizations of virtual screening methods: ligand-based and 
structure-based methods, also known as molecular docking. In the case of ligand-based 
methods, information of the target, usually, a macromolecule or protein is very limited, 
therefore pharmacophore modelling and quantitative structure-activity relationship 
(QSAR) methods are used.[91] Molecular docking can be chosen for different but 
complementary approaches. When the structure of the target is known, large libraries of 
the compounds are evaluated against the target. Therefore, hit molecules can be obtained 
in a relatively short time. Furthermore, molecular docking is valuable for the binding 
mode analysis of the small molecules to a specific target site, as well as the study of the 
binding interactions to predict and model characteristics of the drug lead structures i.e., 
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absorption, distribution, metabolism, elimination and toxicity (ADMET).[92] One 
interesting concept of in silico design used in the field of drug design development is 
called inverse virtual screening. It can be part of both previously mentioned categories, 
besides the concept where one ligand is evaluated versus many targets to identify its 
presumed nonspecific targets, as well as identify possible specific targets, multiple 
libraries of ligands are tested against many targets to determine specific pharmacological 
activity.[93][94] 
 Molecular docking 
Throughout the years docking theories were evolving, from “lock-key” mechanisms[95] 
according to which ligand and target should be rigid in docking simulations, followed by 
the “induced-fit” theory[96], in which it is proposed that the active site is changing upon 
ligand binding. In agreement with that, either, ligand and target or only ligand should be 
considered as flexible in docking calculations.[91] The “Conformational selection” model 
combines pre-equilibrated structures and the random fluctuation of target and 
ligands.[97][98] To obtain the best characterisation of the interaction between ligand and 
target, a combination of the induced fit and conformational selection model was 
proposed.[99] 
To predict ligand conformation in the docking, and to evaluate its binding affinity to a 
target protein, the docking software gives outputs according to the combination of the 
docking theories, and balances between accurate simulations and required computing 
time. Therefore, the perspective of molecular docking theory can be explained with the 
complementary methods: the sampling method, and the scoring function method.[91,100]  
The sampling method is inspecting conformations of the ligand in the active site using 
different algorithms, which are mainly varying in how they map the ligand into an active 
site; i.e., matching algorithm (MA) is using the molecular shape map of a ligand as 
pharmacophore where the distance between a ligand and a protein is calculated. 
Incremental construction (IC) does fragmentation of the ligand and then incremental 
addition of the other functional groups in different orientations, in which they fit to the 
binding site. Multiple Copy Simultaneous Search (MCSS) performs multiple copies and 
randomization of the functional groups. Consequently, new binding sites and ligand 
conformations are calculated from the favourable interaction energies of the multiple 
placed functional groups.[91] 
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Scoring functions have a judge role, in which it is crucial to define the correct poses, as 
well as to eliminate non-binders from the poses obtained and rank the predicted ligand 
poses. This process is important for reliable molecular docking evaluation. So far, there 
are three main categories (force-field based scoring function, empirical, and knowledge-
based function), which are being constantly developed to improve their 
efficiency.[91][100,101] 
4.2.1 AutoDock Vina 
In this work, molecular docking was used to predict the binding of the ligands to the 
hSOD1 target protein and analyse their bound conformations. For the docking, different 
software (SwissDock[102], Mcule[103], AutoDock Vina[104]) was evaluated. There are 
several differences; however, one main difference was that SwissDock and Mcule are 
web-based docking servers, whereas AutoDock Vina is an offline docking software. From 
the web-based docking servers, SwissDock has user-friendly interface and suppresses 
information on how the system is designed. Furthermore, the computational setup was at 
disposal.[105] Therefore it was used as a confirmation of the molecular docking with the 
AutoDock Vina. 
The stochastic methods that are used in AutoDock are Monte Carlo (MC) and Genetic 
algorithms (GA). These methods perform searches of the space by randomization of the 
ligand conformation. Conformations in MC are generated via bond rotation and rigid-
body translation or rotation. A further selection of the conformations is based on the 
energy barriers principle. In GA new conformations are represented when a change in the 
structure occurs due to some mutation or depletion. If that new structure passes the energy 
threshold it will be used for further sampling.[91] 
AutoDock Vina implements simple scoring functions for the estimation of the protein-
ligand affinity, and the search is based on the stochastic MC and GA methods. Vina uses 
a combination of knowledge-based and empirically weighted scoring functions; that 
includes hydrophobic interactions (van-der-Waals), hydrogen bonding, torsion degree 
and repulsion.[106,107] High impact and improvements in speed and precision over the 
previous version (AD4) were achieved with a local search algorithm; where the 
conformations are calculated by the iterative local gradient-based search.[107] 
Conformation pose with the highest binding affinity, also the most negative affinity, is 
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ranked as the top pose. The poses are approved or rejected if the next iteration has a lower 
free energy than the previous iteration.[106] 
 Microscale Thermophoresis 
Microscale thermophoresis (MST) has lately been developed as a very powerful method 
for determining binding dissociation constants at different interactions, i.e. protein-
protein, DNA-protein, and protein-small molecules.[108,109] It is also used as a high-
throughput screening method, along with other biophysical methods to compare and 
confirm promising binding hits.[110]  
The concept is based on the different movement of the molecules through a temperature 
gradient induced by an IR-laser, in which the rate of motion is different between a single 
molecule and complex.[111] The effect of thermophoresis, also known as Soret effect is 
dependent on a change in size, charge, solvation entropy of the molecules, and it is 
detectable in constant buffer conditions.[112] The advantage of the experimental setup is 
that the change of the thermophoretic effect is monitored by fluorescence inside a glass 
capillary, through an objective coupled onto a dichroic mirror when the heat effect is 
induced by an IR-laser.[113]  As shown in Figure 4.1, the IR-laser is applied onto all 
capillaries with serial dilution, and, simultaneously, molecular movements are detected 
by fluorescence detection. A microscopic view of the molecular interactions through 
different stages is shown. In the initial state, also known as Fcold, the IR laser is off and 
fluorescence distribution is homogenously detected inside the capillary and there is no 
directed movement of the molecules at the sample. By inducing a temperature gradient 
with the IR-laser, fluorescence distribution Fhot is obtained from two effects. Drop-in dye 
fluorescence depending on its intrinsic temperature dependence is induced by thermal 
relaxation time, which is usually very fast, and in the diffusion effect, in which the 
labelled sample moves out (positive thermophoresis) or toward (negative thermophoresis) 
the heated region until a steady-state is reached. Back diffusion occurs in the last stage 
when fluorescence jumps back to a homogenous distribution, due to IR-laser being 
deactivated.[111,113,114] 
 
 4.3 Microscale Thermophoresis 
27 
 
Figure 4.1 MST assay setup. Left: Macroscopic view of the experimental setup; Right: 
Microscopic view of the molecular interactions in the MST assay shown through different 
stages. Adapted from.[114] 
For binding affinity analysis, ligand-dependent changes in the MST trace at each capillary 
is shown as normalized fluorescence (∆Fnorm) in which is calculated by dividing Fhot by 
Fcold whereas Fhot and Fcold values correlate to the average fluorescence between the hot 
and cold areas marked as red and blue cursors, respectively. Furthermore, the 
concentration of the titrated non-labelled ligand is plotted against the normalized 
fluorescence to determine a binding constant from a binding curve, as shown in Figure 
4.2.[108] 
 
Figure 4.2 MST binding experiment and analysis. Left: Thermophoretic movement of a 
fluorescent molecule within MST-on time of 20 s, in which the IR-laser is on. Right: Binding 
curve derived from normalized fluorescence and concentration of the titrated ligand. 
Adapted by permission from CC BY licence; The Authors. Published by Elsevier B.V. 
(2014).[108] 
MST-on time can be used for two different time points in MST measurements, first, it 
defines a period, where the IR-laser is on, which is described as the measured time, and 
second, it defines the analysed MST-on time. In Figure 4.2 MST-on times are the same, 
indicated by the red Fhot cursor. To minimize a possible structural destabilization of the 
molecules by applied temperature from IR laser intensity, a shorter MST-on time should 
be used.[113,115]  From the difference between unbound and bound values, a response 
amplitude is obtained. In combination with a signal to noise ratio (S/N) which is 
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calculated by dividing the response amplitude by noise (standard deviation of the fit 
residuals), those parameters are used to estimate the validity of the assay. For a consistent 
analysis of all assays, analysed MST-on time was used at 1.5 s as described in Section 
7.2.4.2.  
 Isothermal Calorimetry 
Isothermal Calorimetry (ITC) is a method which is used to determine how tightly a ligand 
is bound to i.e. a protein measuring the heat that is released or consumed upon the binding 
process.[116] The heat change is monitored and maintained to zero temperature difference 
between the reference and sample cell. The sample cell contains one of the analytes of 
the binding reactions, and a syringe which contains a solution of the ligand is attached to 
it. The reference cell usually contains water. In Figure 4.3, the basic setup of the 
calorimeter is shown, as well as typical raw data obtained after ligand injection into the 
sample cell as heat pulses. The heat pulse is integrated over time and normalized to a 
concentration where the resulting isotherm is obtained, and fitted to determine the binding 
affinity, as well as stoichiometry and enthalpy of the reaction.[117] 
 
Figure 4.3 Basic ITC experiment setup, adapted from[118] Copyright © 2015 Song, Zhang 




 RESULTS AND DISCUSSION 
This chapter is divided into three main sections. Firstly, the ligands’ design through 
analysis of the hSOD1 protein cavity and evaluation of molecular docking simulation 
studies are described (Section 5.1). Secondly, retrosynthetic approaches and synthesis 
strategies towards a ligand library are proposed (Section 5.2). Thirdly, biophysical studies 
of the ligands and the proteins are reported with a focus on protein studies (Section 5.3), 
binding affinity and aggregation (Section 5.4), and structural investigation as well as 
structural analysis and X-ray crystallization (Section 5.5). 
 Ligands design and molecular docking 
5.1.1 Analysis of the hSOD1 protein cavity and ligands design  
Our first molecular docking approach was not a blind docking[93,105], as the cavity of 
interest has already been known, but there were no crystal structures of small molecules 
reported to bind to the cavity. The Lansbury group[83,84,119] reported binding of small 
molecules at the dimer interface in the cavity of Val148, this was later challenged by the 
reports on the Trp32 residue.[69] These findings caught our attention mainly for two 
reasons: 1) an investigation of the controversial cavity, and 2) the presence of a lysine 
residue that can be targeted for NBD fluorescent labelling. The fluorogenic properties of 
the NBD dye, as a “turn-ON” fluorescence concept was reported earlier to be successful 
in a biotin-avidin complex, as well as selective labelling of mitochondria in living 
cells.[120] The X-ray structure of the hSOD1 protein and an enlarged bottom-up view of 
the cavity are depicted in Figure 5.1.  
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Figure 5.1 hSOD1 protein dimer centred at Val148, and enlarged bottom view into the 
cavity. Valine residues are depicted in purple, asparagine in blue and lysine residues in 
green. PDB code 2V0A, visualization by UCSF Chimera.[44] 
In the enlarged representation, the residues pointing into the cavity are depicted at the 
dimer interface, with Val148, Val7 (purple) and Gly147 (light grey) forming the 
hydrophobic cavity. The entrance to the cavity is comprised of polar amino acids with 
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Lys9 shown in green on the left (monomer strand A) and right side (monomer strand F) 
and Asn53 in blue at the top (monomer strand A) and bottom (monomer strand F) of the 
cavity. The approximate distance between Val7 and Val148 of the same monomer is 
~ 8Å, while the distance of Val148 of each monomer is ~ 3.8Å. This can be seen as the 
top of a funnel-like cavity at the dimer interface, where hydrophobic interactions of the 
ligands would be necessary to ensure binding. At the periphery of the cavity, the distance 
between the lysine residues is approximately ~ 11.3 Å, similar to the distance between 
the polar asparagine residues (~ 11.7 Å). This cavity with the hydrophobic core and the 
respective peripheral amino acids was used in our docking studies, and, hence, for the 
ligands design.  
Rules for designing ligands, which bind to the cavity of interest Cav(V148) are as follows: 
1) hydrophobicity to ensure binding to the inner core of the cavity; 2) the possibility to 
form hydrogen bonds with the backbone of the residues; 3) the possibility of transfer of 
a fluorophore attached to the ligand to Lys9 to achieve labelling of the protein; and 4) 
design of a ligand core structure that can easily be modified taking into account 
conformational favourable interaction of the functional groups and the possibility of 
library enlargement. 
Figure 5.2 (top) shows two 3D models of the lead structures, coloured according to the 
elements: oxygen in red, nitrogen in blue, carbon in grey, and hydrogen in white. If both 
molecules are centred on the respective molecule origin, the differences can be observed. 
For instance, the amide bond in molecule A is on the y- axis and the methylene group is 
arranged in x- direction. In lead structure B, the methylene group between the amine and 
the carbonyl group is more flexible and in a different torsion angle, and the aromatic ring 
in y-direction is in an orientation that enables π-π stacking. Both structures are designed 
to bind to Cav(V148). It would be interesting to see how the flexibility of the molecules 
affect their dockings. In Figure 5.2 (bottom), lead structure C is positioned similarly to 
the two previous structures through the 0° plane. Here, the difference is in the position of 
the amide bond next to the aromatic ring, which is now in the direction of the y-axes, and 
also represents, an ideal geometry to point into Cav(V148). 
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Figure 5.2 Designed lead structures centred on the respective structures at 0° in x-, y- and 
z-axes. Top: Lead structure A (left) and B (right). Bottom: Lead structure C. 
The described ligands were designed in such a way that the core structure including the 
biphenyl rings and the third aromatic ring, which are connected via an amide or an amine 
bond, are inside the cavity and the fluorophore (O-NBD) is outside the cavity, close to 
Lys9 for fluorescent labelling. 
A B 
C 
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5.1.2 Molecular docking to the hSOD1 protein 
Molecular docking simulations of the structures of interest were performed with 
AutoDock Vina as explained in Section 7.3 and were comparable to the results from the 
SwissDock web-based server.  
Molecular docking included a simulation search with the lead ligand structures and ligand 
scaffold structures, without a fluorophore attached, and were divided into several stages. 
It was reported that the selection of a bigger grid-box[90] includes more off-target binding 
search and shows more clearly the true ligand-favoured site.[121] The molecular docking, 
in simulation with a big grid resulted in 25-50% off-target binding, for all ligands when 
the exhaustiveness, the computational power to search the space, was small. However, 
the initial poses were in Cav(V148). With an increase of exhaustiveness, the results were 
more consistent and off-target binding was reduced to 10%. Again, the first two to three 
binding poses were in the cavity of interest. For a deeper docking analysis of the lead 
structures, the search space was minimized and centred according to the amino acids in 
the Cav(V148), Val148, Gly147, Asn53, Lys9 and Val7 from both monomers as 
described in the experimental section. A difference within the docked lead structures was 
observed in their first poses; however, the variation of the negative Gibbs energy was in 
a maximum range of ± 1 kcal/mol. Analyses of the lead structures in the cavity revealed 
that structures A and B are properly aligned in the cavity. (Figure 5.3 and Figure 5.4) 
 
Figure 5.3 Lead structures A in the cavity of interest. Left: 1st docking pose with free binding 
energy of - 9.0 kcal/mol. Right: 2nd docking pose with free binding energy of -8.6 kcal/mol. 
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In Figure 5.3, lead structure A (LS A) is shown in the first (left) and the second (right) 
docking pose, which revealed the smallest distance to the Lys9. The NBD fluorophore’s 
oxygen atom of the ligand is in approximate distance of 3.5 Å. While the ligand scaffold, 
which is designed for the hydrophobic interaction with the amino acids of Cav(V148), is 
positioned in such a way, that the mentioned π - π stacking of the molecule is observed. 
Furthermore, ~85 polar and non-polar interactions within the protein Cav(V148) are 
formed with distances of 2.0 - 4.0 Å. The hydrogen bonds to the backbone of the protein 
are mostly affirmed with Val148 and Val7 residues and the -OH groups of the aromatic 
rings along with the amide bond of the ligand and Asn53 of the respective protein chain 
and depend on the obtained binding affinity pose. Moderate and weak non-covalent 
interactions result from the hydrophobic effect of the ligand and the respective amino 
acids in the protein cavity.  
 
Figure 5.4 Lead structure B in the cavity of interest Cav(V148) with a free binding energy 
of -9.1 kcal/mol. 
The docking studies with LS B (Figure 5.4), also revealed an affinity to the Cav(V148). 
Interestingly, all poses of the docking showed the fluorophore part of the molecule to 
point out of the cavity toward the lysine residues. This is in contrast to structure A where 
30% were inside the cavity. However, the RMSD values of these poses in structure A 
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differed by 8.0 Å from the most energetically favoured pose of 0 Å RMSD. Our accepted 
limit for upper and lower bound of the pose studied was set to a maximum of 4.0 Å. The 
binding affinity of the lead structures was not significantly different in the poses within 
the evaluated limits. It ranged from 0.1 kcal/mol up to 0.4 kcal/mol in the last pose 
(Appendix 9.2). The difference in conformational orientation between the lead structures 
A and B can be observed in the binding affinity poses, particularly, with respect to the 
amide and amine bond of the structures. This results in similar poses, which are classified 
differently depending on the highest affinity and favourable position with regard to the 
binding energy between the two structures. However, lead structure B has similar 
interactions with the protein, except that they are observed in different ranking poses in 
comparison to the lead structure A. Examination of lead structure C revealed an affinity 
of the fluorophore unit of the structure for the cavity of interest, while the proposed 
affinity scaffold of the molecule was pointing out indicating that it was not in the ideal 
position for fluorescent labelling on any of the lysine residues. Additionally, the energy 
of binding was significantly lower than for the other two lead structures, and within a 
range of -8.5 kcal/mol to -7.9 kcal/mol.  
 
Figure 5.5 Lead structure C in the cavity of interest, Cav(V148) with a free binding energy 
of -8.5 kcal/mol. 
The evaluation of the molecular docking of the designed lead structures confirms the 
affinity to the cavity of interest, and in case of structures A and B, desired 
multifunctionality of the ligands, to direct the fluorophore to Lys9 while stabilizing 
protein dimer in Cav(V148). Further developments with in silico design and molecular 
docking were mainly based on the scaffolds of lead structures A and B as an affinity site 
5 Results and Discussion 
36 
without a fluorophore attached. It is important to test the ligand scaffolds in the cavity 
alone to ensure a good binding affinity, thus enhancing the possibility to stabilize the 
protein and slow down the protein aggregation. 
  
Figure 5.6 Ligand scaffolds in the cavity of interest, Cav(V148). Left: Lead structure A with 
free binding energy of -8.0 kcal/mol; Right: Lead structure B with free binding energy of -
8.6 kcal/mol. 
Figure 5.6 shows the first binding pose of lead structures A and B and the atoms involved 
in polar and non-polar contacts to the amino acids in the protein cavity. The docking of 
the lead structures A and B shown in Figure 5.6 results in calculated free binding energies 
in all poses for both ligands in the range from -8.6 to -6.9 kcal/mol. The first poses with 
the lowest free binding energy were visualized. Furthermore, other poses with an RMSD 
difference up to max 4.0 Å for each upper and lower bound were checked and their 
position in the cavity was taken into consideration. The analysis revealed that the benzyl 
ring attached to the amide or amine bond, which seem to be involved in π-π stacking in 
both ligands as shown in Figure 5.6, would be suitable for modification to enable an 
enhancement of hydrophobic interactions to Val148 of the protein monomers and to 
increase the overall affinity for the cavity. 
 
Scheme 5.1 Schematic view of the scaffold structures A (left) and B (right). 
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Molecular docking was performed with both, the basic scaffolds of LS A and LS B as 
shown in Scheme 5.1. Variation of the functional groups was performed on the benzyl 
ring connected to an amide and amine bond, here depicted in blue, and the biphenyl rings, 
depicted in green. In Table 5.1, the diversification of the functional groups on LS A and 
LS B structures is summarized with the respective free binding energies of the ligand-
protein complex being in their most stable conformation and highest binding affinity 
according to AutoDock Vina predictions. 
The ΔG-values of the reported functional groups indicate an increased affinity to 
Cav(V148), with blue being aromatic-aliphatic functional groups fall in the lower range 
of -7.3 kcal/mol. In the complex of ligand L1A and hSOD1 a free binding energy of 
-8.0 kcal/mol is obtained. The ligand forms hydrogen bonds to the Val148 main chain 
peptide bond (-OH---N-Val148, 2.0 Å) of strand A, and to the asparagine side chain amide 
group (-CO--- H-Asn53, 2.8 Å) of strand F. Asparagine amide group (-OH---H-Asn53, 
3.2 Å) of strand A is not considered a true hydrogen bond, because the angle is not 
optimal. The bonding to the asparagine residues on both strands has to be considered 
carefully, as it is not clear, how they are conformed for all the PDB structures tested 
(Section 7.3.1). 
  
Figure 5.7 Docking of ligands L1 in the cavity of interest, Cav(V148) with their polar and 
non-polar interactions. Left: L1A with free binding energy of -8.0 kcal/mol; Right: L1B with 
free binding energy of -8.6 kcal/mol. 
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Table 5.1 Comparison of ligands estimated free binding energies for lead structures A and 
B. 
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The ligand L1B shows a free binding energy, which is increased by 0.6 kcal/mol 
compared to L1A. From the position in the cavity we can observe a difference in amide 
vs amine bond flexibility. The active torsion of L1B brings the amine above the plane, 
and more flexibility on the aromatic ring inside as shown in Figure 5.7 (right). This could 
be one of the main reasons for such a difference in binding among the ligands as well as 
more total interactions with Cav(V148). From the position of L1A in the cavity, it can be 
seen how the hydrophobic part of the ligand is oriented toward the inner cavity, where 
non-polar contacts with the amino acids are attained. Polar contacts with the more 
hydrophilic part of the cavity (mostly lysine and asparagine) are also formed. Contacts 
are shown as orange-red dotted line. The difference between ligands L1A and L1B could 
be designated to a higher hydrophobic interaction that contributes to the entropic binding 
and free energy calculation. When the free energy (-8.4 kcal/mol) of L2A is compared to 
the L1A, an increase in binding affinity to the cavity is confirmed. The additional 
hydrogen bond with the asparagine amide side chain (-OMe---H-Asn53, 2.3 Å) of strand 
A together with the amide on the asparagine on strand F (-CO---H-Asn53, 2.6 Å) 
contribute to a higher affinity to the cavity. However, what seems to result in a higher 
affinity is the binding of the hydrophobic methyl groups to the inner cavity. 
 
Figure 5.8 Ligand L2A in the cavity of interest with free binding energy of -8.4 kcal/mol, 
polar and non-polar contacts are shown with orange-red dotted lines. 
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As shown in Figure 5.8, non-polar contacts are contributing to the interaction with the 
valine residues (purple) of both protein strands. For all docking poses, π-π stacking of the 
aromatic rings within the ligand is observed, except in the pose with the lowest affinity, 
when the RMSD value exceeds the set limit, at which the ligand stretches vertically along 
the cavity, while forming four hydrogen bonds with both monomers of the protein. No 
additional interactions were identified for L1B, and the position within the cavity was 
practically the same. This could also indicate that the position of the methylene group 
does not have a tremendous impact on the binding itself rather on the flexibility of the 
ligand. Docking of ligand L4A (Figure 5.9), in which hydrogen bonding from dimethoxy 
groups to the protein strands is omitted, gave a binding free energy difference of 
- 0.1 kcal/mol compared to ligand L2A, and a lower estimated affinity of L4A. However, 
a higher affinity of L4A (-8.4 kcal/mol), compared to L1A (- 8.0 kcal/mol) is likely due 
to the hydrophobic interactions with the amino acids in the protein’s inner cavity, because 
the total number of hydrogen bonds is the same.  
   
Figure 5.9 Ligand L4A in the cavity of interest, Cav(V148) with -8.3 kcal/mol free binding 
energy; red-orange dotted lines indicate contacts within the cavity. 
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Furthermore, the conformation of ligand L3A complements earlier conclusions. A free 
binding energy of -8.6 kcal/mol is obtained in the most stable pose scored that showed no 
hydrogen bonding with any of the abovementioned amino acids in the cavity. However, 
the distances of the polar and non-polar contacts of the Cav(V148) amino acids are in the 
range of 1.3 - 4.0 Å and the total number of interactions is high compared to the ligands 
previously described. The interactions are shown in Figure 5.10. It can be seen that the 
benzyl ring directly connected to the amide bond points in other directions and that π-π 
stacking interaction between the biphenyl rings is configured parallel-displaced. 
 
Figure 5.10 Ligand L3A in the cavity of interest, Cav(V148), with -8.6 kcal/mol free binding 
energy. 
 
The binding affinity of the ligand L5A has the same score as L3A, but the obtained 
binding energy results from hydrogen bonds and from hydrophobic interactions. In the 
pose with the most stable conformation Figure 5.11 the ligand forms hydrogen bonds to 
the amide bond of the asparagine (-CO--- H-Asn53, 3.0 Å) of strand F. Furthermore, two 
hydrogen bonds are formed between the carbonyl group of the thymine-based structure 
and with the asparagine amide side chain and the main chain of the valine residue on 
strand A (-CO---H-Asn53, 2.1Å, -CO---H-Val148, 2.2 Å). 
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Figure 5.11 Ligand L5A in the cavity of interest, Cav(V148) with a free binding energy of 
- 8.6 kcal/mol. Hydrogen bonds are depicted with a straight lines (blue), other interactions 
are depicted with orange-red dotted lines. 
It is interesting to compare the binding affinity between the ligands with the same highest-
ranking score; in one, the binding seems to be completely obtained through largely 
hydrophobic interaction, while the other binding is occurring mostly from hydrogen 
bonds. To achieve higher affinity, both, enthalpy and entropy, have to be favoured in the 
binding. The conformation of the ligands with the aliphatic chains (L6, L7, L8) in Table 
5.1 showed a lower binding affinity for both lead structures with a higher free binding 
energy in the range of  -7.5 kcal/mol to -7.3 kcal/mol. Ligand L8A has a lower binding 
energy of -7.5 kcal/mol contributed from one hydrogen bond to the asparagine amide side 
chain of strand F (-CO---H-Asn53.F, 2.1 Å) and 79 polar and non-polar contacts to the 
other amino acids in the cavity, (Figure 5.12, left). 
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Figure 5.12 Ligands of lead structure A in the cavity of interest, Cav(V148) with their free 
binding energies. Left: L8A (- 7.5 kcal/mol), Right: L6A (- 7.3 kcal/mol). 
In the binding conformation of L7 (Figure 5.13), hydrogen bonding from the oxygen of 
the carbonyl group as well as the ether group are directed to differently positioned amide 
side chains of the same asparagine on strand F. Therefore, it could be assumed that only 
one of these hydrogen bonds can possibly be formed. The angle of 3° and the length 
difference of 0.2 Å, respectively, are relatively small just to eliminate one of them. 
However, it can be concluded that the position of the ligand in the cavity is in proximity 
to the Asn53 with the possibility to form hydrogen bonds. Although, the number of 
hydrogen bonds in L7A is the same and additional 26 polar and non-polar contacts are 
observed compared to the L8A, there is no difference in the calculated binding energies 
of both ligands. 
The binding affinity of ligand L6A to the protein was estimated to have the highest free 
binding energy according to the AutoDock Vina. From the interaction with the amino 
acids in the cavity, ligand L7A has the most non-polar and most polar contacts compared 
to the other two ligands with the aliphatic functional groups.  If we add the hydrogen bond 
to the amide side chain of the asparagine of strand F (-CO---H-Asn53, 1.7Å) it is difficult 
to conclude on the better binding affinity among them. However, it can be observed that 
the space in the cavity is not completely occupied by any of the ligands with aliphatic 
groups (Figure 5.12 and Figure 5.13), and the enthalpic contributions to the binding can 
be improved. 
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Figure 5.13 Ligand L7A in the cavity of interest, Cav(V148) with a free binding energy of 
- 7.5 kcal/mol. 
From the analysis of the ligands shown in Table 5.1, it can be concluded that the aromatic 
functional groups are necessary for a high binding affinity to Cav(V148). Furthermore, 
the ranking among the best ligands with the lowest free binding energies can be based not 
only on enthalpic interactions, which mostly take hydrogen bonding into account, but also 
on entropic binding, as seen in the case of L5 and L3. Especially as Cav(V148) is 
hydrophobic at the inner core and more hydrophilic at the periphery. The flexibility of 
the ligands has to be considered carefully, especially if the space is not fully occupied, 
which could lead to greater discrepancies among the scored poses, and the accuracy of 
the docking is more likely to be compromised. Additionally, the positioning of the 
functional groups that influence the affinity by entropic and enthalpic binding is 
important, as can be seen from the docking of ligands L2 and L4. Moreover, ligand L1 is 
shown to be a good starting point for ligand optimization, considering that the in silico 
design is half the reality, in which a lot of important aspects are simplified that contribute 
to the real binding. 
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The previous paragraphs were focused on variation of the blue structural moiety (Scheme 
5.1). Additionally, molecular docking was also performed with functional group 
diversification on the biphenyl ring marked in green (Table 5.2) to be able to compare the 
influence of functional groups on the binding to Cav(V148). In the analysis of the ligand 
L10A (Figure 5.14), a certain contribution to the free binding energy (-8.4 kcal/mol) is 
obtained from hydrogen bonding of the hydroxyl group to the Val7 main chain (-OH---
H-Val7, 1.8Å) and another 120 interactions were identified within the cavity. L10A also 
shows a π-π stacking, but the black benzyl ring points inside the cavity, which results in 
a hydrogen bond to Val7. From the docking obtained for L10 it can be seen that the impact 
of the functional group on the binding to Cav(V148) is rather small, as it points outside 
the cavity in both lead structures. 
Table 5.2 Comparison of the ligands estimated free binding energies for lead structures A 
and B with diversification on biphenyl ring (green). 
ID  -ΔG (kcal/mol) 
 
 
  A B 
L1 
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Figure 5.14 Ligands L10 in the cavity of interest, Cav(V148) with their free binding energies 
of - 8.4 kcal/mol. Left: lead structure A; Right: lead structure B. 
If a CF3 group is placed in the para- position, as seen in L9, the free binding energy 
difference to L10 is still low, while it is more significant compared to L1. The interaction 
of the CF3 group in L9A is to the valine and asparagine residues of only one monomer of 
the protein. Moreover, the position of the core benzyl ring is pointed inside Cav(V148) 
and it is involved in π-π stacking with the aromatic ring with the CF3 group in para- 
position, which is positioned above the plane (Figure 5.15, left). In contrast, ligand L9B 
gives a lower free binding energy in molecular docking, and a better positioning of the 
ligand inside Cav(V148) with interactions to Val148 of both monomers of the protein and 
to Val7 and Asn53 on one monomer, with distances ranging from 2.3 Å to 3.5 Å. The 
difference is also visible in the arrangement of the core aromatic ring, which is now 
positioned toward the periphery of the cavity, (Figure 5.15, right). However, 
hydrophobicity of the CF3 results in burial into the hydrophobic interior, which leads to 
a decrease in binding energy. 
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Figure 5.15 Ligands L9 in the cavity of interest, Cav(V148). Left: L9A with free binding 
energy of - 8.3 kcal/mol; Right: L9B with free binding energy of - 8.8 kcal/mol. 
If a methyl group is placed in para- position of the aromatic ring, the ligand L11A in the 
most stable scoring pose has a free binding energy of -8.9 kcal/mol, potentially results 
from two additional hydrogen bonds to strand F of the protein, including the amide side 
chain of the asparagine and the carbonyl in the lysine main chain; (-CO---H-Asn53, 2.2 
Å), (-OH---O-Lys9, 2.2 Å). On the other hand, ligand L11B has a higher free binding 
energy, which could be explained by the lack of hydrogen bonding and other weak 
interactions with the cavity. However, the methyl group is still buried inside the cavity 
and forms interactions with non-polar amino acids, Figure 5.16. 
  
Figure 5.16 Ligands L11 in the cavity of interest, Cav(V148). Left: L11A with free binding 
energy of - 8.9 kcal/mol; Right: L11B with free binding energy of - 8.4 kcal/mol. 
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The free binding energy of L12A with a nitro group in para- position is similar to L12B 
with a difference of 0.2 kcal/mol. Additionally, both ligands form two hydrogen bonds 
with the protein, but L12B has fourteen additional interactions. However, if we compare 
their conformation in the cavity (Figure 5.17), it is clear that L12B (right) may occupy a 
more favourable position with the nitro group being buried in the cavity and forming 
hydrogen bonds to two strands of the protein: (-NO---H-Val7, 2.1 Å), (-NO---H-Asn53, 
2.4 Å). In contrast, the nitro group of L12A (left) is directed out of the cavity and reveals 
interactions with the Lys9 and Gly10 with an approximate distance in the range of 2.5 Å 
to 3.8 Å. 
  
Figure 5.17 Ligands L12 in Cav(V148) with polar and non-polar contacts < 3.8 Å (orange-
red dotted lines), and hydrogen bonding < 2.4Å (blue straigth lines). Left: L12A with free 
binding energy of - 8.8 kcal/mol; Right: L12B with free binding energy of - 8.6 kcal/mol. 
 
If we compare ligand L12A, Figure 5.17 (left) and L9A Figure 5.15 (left), it can be 
observed how the polar nitro- group is positioned at the periphery and the binding energy 
is 0.5 kcal/mol lower than the one of L9A. 
Some in silico studies were conducted upon indication of better binders after in vitro 
binding experiments, see Section 5.4. Improved binding affinity was confirmed for ligand 
L4A. Therefore, the blue building block was introduced first, and diversification with a 
nitro or a CF3 group was performed at the green building block especially due to their 
different position in molecular docking. (Table 5.3) 
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Table 5.3 Estimated free binding energies for putative ligands of lead structure A 
  
 
   
ID L4 L13 L14 
-ΔG (kcal/mol) 8.3 8.3 8.7 
The interaction of the methoxy groups of L14A is visible in Figure 5.18. The interaction 
with valine residues of both protein strands, and the nitro group in para- position results 
in hydrogen bonding to the amide side chain of Asn53. Interestingly, L13 positioned 
opposite with the CF3-group being buried inside the Cav(V148). 
 
Figure 5.18 Ligand L14A in Cav(V148) with the free binding energy of - 8.7 kcal/mol; 
orange-red dotted lines represent the interaction within the cavity, and hydrogen bonding 
between the nitro- group and Asp53.F is shown with blue straight line. 
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Figure 5.19 Ligand L13 in Cav(V148) with free binding energy of -8.3 kcal/mol. 
Furthermore, both ligands, L13 and L14, and their conformation in the cavity could be 
influenced by the restricted position and the interaction of the methoxy functional groups 
on the blue aromatic ring. This could also be compared with L9A (Figure 5.15) and L12A 
(Figure 5.17), which lack these substituents. 
From the in silico design and the molecular docking of different ligands we were able to 
confirm putative interactions within the cavity of interest. Also, different functional 
groups have impact on the binding, as seen in the comparison of aliphatic and aromatic 
moieties. This is consistent for both lead structures. The cavity of interest is hydrophobic 
and peripheral area hydrophilic. Due to the interactions with the presented ligands, the 
hydrophobic/hydrophilic interactions were matching the protein cavity. Furthermore, 
analysis of binding energies is not definite and does not have complete tolerance for each 
individual interaction. In reality, additional attractive and repulsive interactions between 
protein and ligands could easily be misinterpreted, if not all conformational changes are 
considered. To improve the affinity of the ligands for the hydrophobic cavity of our 
protein of interest, it would be strategically ideal to first prove the interaction and then 
design the functional group. We have observed much conformational flexibility during 
the scored poses with AutoDock Vina; however, it can be difficult to take the boundaries 
for flexibility into consideration. We have seen from already approved drugs, that it is 
necessary to lock them in the active conformation in order to enhance the interaction. One 
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example is diclofenac, which inhibits the enzyme cyclooxygenase more efficiently 
compared to ketoprofen because it is in a more preferred conformation.[122] From an 
example of other inhibitors by Llorens et.al. it can be seen, how the omitted halogens in 
the aromatic fenoprofen allow more flexibility and free rotation of an ether bond between 
two rings. Diclofenac restricts the flexibility with two chlorine atoms in ortho- positions 
on the aromatic ring.[123] Both inhibitors interact with the enzyme, but the fenoprofen 
affinity is lower, because more energy is required to reach the optimal conformation for 
the interaction. In our docking studies, most attention was given to the first scored poses, 
but also to the other poses with the lowest RMSD difference compared to the first zero 
value. However, restricting flexibility without any confirmation of the real binding would 
be immature, as the other enthalpy-entropy compensation cannot be fully encountered in 
the simulation, and we would need biophysical studies to examine possible interactions 
in the cavity, and ideally a structural validation. 
The major limitations in computational docking are correlated with molecular 
conformation sampling and scoring functions, especially, because the flexibility of the 
target is mostly excluded, which can cause inaccurate pose prediction. Additionally, the 
solvent might be of great importance for ligand binding. It could serve as a chaperone to 
allow hydrogen bonding between ligands and target or simply add an entropic effect in 
the binding site. Crystal structures can also have a big impact on the reliability of the 
modelled binding if differences in crystal packing are not considered properly.[124][89] 
Altogether, it is crucial to keep the drawbacks in mind that molecular docking is bearing, 
to overcome the obstacles and have reliable studies. Finally, a combination of different 
biophysical and structural studies should be obtained and verified to confirm the 
reliabilities of the docking studies. 
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 Synthesis 
In order to validate the in silico analysis and library design, ligands had to be synthesized. 
Therefore, a synthesis approach was proposed, and revised along the way. This section 
describes the retrosynthetic approach and the synthesis design of the lead structures (LS) 
as well as their synthesis and library development. From the schematic view of the lead 
structures (Figure 5.20) it is possible to subdivide them into a basic structural unit, which 
consists of a biphenyl unit shown in black and green, which carries either a secondary 
amine (structure B) or an amide (structure A) in ortho- position of the core phenyl ring. 
In lead structure C (LS C), a methylene group is bound in ortho- position to the core 
phenyl ring, while the amide bond originates from the third aromatic ring shown in blue. 
The final lead structures (LS) are connected to the fluorophore O-nitrobenzoxadiazole. 
The advantage of the presented structures is the possibility of a modular synthesis 
approach, which facilitates the variation of functional groups and library enlargement.  
 
Figure 5.20 Lead structures A, B and C. The four basic structural units are shown in 
green, black, blue and red colour. 
5.2.1 Modular synthesis approach 
Predicting and planning synthetic pathways is a key step for a synthetic chemist, yet in 
medicinal chemistry and drug development, the task could be even more challenging. To 
optimize a non-binding ligand to a drug, sometimes only one functional group needs to 
be varied. Therefore, a modular approach should be considered and implemented in the 
early stages of synthesis planning. A possible modular synthesis of lead structures A 
(LS A) and (LS B) is shown in Scheme 5.2. The building block O-nitrobenzoxadiazole 
shown in red represents the previously mentioned fluorogenic dye for the labelling of 
lysine residues, and will be attached in a last synthesis step by C-O bond formation c. 
Furthermore, the ligand scaffold branches into three main building blocks as described 
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earlier and could be synthesized by amide bond formation or a nucleophilic substitution 
reaction marked in b, and the biphenyl ring can be obtained in a C-C coupling reaction a.  
 
Scheme 5.2 Modular synthesis strategy of the lead structures. Left: LS A; Right: LS B. 
5.2.2 Retrosynthetic approach of lead structure A 
The retrosynthesis of lead structure A focuses on the synthesis of ligand structure 10 
(Scheme 5.3), which will be tested as potential ligand for hSOD1. Later, the ligand 
structure 10 could be combined with the NBD fluorophore in a nucleophilic substitution 
reaction [125], followed by the deprotection of the protecting groups (PG) of structure 11 
in the final step. Tetrahydropyran ether as PG group can be easily removed under mildly 
acidic conditions.[126] It is important to choose appropriate PGs, as this could be a critical 
reaction step. Ideally, the removal of the PGs should be performed in one step. For the 
synthesis of ligand 10, an amide bond formation on structure 7 with a protected 
synthesized or a commercially available acid 8 and a further deprotection step will be 
employed. Aniline 7 can be obtained by reducing a nitro group in ortho- position on the 
biphenyl system 6, which can be obtained by Negishi or Suzuki coupling.[127] This leaves 
us with three structures that are either commercially available, as in 3-iodo-4-nitrophenol 
(1), 4-bromophenol (3), and boronic acids (5), or could be functionalized and synthesized 
from aryl halides. 
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Scheme 5.3 Retrosynthetic route of lead structure A. 
5.2.2.1 Synthesis development toward the ligands A 
From the retrosynthetic analysis of lead structure A, the synthesis was divided into three 
building blocks (2, 7 and 8), which will be combined to the final structure. The core 
building block 3-iodo-4-nitrophenol (1) was initially obtained by electrophilic aromatic 
substitution from 3-iodo phenol (0) with nitric acid as a nitro source in acetic acid, as well 
as by reaction of 0 with sodium nitrite and sulfuric acid.[128][129] The product 1 was 
obtained in 37-40% yield under both reaction conditions. The moderate yield is the result 
of the unspecific nitration of 3-iodophenol in o-, and p- positions, as well as the 
difficulties of separating the ortho- product from the other substituted compounds. 
However, the product could be obtained, and further protecting groups were deployed. It 
is important to notice that the PG on structure 2 had to be orthogonal to the other PGs of 
the building blocks, to allow selective deprotection prior to the nucleophilic substitution 
with the NBD fluorophore. Furthermore, it should be stable to the basic conditions that 
were required in the next synthesis steps. As shown in Scheme 5.4, the tert-
butyldisopropylsilyloxy group was used to protect 1, as a relatively stable and robust 
protecting group toward acidic and basic conditions.[130] Although the yield of 93% was 
obtained after purification by column chromatography, NMR analysis confirmed only 
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~50% of product 2, that was purified portionwise by HPLC. The protection with TBDPS 
was not always straightforward, and the yield of the pure substance was only ~50%, 
which was due to the electron poor character of 1. 
 
Scheme 5.4 Reaction scheme of compound 2. a) HNO3, HOAc, rt; b) NEt3, TPDPSCl, 
CH2Cl2. 
For the synthesis of the biphenyl structure in compound 6, it was necessary to first 
synthesize the aryl halide, which could be further converted into the tert-butyl Grignard 
for a Negishi cross coupling or into a boronic acid for a Suzuki coupling.[131][132] Scheme 
5.5 shows the protection reaction a of 4-bromophenol (3) with tert-butyl bromide in 
pyridine to obtain compound 4, which was further used in reactions b and d to obtain the 
reactant 5 for the Suzuki coupling, and b for Negishi. 
 
Scheme 5.5 Protection of aryl halides as a precursor in Negishi and Suzuki coupling a) t-
BuBr, pyridine; b) Mg, LiCl, THF; d) triethlylborate, HCl. 
Tert-butyl bromide in pyridine was used in the reaction a to obtain 4 in 49% yield. The 
unreacted 4-bromophenol was recovered by distillation. The intermediate compound 12 
was prepared by a Grignard reaction in b with LiCl and Mg in anhydrous THF, which 
was further used with triethyl borate and hydrochloric acid to convert it into the boronic 
acid 5. However, only a low yield of 23% was obtained. The Negishi coupling c was tried 
with ZnCl2, Pd(dba)2 as an air stable Pd complex and Grignard intermediate 12, yet the 
reaction was not successful. There could be several reasons involved, the bulky protecting 
5 Results and Discussion 
56 
group TBDPS or the nitro group as a very deactivating and m- directing substituent, as 
well as the effect of nitro group to form an indole in a Bartoli reaction.[133] The Suzuki 
coupling of compounds 5 and 2 with tetrakis(triphenylphosphine) palladium as a catalyst, 
and barium hydroxide in aqueous dioxane gave coupling products without tert-butyl and 
TBDPS groups as well as tert-butyl diphenyl silanol as detected by mass spectrometry. 
However, the main product was not observed, and no further purification of the resulting 
mixture was continued. Therefore, a step backwards was taken and a Suzuki coupling 
without protecting groups on any of the reactants was performed, as shown in Scheme 
5.6. Here, the commercially available reactants 3-iodo-4-nitrophenol and phenylboronic 
acid were used applying the same reaction conditions as previously tested. The product 
was isolated successfully but with a low yield of only 20%. 
 
Scheme 5.6 Suzuki coupling of compound 21. a) Ba(OH)2 (2.8 eq), Pd(PPh3)4, dioxane/H2O. 
In this exploration phase of the coupling reaction and the formation of C-C bonds, we 
decided to optimize the Suzuki reaction. Some advantages include a high functional group 
tolerance, nontoxic conditions, and commercial reactant availability, among others.[132] 
Schmidt and Riemer investigated different phenols and phenol boronic acids for coupling 
with Pd/C in water.[134] They also showed potassium carbonate to be a very good base for 
the coupling with varying equivalents of the reactants under different conditions. The 
conditions from different approaches were adapted to our system.[135][136] We introduced 
potassium carbonate as a base with tetrakis(triphenylphosphine) palladium as a catalyst 
in a methanol/water mixture and added tetrabutylammonium iodide as an additive. It has 
been reported that the reaction of aryl bromide is facilitated, while the reaction with aryl 
iodides has no positive effect on the completion of the reaction with palladium acetate as 
a catalyst.[135] In the planned coupling reaction shown in Scheme 5.7 the biphenyl 
structures 18 and 19 were obtained in 60-90% yield with different functional groups in 
para- position. The coupling with aryl iodide and aryl boronic acid bearing an electron-
withdrawing group led to a moderate yield of 60% and required prolonged reaction time, 
while with a moderate electron-donating group on the aryl boronic acid gave a yield of 
90% and the reaction was completed after six hours at reflux. 
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Scheme 5.7 Suzuki coupling of 3-iodo-4-nitrophenol and aryl boronic acids to corresponding 
biphenyls 18 and 19. 
On the retrosynthetic route of the lead structure A, the biphenyl amine structure 7 was 
required for an amide bond formation reaction and the synthesis of ligand 10. As the 
amine functionality was planned to be obtained from the reduction of the nitro group, an 
initial test reaction was performed to optimize this step. Therefore, 3-phenylphenol was 
converted into 21. The reaction proceeded in acetic acid with an overall yield of 81%, 
with the compound of interest 21 being obtained in 41% while o- and p- positions were 
substituted in 14% and 26%.[137] Furthermore, the protection of the hydroxyl group was 
carried out prior to the reduction of the nitro group, since this could easily be 
deprotonated. Subsequent esterification with propionic acid [138] was obtained without 
difficulty in 85% yield, followed by the reduction in 62% yield using Pd/C and H2 
(Scheme 5.8). 
 
Scheme 5.8 Synthesis toward the biphenyl amine 23: a) HNO3, HOAc, 0°C → rt.; b) C3H6O2, 
EDC-HCl, DMAP; c) Pd/C, H2.  
For the amide coupling with the amine biphenyl derivatives 4, acids were synthesized that 
had benzyl or tetrahydropyran ether as protection groups in p- position. Initially, a benzyl 
protection was applied because of the benzyl protected hydroxyl group on the aryl boronic 
acid to ensure simultaneous deprotection in the last step after the ether synthesis. 
However, this was not compatible with the reduction of the nitro group. Therefore, the 
tetrahydropyran group was used for hydroxyl protection, with the advantage of an easy 
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removal under acidic conditions. In general, the synthesis of the acids is shown in Scheme 
5.9.[139] 
 
Scheme 5.9 Synthesis of protected acid derivatives 5: a) 24, R1,C7H7Br, KOH, NaI, EtOH; 
b) i) 25, C5H8O, p-TsO
-py+ CH2Cl2, ii) LiOH, THF/MeOH/H2O. 
Following the retrosynthetic approach of the lead structure A toward the ligand 
derivatives 10, the amide reactions between biphenyl amine derivatives and protected 
acids are shown in Scheme 5.10. Reaction a with oxalyl chloride was performed with the 
reactant 23 with benzyl protected acid, where the product 28 was obtained in 40% yield. 
A slight increase in yield was observed in reaction b with EDC-Cl and HOBt. 
 
Scheme 5.10 Synthesis of ligand derivatives 10 via amide bond formation a) i)Cl2O2, DCM, 
cat. DMF; ii)23 (1.0 eq), K2CO3, toluene; b) EDC.HCl, HOBt, DCM 
In our case we pursued with reaction b, which showed improved yield and a lower toxicity 
compared to oxalyl chloride. However, the yield can be optimised and conditions can be 
improved. Although amide bond formation is a well-established method, the poor 
reactivity of the aniline and the bulkiness of the protecting group (PG) made this step 
problematic.[140][141][142] For instance, using TIPS instead of propionic ester as PG 
supressed the reaction more or less completely (data not shown). Further steps in the 
synthesis toward the lead structure were the hydrolysis of ester group, the NBD group 
attachment in m- position of the main phenyl ring, and, in the last step, the removal of the 
protecting groups. 
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Scheme 5.11 Synthesis toward the compounds 34, L1, 35 and lead structures 36, 38. a) KOH, 
MeOH; b) Pd/C, H2; c) NBD-Cl, Et3N, MeCN d) PPTS, MeOH. 
The hydrolysis a proceeded smoothly in methanol and potassium hydroxide as a base in 
99% yield. In the hydrogenation b, the benzyl groups were removed with palladium on 
charcoal and hydrogen under atmospheric pressure to obtain L1 in quantitative yields. 
Ligand 34 with a benzyl group underwent further reaction with NBD-Cl to form lead 
structure A in 73% yield while maintaining the benzyl protection. Here, our attempt to 
remove the protecting group by hydrogenation was successful, but it also resulted in 
reduction of the nitro group in NBD. It was therefore necessary to rethink the protecting 
group strategy. The attachment of the NBD on the ligand bearing a CF3 group and the 
further removal of the THP in the last step went well with 62% overall yield of the lead 
structure 38. 
The following Scheme 5.12 shows the complete synthesis of lead structure A with 
diversification of the functional groups in para- position of the biphenyl ring. In reaction 
a, Suzuki cross coupling was performed, and the product was obtained in 60-90% yield, 
depending on the functional group on the aryl boronic acid. Furthermore, the 
esterification of the phenol b proceeded smoothly in 92-95% yield, for both, the electron-
withdrawing group, CF3 and the electron-donating group benzylether. In the 
hydrogenation c, the reduction of the nitro group went well, but difficulties were 
encountered with the benzyl deprotection which reduced the yield to 40%. The amide 
bond formation d with different protected hydroxyl group was successful, but only in 
moderate yields of 55-60% and relatively long reaction times of up to two days. The 
hydrolysis reaction e with potassium hydroxide as a base, and the removal of the 
protection group under acidic conditions g were quantitative for all ligands. The ether 
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synthesis in reaction f on the aromatic phenol was successful and gave moderate yields 
(50-75%).  
 
Scheme 5.12 Synthesis toward the lead structures A: a) Pd(PPh3)4, TBAI, K2CO3, 
MeOH/H2O; b) EDC-HCl, DMAP, CH2Cl2 c) Pd/C, H2, EtOH/EtOAc; d) EDC-HCl, HOBt, 
CH2Cl2; e) KOH, MeOH; f) NBD-Cl, Et3N, MeCN; g) PPTS, MeOH. 
5.2.3 Retrosynthesis and synthesis of lead structure B 
As already shown in Figure 5.20, a major difference between lead structures A and B is 
the methylene bridge, which for lead structure B is between the secondary amine and a 
carbonyl group, and, hence, requires a different retrosynthetic approach (Scheme 5.13).
 
Scheme 5.13 Retrosynthesis approach of the lead structure B. 
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The key step in the synthesis of lead structure B (LS B1) is the nucleophilic substitution 
of the aniline 7 and the haloalkane 40 after the Suzuki coupling. The rest of the synthesis 
is similar to LS A. Therefore, the nucleophilic substitution toward the secondary amine 
41 is discussed only. 
The first approach toward 40 was the α-bromination of 4-hydroxy acetophenone with 
pyridinium tribromide as the bromine source in acetic acid; however, only a dibrominated 
product was obtained. Following different attempts with copper (II) bromide and 
previously tert-butyl protected 4-hydroxyacetophenone, mono- and dibrominated 
products in 79% yield were obtained, but the isolation was not straightforward, as the 
purification via flash column chromatography was not possible, and isolation by HPLC 
was not an efficient option, too.  
 
Scheme 5.14 Synthesis of compound 40 for the nucleophilic substitution reaction. 
To avoid costly purification procedures between mono- and dibrominated products, 
commercially available 2-bromo-4-hydroxy acetophenone was protected as 
tetrahydropyranyl ether group in 60% yield,[143] (Scheme 5.15). 
 
Scheme 5.15 Synthesis of compound 43. 
The key reaction of this synthesis strategy toward lead structure B is nucleophilic 
substitution to obtain the lead structure for further testing. Some initial tests were 
performed evaluating nucleophilic substitution conditions, in which potassium carbonate 
and triethyl amine were used as a base in various solvents and varying temperatures. 
However, no conversion was observed. 
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Scheme 5.16 Attempted nucleophilic substitution reaction toward compound 44. 
Another approach to the secondary amine was applied through 4-nitrobenzensulfonyl 
chloride, which was reacted with a primary amine in pyridine as basic solvent. The mono- 
substituted sulfonamide 46 was obtained in 58% yield. The secondary amine was planned 
to be obtained from alkylation of the sulfonamide 46 and subsequent cleavage of p-nitro 
phenylsulfonic acid in 47 via Meisenheimer complex.[144] However, the alkylation step b 
was not successful. (Scheme 5.17). 
 
Scheme 5.17 Attempt toward secondary amine synthesis: a) pyridine, DCM ∆T; b) K2CO3, 
MeCN. 
Further synthesis approaches were not tested because the idea was to compare the best 
ligands from proposed, designed and modelled ligands. The aim of this work was not only 
to synthesise the ligands, but to test their function and to establish a binding affinity assay. 
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Therefore, at this point, the focus was laid on the further development of the lead structure 
A. 
5.2.4 Retrosynthesis and synthesis of lead structure C 
The difference of this lead structure compared to the two previously described structures 
is the position of the amide bond in the molecule. As it can be seen in the Scheme 5.18, 
an amide bond is formed from a primary amine attached to the aromatic building block 
51 in blue and the acid on the 3-bromophenol as the core building block 50 shown in 
black. The flexibility of the molecule is slightly changed, because the biphenyl has no 
restraint from the amide bond and can rotate freely on the C-C bond of the methylene 
group and the carbonyl carbon. Therefore, to obtain the structure 52 an amide bond 
formation was envisaged on compound 51 with a previously synthesized or commercially 
obtained building block 50. In the following step, the lead structure was planned to be 
synthesized by a Suzuki coupling with the commercially obtained or modified boronic 
acid 5. The lead structure was further optimized for a coupling to fluorophore 9 to obtain 
the final structure for fluorescent dye transfer, as well as for the binding affinity tests, for 
which the protecting groups on the molecule had to be removed. This synthetic strategy 
was pursued by V. Theuer during her bachelor thesis.[145] 
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Scheme 5.18 Retrosynthesis of the lead structure C. 
The acid of the core building block was obtained in two steps according to a literature-
known procedure.[146] In the nucleophilic reaction step with sodium hydroxide and 
glyoxylic acid, the product was isolated in 63% yield. Furthermore, the acid 50 was 
obtained upon reduction with tin chloride and gave a yield of 67%, (Scheme 5.19). 
 
Scheme 5.19 Synthesis of compound 50.[146] 
Prior to the formation of the amide bond with commercially available benzyloxy aniline, 
protection of the phenolic OH-group with tert-butyldimethylsilyl chloride was necessary 
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in order to avoid side reactions in the following step. In the first step of the amide bond 
synthesis, oxalyl chloride was used to prepare the corresponding acyl chloride, which was 
then reacted further with 4-benzyloxylaniline to obtain the product 52 in 70% yield. 
 
Scheme 5.20 Synthesis of compound 52: a) TBSCl (1.5 eq), Et3N (2.0 eq), THF; b) C2Cl2O2 
(1.5 eq), DMF cat., dioxane; c) 4(benzyloxyl)anilin (1.2 eq), K2CO3 (4 eq), dioxane.[145] 
Prior to the next critical step, the Suzuki coupling, the TBS protecting group was 
removed, the Suzuki product 54 was obtained in a 79% yield as shown in the Scheme 
5.21.  
In the next step, compound 53 was reduced with palladium on charcoal and lead structure 
C was obtained in 98%. The introduction of the fluorophore in 54 was not performed, as 
the ligand was first submitted to binding affinity tests. 
 
 
Scheme 5.21 Synthesis of compound 54: a) TBAF(3.0 eq), THF, rt;b) Pd(PPh3)4 (10 mol%), 
K2CO3 (4.5 eq), (4-(trifluromethyl)phenyl)boronic acid (1.5 eq), 24h, MeOH/H2O; c) Pd/C, 
H2.[145] 
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5.2.5 Improved synthesis strategy A for a library enlargement  
In the previously established synthesis, some problems and disadvantages were 
encountered from the protecting group strategy, purification steps and expensive starting 
material. It was also observed that one way around the steric hindrance of the PG in the 
amide bond formation could be to change the reaction sequence to perform the Suzuki 
coupling reaction after the amide bond formation. Furthermore, this strategy made it 
possible to introduce various functional groups and building blocks on the core aromatic 
ring and, hence, simplified a library enlargement. In addition, we were able to start from 
inexpensive compounds. The following synthesis route shows, how we can reach the 
main starting point in just 2 to 3 synthesis steps and, from there, decide, which building 
block we want to vary. This gives us more options for a faster library synthesis. 
 
Scheme 5.22 Synthesis toward core scaffold for improving synthesis strategy: a) Pd/C, H2, 
(2.5 bar), EtOH/EtOAc, 3.5h;b) NBS, DCM, rt; c) CBzCl, pyridine, EtOAc, rt. 
The first hydrogenation step from commercially available 55 to 4-aminophenyl benzoate 
went smoothly in 95% yield. The reduction was also carried out with tin (II) chloride, but 
the basic work up led to the cleavage of the benzoate, and to a moderate yield of only 
50% compared to the reaction with palladium on charcoal and hydrogen. In the next step, 
bromination with N-bromosuccinimide (NBS) was performed, which resulted in 80% 
yield. Since double bromination was confirmed by mass spectrometry, this could be 
avoided by adding the NBS in portions, in order to give a better yield. From this 
compound it was possible to proceed with the amide bond formation or with the Suzuki 
coupling. Before Suzuki coupling, an amine protecting group had to be introduced to 
restrain its basic and nucleophilic properties, as initial Suzuki trials with unprotected 
amine showed no product formation.  
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It was assumed that the reactivity of bromine is reduced compared to iodine for the Suzuki 
coupling. However, this could have resulted in prolonged reaction times, but less likely 
in no product formation after days of reaction monitoring. The reaction with benzyl 
chloroformate in pyridine c was obtained in 87% yield.  
Blaise et al. [147] reported the successful regioselective Suzuki coupling on very 
electrophilic chloropyridazines with different solvents under microwave irradiation. 
Furthermore, other research groups reported that dimethoxyethane had a reductive effect 
on palladium.[148][149] In view of this, the Suzuki coupling was tested under slightly 
different conditions under microwave irradiation and we were able to obtain our biaryl 
products in yields of 70 - 90 % with reaction times of 10 min. Furthermore, the reactions 
were also successful under reflux, by increasing the reaction times to eight hours. 
(Scheme 5.23). 
 
Scheme 5.23 Synthesis of biaryl structure 60 in Suzuki coupling. a) Pd(PPh3)4 (5 mol%), 
Na2CO3 (2.0 eq), DME/H2O, 110 °C, 10 min, µw/∆T, 8h. 
Due to the basic conditions of the Suzuki coupling the benzoate group was partially 
saponicated. Therefore, reprotection was required. In summary, the biphenyl core can be 
synthesized in three steps of which two are PG insertion and removal. In the first step a 
conversion with tetrahydropyran aryl boronic acid via Suzuki coupling to the biphenyl 
products was performed in a total yield of 90 %. In the second step b, the obtained 
hydrolysed biphenyl products were reacted with 2-fold excess of benzoic acid in a 
Steglich esterification. EDC.HCl was used because of its water soluble by-products in the 
workup process.[150] The benzyl alcohol protected ester was obtained in 83% yield. In the 
final step c, the carbamate protecting group was removed in a hydrogenation reaction in 
94% yield. Overall, a total yield of 82% was obtained in the synthesis of biphenyl 62 
(Scheme 5.24). 
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Scheme 5.24 Synthesis toward biphenyl amine a) R-B(OH)2, Pd(PPh3)4, (5 mol%), Na2CO3, 
DME/H2O; b) EDC.HCl (1.1 eq), DMAP (0.1 eq), DCM; c) Pd/C, H2, EtOH/EtOAc. 
The, ligands previously described in terms of in silico studies were synthesized via amide 
coupling. In the general Scheme 5.25, derivatisation of the ligands with different 
commercially available acids was obtained with some slight variations on the solvent 
system and the equivalents of the activation agents. The acid derivatisation is shown in 
Table 5.4. 
 
Scheme 5.25 Synthesis by amide bond formation; entry 1-7, Table 5.4. 
In entry 1, biphenyl amine 62 and 3,5-dimetoxyphenylacetic acid were reacted in toluene 
as a solvent with a higher boiling point than dichloromethane to shorten the reaction time 
compared to dichloromethane and chloroform. Here, the reaction was refluxed for 6 h and 
stirred at room temperature for an additional 12 h and the product 63 was obtained in 85% 
yield. The reaction with 2,5-dimetoyphenylacetic acid in entry 2 was performed under 
reflux for a total of 24 h and the product 64 was obtained in 76% yield. In entry 3, reaction 
with 2-methylphenoxy acetic acid in chloroform the product was obtained after 22 h in 
80% yield. The same reaction in DMF led to the deprotection of the THP protected 
phenol. With 1-thymine acetic acid, entry 4, reaction gave no conversion after two days 
under reflux in toluene. In another attempt with DMF, the reaction was performed at 
160 °C for 6 h until no more starting material was observed. Mass analysis confirmed the 
reactants and the products in which the protecting groups were completely or partially 
cleaved. The reason could be the excess of acid and high temperature, which is beneficial 
for tetrahydropyran removal, however, the benzoate group is usually removed under basic 
conditions, but under high temperature and low pH it could be more labile. Therefore, the 
yield of final ligand 67 was only 30% after column chromatography followed by HPLC, 
but it was sufficient for subsequent biophysical studies. Further synthesis with nucleic-
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acid-like structures should be done under less acidic conditions, more monitoring and 
temperature-controlled conditions. In reaction with aliphatic acids, entry 5, 6 and 7, 
reactions were performed in chloroform and resulted in high yields for isobutyric acid, 
entry 6, and isovaleric acid 5; however, with much longer reaction times compared to the 
aromatic acids. Reaction with metoxyacetic acid (entry 7) in DMF resulted in complete 
cleavage of the protecting groups, and compound 70 was obtained in 50% yield, while 
partial cleaving of benzoate group was obtained in 30% yield.  
Table 5.4 Acid derivatisation via amide bond formation. (Entries 2, 3, 5, and 6 were made 
by R. Keller during his bachelor thesis).[151] 
Entry 1 2 3 4 5 6 7 
Acid 
(R) 






toluene toluene CHCl3 DMF CHCl3 CHCl3 DMF 
Time 18 h 27h 12h 72h 36h 40h 12h 
Yield 85% 76% 80% 30% 93% 83% 50% 
Product 63 64 65 67 68 69 70 
 
In the synthesis of lead structures with variation on the biphenyl unit, amide bond reaction 
was performed prior to Suzuki coupling (Scheme 5.26). 
Starting from ligand 57 the amide bond reaction succeeded under conditions similar to 
those discussed above. A slightly reduced yield of 57% was observed with 2,5-
dimetoxyphenylacetic acid, as can be seen from Scheme 5.26. Here, the order of reactions 
has been changed, and in o- position we have weekly deactivating bromine, which might 
reduce the reactivity of 57. In the second step b, Suzuki coupling was performed under 
the conditions described above. Here, the amount of acid was reduced to 1.1 eq in order 
to reduce unreacted boronic acid and to ease the workup process. 
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Scheme 5.26 Synthesis of 72 and 73: a) 2,5-dimetoxyphenyl acetic acid (2.0 eq), EDC-HCl 
(3.0 eq), HOBt (0.3 eq), CHCl3; b) R-B(OH)2 (1.1 eq), Pd(PPh3)4 (5 mol%) Na2CO3 (2.0 eq), 
DME/H2O. 
The final steps of the ligand synthesis required removal of protected groups. As shown in 
the following scheme in the first step, the benzoate group was removed under basic 
conditions using potassium carbonate in methanol and the reactions were terminated after 
3 h at room temperature. In case of insoluble reactants, it was heated to 60 °C.  
 
Scheme 5.27 Final synthesis steps toward the ligands. 
In the next step, the acidic removal of the tetrahydropyran ether under acidic conditions 
with 1 mM aq. hydrochloric acid was also straight forward and the reactions were 
quantitative. The reaction order was switched for the ligands 77 and 75, however the 
reason for the lower yield might be use of too high concentrated hydrochloric acid (6 M) 
which resulted in 20% of hydrolysed amide. The Figure 5.21 shows the synthesized 
library of ligands from lead structure A. 
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Figure 5.21 Ligands library of the lead structure A. 
 
Different approaches toward the lead structures using a modular synthesis strategy were 
shown in the previous sections. In the early stages of the synthetic approach to lead 
structure A, problems with the formation of the C-C bond arose. The attempts by Negishi 
and Suzuki coupling reactions did not result in the desired biphenyl structure. One of the 
problems was the reproducibility of the Grignard formation. Furthermore, the bulky silyl 
protecting groups hindered the reaction. We changed the strategy to protect functional 
groups using the benzyl protecting group, yet it was not the ideal group due to the further 
reduction reactions. To overcome that problem the benzoate and tetrahydropyranyl ether 
protecting groups were used for hydroxyl protection. 
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The early synthesis towards lead structure B was hampered by unsuccessful formation of 
the secondary amine positioned ortho to sp2-sp2 carbon bond of the biaryl. With an 
improved synthetic approach towards lead structure A more modularity was introduced, 
which paved the way for an easier library synthesis and enlargement. The synthesized 
ligands have diverse functional groups with electron donating and withdrawing character, 
which influenced the synthesis of the ligand and is differently reflected the synthesis 
reaction time and the overall yield. Furthermore, fine-tuning and synthesis optimization 
was not the only goal of this thesis, and as the synthesis was revised along the way, more 
attention could be paid to its improvement in the later stage upon confirmation of the 
protein-ligand interactions.  
5.2.6 Proof of concept - NBD transfer reaction 
As mentioned earlier, the goal of the fluorophore moiety was to label the protein on the 
lysine residue in the proximity of the cavity of interest. With the improved synthesis A 
ligand LS A was obtained and tested in a model system shown in Scheme 5.28. 
 
Scheme 5.28 Proof of concept reaction, mediating fluorescence on the lysine residue in a 
model system; a) DIPEA (5.0 eq), DMSO, 25 °C, 2h. 
The main advantage of this process is that the O-NBD moiety does not exhibit 
fluorescence but upon binding to the lysine residue fluorescence emission is observed, as 
described earlier in Section 5.1.  
In the model system, reaction of the nucleophilic lysine with the O-NBD moiety gives 
compound 85 after 2 h reaction time at 25 °C while L1 is simultaneously released. This 
reaction was monitored by HPLC, Figure 5.22. Compound 85, at 450 nm, is observed 
with a retention time (tR) of 18.5 min, while L1 was confirmed at 14.5 min and 280 nm. 
LS A has (tR) of 24.5 min, and it is visible that there is no absorbance at 450 nm.  
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Figure 5.22 HPLC chromatograms of LS A (100 µM) with 85 (100 µM) in DMSO, as a 
proof of concept reaction after 2h incubation at 25 °C, (analytical C-18; 20 → 100% 
MeCN in 35 min); full chromatogram (see Figure 9.15). 
The general proof of concept was successful. The reaction monitoring showed product 
formation after 2 h at 25 °C, for which, analytical C-18 column with a gradient of 20% to 
100% MeCN in 35 min was used. With the model system, we confirmed that the basic 
principle of fluorogenic labelling should work, and further fluorescence studies on SOD1 
proteins should be conducted. However, it would be beneficial first to confirm the affinity 
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 Biophysical and Protein studies 
Protein studies and biophysical investigation were performed in close collaboration with 
Lisa-Marie Funk in the group of Prof. Dr. Kai Tittmann. 
5.3.1 Expression and purification of the hSOD1 proteins 
In the present work, the expression and purification protocol from the group of Prof. 
Hasnain were optimized to obtain a respectable amount of the active protein, hSOD1 wt 
and the A4V variant. The pET303C-hSOD1wt plasmid was expressed in E. coli BL21 
Star™ (DE3) controlled by IPTG induced T7 expression. For the analysis of the 
expression, samples were taken hourly, and cell growth was followed by optical density 
at wavelength of 600 nm, (Figure 9.1). The cells were harvested after 20 h of incubation, 
see Figure 5.23 and yielded in ~32 g cells from 6 L culture, which is 5.28 g/L. 
 
Figure 5.23 Expression of the hSOD1wt protein from the pET303C-hSOD1wt plasmid 
(SDS-PAGE, 15%). -/+ IPTG: before and after induction with 0.4 mM IPTG, respectively. 
Subsequently, the cell pellets were disrupted and purified as described in Section 7.2.2.2. 
For purification fractions samples were taken and analysed on a 15% SDS-gel (Figure 
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supernatant, whereas the loss of the insoluble protein in the pellet is very small. 
Furthermore, it can be observed that the largest amount of the purified protein is obtained 
in the elution step with a high purity. 
 
Figure 5.24 Purification of the hSOD1wt (SDS-PAGE 15%). S and P: supernatant and pellet 
fractions after cell disruption. Load, Elution: fractions of the TMAE chromatography. 
From gel electrophoresis, it can be observed that the amount of protein in the loading step 
is considerably small. In the early elution steps, slight impurities with a molecular weight 
of 40 and 60 kDa can be observed; however, at this point such impurities were negligible, 
especially, as most of the protein eluted in the later steps was pure. The protein was 
purified yielding ~60 mg protein per 1 g cell pellet. Following reconstitution of the 
cofactors (Cu and Zn), as explained in Section 7.2.2.5, fully reconstituted protein was 
obtained with a homogeneity yielding 17-20 mg hSOD1 wt protein per 1 g cells. 
The expression and purification of the hSOD1A4V variant was performed similar to the 
wildtype protein. We confirmed the instability of the variant before the cofactor 
exchange, which led to a higher aggregation and, additionally, to a 15% lower yield of 
the purified variant in comparison to the hSOD1wt. One of the reasons might be a reduced 
affinity for Zn, which is shown in A4V to be almost 30-fold decreased compared to the 
wt protein.[152] Compared to previous research throughout the years, the expression of the 
protein in different systems and the purification protocol have changed and were required 
to be adapted, but the expression and purification yield of the SOD1 proteins is still 
comparable.[153][154] Recently, the group showed periplasmic expression of SOD1 proteins 
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5.3.2 Activity analysis of hSOD1wt and A4V proteins 
The activity analysis of the purified proteins was carried out according to Section 7.2.2.6, 
in which the activity of the protein was determined by inhibition of the reduction reaction, 
which was measured spectrophotometrically by absorbance depletion of the WST-1 
dye.[156] The principle of the assay is based on an indirect measurement of the SOD1 
activity. As shown in Scheme 5.29, xanthine and xanthine oxidase generate superoxide 
radicals, which are oxidized upon reaction with 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-
(2,4-disulfophenyl)-2H-tetrazolium monosodium salt, also known as water soluble 
tetrazolium salt (WST-1), producing WST-1 formazan as yellow dye. The SOD1 activity 
is measured by the inhibition of the reduction reaction, where absorbance depletion of the 
WST-1 formazan dye is determined spectrophotometrically at 440 nm. [157] 
 
Scheme 5.29 Schematic view of the activity assay 
 
We confirmed the activity of the fully reconstituted protein, as well as the reduced activity 
of the protein with only zinc as a cofactor, which was comparable to the control of bovine 
SOD1, Figure 5.25. Although impaired activity of hSOD1 in zinc deficient cells was 
observed by 50%, it was confirmed that only a 10-fold higher zinc concentration 
compared to the copper concentration is required to achieve a specific activity.[158] Yet, it 
was shown much earlier with the bovine SOD1 that stoichiometric zinc increases the 
possibility of folding and has an effect on the structure, while copper is essential for the 
activity of the protein.[45][159] 
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Figure 5.25 Activity assay of hSOD1 wt protein with both cofactors (Cu, Zn), and Zn only.  
We have also investigated the influence of DMSO on the activity of the hSOD1 proteins 
as one of the important co-solvents used to increase the solubility of small molecules and 
drugs for hydrophobic macromolecules. 
From the results obtained and shown in Figure 5.26 a reduced reaction inhibition was 
confirmed, which indicates a lower activity for both, apo and holo wt proteins with 20% 
DMSO in 50 mM sodium phosphate (SP) buffer. The reaction inhibition was reduced by 
almost 50% as compared to the activity obtained without co-solvent, which is shown in 
blue on the left. The decrease in the activity of the apo proteins compared to the holo 
under the same conditions was less than 10%. The activity of the A4V apo and holo 
protein was similar in buffer and with 20% DMSO. However, the lower activity of the 
A4V apo variant compared to the holo is more pronounced; approximately 40% of the 
activity was lost under the same conditions (shown in red on the right side of Figure 5.26). 
When comparing the A4V variant and the wt protein in buffer, the activity of the holo 
and apo variants is 30 to 40% less than for the wt proteins, respectively. However, this 
effect is different in DMSO; the activity of holo A4V is approximately 18% less 
compared to holo wt, while the apo A4V variant kept its activity decrease compared to 
the wt holo protein of around 40%. Furthermore, it must be stated that the concentration 
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because the activity of the A4V variant at a concentration of 0.02 µg/mL was so low that 
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 apo - hSOD1 A4V (0.2 µg/mL) 
 holo - hSOD1 A4V (0.2 µg/mL) 
 
Figure 5.26 Activity of the hSOD1 proteins shown as reaction inhibition in 50 mM sodium 
phosphate buffer, pH 7.4 with 20% DMSO, and buffer with 0% DMSO. Left: hSOD1 wt 
holo and apo proteins with 0.02 µg/mL concentration; Right: hSOD1 A4V holo and apo 
proteins at a concentration of 0.2 µg/mL (experiments performed with F. Otto) 
The data confirmed a higher DMSO influence on the activity of the wt protein, yet this 
effect was less pronounced in the mutant. Moreover, it was still acceptable to use DMSO 
for the ligand solubility, since the wt activity, with its higher 10-fold concentration, was 
only impaired to a range of the mutant’s normal activity. Furthermore, we have confirmed 
the influence of DMSO on the protein stability in different buffers. In experiments with 
proteins in 100 mM hepes buffer, 150 mM NaCl, pH 7.4 as well as with aforementioned 
50 mM sodium phosphate buffer without DMSO, there was no significant difference 
(data not shown), whereas for the wt and A4V proteins with DMSO, impairment observed 
in sodium phosphate (SP) buffer was approximately only 5 to 10%, respectively (Figure 
5.27). 






















 holo - hSOD1 wt (0.02 µg/mL)
 holo - hSOD1 A4V (0.2 µg/mL)
 
Figure 5.27 Activity of the hSOD1 proteins shown as reaction inhibition with 20% DMSO 
in 100 mM hepes buffer, 150 mM NaCl, pH 7.4 and 50 mM sodium phosphate (SP) buffer, 
pH 7.4  
The influence of DMSO on the enzymatic activity of the hSOD1 proteins was rather 
negligible when the concentration was taken into account. Besides, it is known that 
decreased enzymatic activity of the SOD1 proteins is not a direct cause for ALS but can 
alter the disease.[6] Moreover it is also reported that the influence of DMSO on enzymatic 
activity does not always correlate with the binding affinity and protein misfolding. Even 
amounts less than 5% lead to a change in the stability and unfolding in bacterial NAD+ 
synthetase.[160] There is not much literature reported on the influence of DMSO on SOD1 
proteins, which is usually used as a co-solvent in various in vitro experiments. However, 
the efficiency of polyphenol, resveratrol, dissolved in 25% DMSO was tested onto 
mutated mice intraperitoneal, to see the effect on motor neuron loss, and no negative 
effect on DMSO concentration was reported.[161] However, in the native-MS experiment, 
it was shown that a low percentage of 0 to 1% DMSO can stabilize the SOD1 apo proteins, 
while with higher concentration the effect is destructive.[162] Overall, the effect of DMSO 
on the SOD1 proteins should be considered individually according to the experiments 
conducted.  
Initially, multiangle light scattering (MALS) experiment was performed for hSOD1 
protein size confirmation, and a tight dimer (~28 kDa) was confirmed, Figure 5.28. 

















































Figure 5.28 Confirmation of hSOD1wt protein by MALS experiment 
Afterwards, prior to binding studies, proteins were also analysed by size exclusion 
chromatography (SEC), as explained in Section 7.2.2.7. It was also in agreement with 
initial MALS data, as shown in Figure 5.29. 
 
Figure 5.29 Size exclusion chromtography: hSOD1 wt 5 mg/mL (orange), Biorad-
Standard (blue) 
 
We confirmed an impaired stability of the A4V variant and its high propensity for 
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A4V apo protein at lower concentrations and after 48 h incubation at 37 °C. Furthermore, 
the A4V apo monomer-dimer equilibrium was not distinguishable as the protein 
aggregated towards a 100 kDa species Figure 5.30 (bottom). This was consistent with 
literature data on the A4V aggregation potential and the wt stability.[52,69] 
 
Figure 5.30 SEC studies after 48 h incubation at 37 °C. Top: hSOD1 wt; Bottom: hSOD1 
A4V; holo and apo proteins showed in blue and orange, respectively. (Experiments 
performed with F. Otto during her bachelor thesis)  
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 Binding affinity assays and aggregation studies 
Determination of the binding affinity is a very important approach in drug design and 
development. It indicates an interaction between the identified hit molecules and the 
protein. To ensure a better understanding of the ligand-protein interaction and its 
characteristics, and to confirm whether there are any interactions at all, the binding 
affinity of ligands was measured. Therefore, different approaches were examined and 
developed to answer questions about the ligand affinity and the aggregation processes 
with hSOD1 proteins. 
5.4.1 Microscale Thermophoresis (MST) 
As described in Section 4.3, an MST assay was used to confirm the interaction of 
synthesized ligands with the hSOD1 protein. In various publications, binding studies of 
the reported compounds with hSOD1 proteins were omitted, whereas they obtained 
crystal structures with the compounds.[56][69] Recently, Manjula and Sruthi showed ligand 
interactions with the hSOD1 Trp32 site using MST.[86] In our approach, we wanted to 
confirm the interactions of the ligands we have designed with the hSOD1 protein, and 
continue with structural investigations. Initial experiments involved labelling of the 
protein with different fluorophores that are suitable for the channel set-up of the 
instrument. The early tests were performed on a label-free instruments, in which 
fluorescence was detected intrinsically from the tryptophan amino acids of hSOD1. This 
approach was dismissed, because of the interfering autofluorescence of the ligands. For 
the measurements on the instrument with pico-red channel, Atto647N dye was initially 
tried due to the strong absorption, the high fluorescence efficiency and the 
photostability.[163] The protein was preferably labelled on a lysine residue via an NHS 
ester instead of a cysteine residue via maleimide. The latter is not an option because the 
available cysteine residues (Cys111) are at the dimer interface and the dye attachment 
could also induce protein misfolding, and aggregation, which was also confirmed in our 
MST experiment (Figure 9.8). Furthermore, it was not applicable in a parallel project in 
the group that is focused on Cav(C111). Ultimately, labelling the lysine residues was a 
lower risk, as hSOD1 has in total twenty-two lysine residues, eleven per monomer, and 
the possibility to attach the dye on both lysine residues in our cavity of interest was only 
~10%. 
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Experiments with Atto647 cysteine labelled hSOD1 showed strong aggregation of the 
target, as expected, even in the absence of the ligands. In this case, an MST optimized 
buffer was used (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM MgCl2, 0.05% Tween-
20). Additional optimization by adjusting the buffer conditions and the detergent 
concentrations did not help with the aggregation problems. Ligands were tested in the 
same setup to determine the influence and behaviour with the protein. However, 
aggregates were detected in most of the capillaries (Figure 9.8). Labelling with Atto647N 
via an NHS ester on a lysine residue prevented immediate aggregation of the target 
protein, which confirmed the hypothesis with the cysteine residues. However, some 
difficulties were still obtained, such as the low fluorescence intensity of the target, and 
reduced but still significant aggregation. Furthermore, ligands showed autofluorescence. 
Attempting to make use of the ligand autofluorescence and titrate the protein instead of 
the ligand was not an option, as the fluorescence intensity of the ligands was too low for 
a valid assay. 
An increase in the concentration of one of the fluorescent targets was limited by the low 
solubility of the ligands in aqueous buffer. In the case of an increase in the target protein 
concentration, it was required to enhance the ligand concentration as well, since 
otherwise, the binding curve would not reach saturation. Even with the highest possible 
concentration of DMSO that the protein could tolerate (25%), ligand concentration was 
not sufficient to achieve high fluorescence intensity. Therefore, the labelling strategy was 
changed and a labelling kit with a red NHS ester dye was used by applying a slightly 
modified protocol as described in Section 7.2.4.2. Then the influence of the dye on the 
misfolding and aggregation of the labelled protein by separating the monomer and dimer 
using size exclusion chromatography was excluded (Section 7.2.2.7). In addition, we 
confirmed that the enzymatic activity was not reduced, (Figure 9.6). The next steps in 
assay development included validation of the labelled protein, its adequate fluorescence, 
stability, and buffer optimization. In Figure 5.31, a difference in fluorescence intensity 
can be observed for each individual labelled protein batch at the same or different 
concentrations. Batch 3, with a concentration of 5 nM was comparable to batch 2 with 
the same MST power. Here, the fluorescence was consistent, except the largest 
discrepancy for batch 1, as shown in green. To avoid such effects, a minimum of three 
independent measurements was conducted for each binding experiment. 
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Figure 5.31 Raw fluorescence signal from different batches of hSOD1wt protein labelled 
with red NHS ester labelling kit. 
Another point in assay development was to confirm and exclude protein aggregation. As 
can be seen from the thermophoretic trace of the labelled protein, no aggregation was 
observed (Figure 5.32). 
 
Figure 5.32 Thermophoretic traces of NHS ester labelled hSODwt protein batches. 
Buffers also play a crucial role in biophysical studies[164][165], and can influence the 
stability and assay performance. In view of the stability of the hSOD1 protein in the 
cellular and cytosolic environment, different buffers were tested for in vitro assays and 
some of them were excluded. As previously shown, SOD1 proteins were active in both, 
the HEPES and sodium phosphate buffers, the latter one being used for the MST binding 
assays, as it performed well in the initial screening phase with the ligand. 
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The initial testing of the assay was approached with a single test screening in which only 
the highest concentration of ligands was titrated with a labelled protein, incubated for 15 
to 30 min, and measured. However, this method was not reliable as many possible ligands 
were omitted, mostly because their highest concentration was not sufficient to reach 
saturation. When full titration experiments were carried out, usually sixteen 
concentrations were measured. Best to our knowledge, a validation of the assay with a 
reference standard was not possible because not many binding assay studies were 
performed with hSOD1 proteins. Lately, some groups have reported that small molecules 
affect the oxidative effects on the SOD1 proteins[166][86], but there was no accessible 
standard available for testing.  
Our MST binding studies were largely established with ligand L1. At the beginning, we 
tested different incubation times, to confirm the optimal equilibrium time, shown in 
Figure 5.33. Here, the L1 with 10% DMSO in concentration ranged from 6.69 mM to 
0.204 µM while the concentration of the labelled protein target was kept constant at 5 nM. 
 
Figure 5.33 MST binding affinity data of ligand L1. Development of the assay through 
incubation time screening with the ligand and the protein. 
The difference in the obtained Kd values was mostly in the range of the error, 0.988 mM 
± 0.349 mM for 1 h incubation time (green), 1.77 mM ± 0.589 mM for 4 h (red) and 
1.31 mM ± 0.400 mM for 20 h incubation time (blue). However, the best Kd value with 
an incubation time of 1 h had the lowest signal-to-noise (S/N) ratio of 12.93 compared to 
17.08 and 16.51 for the incubation at 4 h and 20 h, respectively. Moreover, a similar range 
of S/N ratio was observed in the analysis with different MST-on time (up to 5 s). In our 
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analyses the MST-on time was kept at 1.5s to minimize the effect of a possible structural 
destabilization on the Kd values, (Figure 9.9). Therefore, it was concluded that the 
incubation time can range from 1h and 4h, and, in itself, is likely not to be a crucial 
parameter for the ligand binding affinity in the concentration range used. The error 
discrepancy between the individual replicates was still high, with the high DMSO 
concentration and the low ligand concentration being the most likely reasons. 
Unfortunately, the requirement of DMSO was the main issue in the assay due to the low 
solubility of the ligands without DMSO. A DMSO tolerance test was performed with the 
hSOD1 proteins and we observed a slightly impaired protein activity as shown earlier in 
Section 5.3.2. Even with DMSO, the hSOD1 wt was even more active compared to the 
variant. Quality tests and the influence of DMSO against the labelled protein target were 
done to exclude negative effects, i.e. fluorescence, adsorption, aggregation and 
photobleaching. The thermophoretic effect was observed in the titration experiment with 
0% to 20% DMSO, where we were able to confirm the importance of a constant 
concentration across the capillaries during the binding affinity measurements. When the 
concentration in our binding assay was kept constant, there was no DMSO influence on 
the binding affinity in comparison to the negative control measurements of DMSO and 
protein. (Figure 5.34). 
 
Figure 5.34 MST experiment without a ligand as a control measurement. Experiments 
performed in triplicates (E1-E3), titrated as 1:1 serial dilution with constant DMSO 
concentration (20%) in 50 mM sodium phosphate buffer and labelled hSOD1wt protein. 
 
On the one hand, DMSO did not have a detrimental effect on protein functionality and 
stability, and it was acceptable to use it for the benefit of the ligand solubility in the MST 
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assay. However, an influence on the fluorescence was observed, thus affecting the data 
quality, the discrepancy between individual replicates, which led to a high error and a 
large range of Kd confidence. 
In the literature, the influence of DMSO on a non-covalent protein ligand complex was 
reported, pointing to an increase of the Kd value of about an order of magnitude, which 
masked the real binding affinity of the complex.[167] Other studies suggested the effect of 
DMSO on the stability of the protein and apparent binding, yet with a contrasting effect 
upon concentration adjustment.[168][169][170] Recently, Zhao et al. showed the effect of 
aprotic solvents on the hSOD1 apo protein by native electrospray ionization–ion 
mobility–mass spectrometry (ESI‐IM‐MS). There, the influence of DMSO and DMF on 
the stabilization, unfolding and dissociation of apo SOD1 depends strongly on the 
percentage concentration of the added solvents. Up to 1% of the results indicate an 
increase in the apo SOD1 stability, while from 1 - 20% the effect is opposite.[162] This 
effect of DMSO was not confirmed in our MST assay, as the labelled protein was holo, 
which is structurally already more stable than apo protein.  
Furthermore, the binding affinity analysis of the synthesized ligands was assessed with 
the MST. However, to overcome the solubility problem, the DMSO percentage 
concentration had to be increased. As already discussed, it did not have a big impact on 
the protein stability, but rather on the data quality. For consistent analysis and comparison 
of the ligands, the reference ligand L1 was tested with 20% DMSO concentration. From 
the binding affinity curves of the ligand L1 with 10 and 20% DMSO shown in Figure 
5.35, we were not able to see any significant difference in the binding affinity. The ligand 
concentration for the dilution series of L1 with 20% DMSO ranged from 7.00 mM to 
0.214 µM, while the concentration of the target protein was kept constant at 25 nM, after 
an incubation time of 2h, measurements were performed using 10% excitation power and 
medium MST power (40%), shown in green. The MST-on time was 1.5s and the obtained 
Kd was 0.634 mM ± 0.235 mM, which is in the same range as previously described. A 
slight difference between the different percentage concentration of DMSO is observed in 
a lower S/N ratio (10.89) for ligand L1 with 20% DMSO (green). However, this had no 
influence on further analysis, as we could not confirm any drastic impact of DMSO on 
the binding affinity of the reference ligand and on the protein stability. Therefore, the 
ligand L1 was used as a reference for further binding affinity studies with the other 
ligands, after which we ranked the ligands with the best to worst binding affinity to the 
protein and their respective Kd values. 
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Figure 5.35 MST binding experiments of L1 to hSOD1wt labelled protein. Comparison of 
L1 with different DMSO concentration 20% (green) and 10% (red); error bars represented 
as the standard deviation of three individual replicates in each experiment. 
The MST assay was performed with ligands L9 and L10, in which the difference in their 
structure compared to L1 was in the functional groups in p- position of the biphenyl ring 
structures (Figure 5.21). For the ligand L9 with trifluoromethyl group, the measurement 
was not possible under the established conditions, because the solubility of the molecule 
was very poor, and when the concentration of DMSO was higher than 20%, the protein 
started to aggregate, and the concentration was low. Solubility of ligand L10 was obtained 
with 20% DMSO in 50 mM sodium phosphate buffer, pH 7.4, and the maximal ligand 
concentration obtained was in the range from 5.27 mM to 0.161 μM. Compared to L1, 
L10 had a higher S/N ratio (15.32) and an almost two times higher response amplitude, 
which resulted in better fitting of the binding affinity curve (Kd = 1.73 mM ± 0.71 mM), 
Figure 5.36. This indicated that L10 (red) has a weaker binding affinity than L1 (green) 
for hSOD1, yet is still in a very narrow range when the standard deviation of three 
individual replicates (represented in error bars) is taken into account. 
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Figure 5.36 MST binding experiment of ligand L10 (red) and comparison with the reference 
ligand L1 (green); Kd (L10) = 1.7 mM ± 0.7 mM; S/N 15.32; response amplitude: 6.24. 
Ligands previously elaborated with the aromatic moiety showed better predicted binding 
affinities by in silico simulations; this trend was also observed in the MST assays. Ligand 
L4 (Figure 5.37) shows a binding affinity with a dissociation constant of Kd = 315 µM ± 
115 µM, and with a slightly lower S/N ratio of 10.76 compared to L1. However, this S/N 
ratio is still higher than the validity limitation of the quality of the data. The Kd fit was 
not affected, whereas for ligand L2, the S/N ratio was just above the limit, and the fitted 
data obtained were very noisy. The standard deviation from triplicates was in the same 
range as the fitted Kd value (168 µM ± 146 µM). The most likely reason for this difference 
between the two ligands (L4 and L2) lies in a lower concentration of L2 in the binding 
experiment (1.0 mM – 0.032 µM), which is actually four times lower than for ligand L4, 
and saturation could not be reached. No aggregation was observed from the MST traces 
and the raw data, meaning there was not an influence on the affinity (Figure 9.10). 
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Figure 5.37 MST binding experiment of ligand L4. Binding curve obtained from three 
independent measurements; error bars calculated as their standard deviation; Compared 
to L1 ligand, Kd value of L4 is lower (315 µM ± 115 µM; S/N = 10.76). 
Ligands L13 and L14 are structurally very similar to L4, with the exception of the 
functional group in p- position of the biphenyl ring. Ligand L13 with a trifluoromethyl 
group in this position had a lower binding affinity according to the in silico data and a 
low solubility, as already confirmed with L9. Therefore, we continued the assay with L14 
and the nitro group in p- position. Figure 5.38 shows three independent binding affinity 
assays of L14 and labelled target protein. In all MST experiments, the concentration of 
the labelled protein was kept constant (5 nM or 25 nM), while the concentration of the 
ligand L14 was in the range from 0.50 mM to 15.3 nM. This ligand indicated an increased 
binding affinity toward hSOD1 compared to the other ligands with a binding constant of 
21.0 µM ± 7.4 µM, shown with the green curve, S/N ratio was 10.15 and response 
amplitude 3.66 which was still in the range of our reference ligand L1. (Error bars are 
represented as standard deviation from three independent measurements). The entire 
assay was repeated with different batches to confirm reproducibility. The concentration 
of the ligand could not be increased, due to its low solubility, nor high errors could be 
eliminated between individual measurements. The MST assay with L14 shown in brown 
had a worse S/N ratio than previously discussed, only 6.47, and a response amplitude of 
2.74, which explains the binding constant, where the confidence was half its value (Kd = 
14 µM ± 7 µM). In the binding affinity assay with the curve shown in blue, the binding 
constant for the ligand L14 was the highest (Kd = 108 µM ± 32 µM). However, in this 
assay we have obtained the best S/N ratio of 17.53 with a response amplitude of 3.85. 
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Figure 5.38 MST binding experiments of ligand L14 to different batches of the labelled 
hSOD1wt protein. Binding curves obtained from three independent measurements; error 
bars calculated as their standard deviation; obtained dissociation constants: Kd = 14 µM ± 
7 µM (green, batch-1), Kd = 108 µM ± 32 µM (blue, batch-2), Kd = 60.28 µM ± 36.51 µM 
(light brown, batch-3). 
 
From the MST assay with ligand L14 we could confirm a better binding than with 
reference ligand L1, which is also consistent with the theoretical in silico predictions. 
However, we cannot establish a definite binding constant among those obtained for ligand 
L14. It can only be concluded that the range lies between 20 and 100 µM, and further 
experiments and methods would be required to confirm whether this ligand really has 
such affinity toward the protein. In the experiment with ligand L3 with a concentration 
range of 1.00 mM – 30.50 nM a similar effect was observed. The difference in the binding 
constants obtained from different experiments varied between three to six times. For 
ligand L3 we also observed the influence of the incubation time, in which, after 24h 
incubation, with the same sample S/N ratio increased from 6.17 to 10.81, compared to 
2h, respectively increasing the Kd value to 108.69 µM ± 42.24 µM from previously 
obtained 60.28 µM ± 36.51 µM for a shorter incubation time. In another experiment from 
a different batch, the binding constant was in a higher range with a Kd of 380.89 µM ± 
206.29 µM, and S/N ratio of 12.65. (Figure 5.39) A comparison with the reference L1 
showed that the ligand L3 has a higher affinity for the hSOD1wt protein, and it is most 
likely in the range of the ligands L4 and L14. 
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Figure 5.39 Binding affinity curves of ligand L3 in MST experiments with different batches 
of the labelled protein; obtained dissociation constants: Kd = 60.28 µM ± 36.51 µM (light 
brown, batch-1), Kd = 380.89 µM ± 206.29 µM (green, batch-3). 
For ligand L5, which was also ranked the same as L3 from the predicted in silico studies, 
the binding constant was also in a similar range compared to the other ligands with the 
aromatic moiety. The concentration of ligand L5 was higher (10.00 mM – 0.305 µM) due 
to the better solubility under the assay conditions, but the error among individual 
experiment was still high as can be seen in Figure 5.40. The obtained dissociation constant 
(Kd = 555.56 µM ± 181.11 µM), was lower compared to the reference ligand L1, but the 
binding affinity was not significantly improved, yet we obtained the result that indicates 
the binding affinity of the ligand with a thymine-like moiety to the protein. 
 
Figure 5.40 Ligand L5 in the MST experiment with labelled hSDO1wt protein. 
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Ligands with aliphatic moieties, L6, L7 and L8 (Figure 5.21), generally showed lower 
binding affinities. By comparing L6 and L8, the latter indicated an almost three times 
lower binding constant in the assay with 10% DMSO. However, the S/N ratio was also 
lower. Taking that into account, the Kd obtained for the ligand L6 was more a 
representation of the true value. Furthermore, in the MST experiment with ligand L6 in 
20% DMSO, the concentration was increased to a range from 10 mM to 0.305 µM, which 
result in an better S/N ratio (31.99) and a more reliable dissociation constant, Kd = 2.7 mM 
± 0.5 mM; Figure 5.41. 
 
Figure 5.41 MST binding experiment of L6 to hSOD1wt protein and obtained binding 
constant (Kd = 2.70 mM ± 0.484 mM). 
In the experiment with ligand L7, the initial fluorescence signal was not constant, 
indicating a concentration dependent change, as shown in Figure 5.42. After  performing 
the SD-test, a specificity test, in which it is confirmed if the ligand induced fluorescence 
change is an artefact and the assay needs to be optimized or whether the increase was part 
of the binding affinity[171], it was confirmed that the ligand induces fluorescence upon 
binding (see Figure 9.12). Hence, the initial fluorescence was used to derive the binding 
constant. The initial fluorescence and binding affinity curve of ligand L7 are shown in 
Figure 5.42, with a fitted Kd of 4.7 mM, whereas the confidence of the fit was not 
applicable. The concentration of the ligand was in a range of 9.30 mM to 0.284 µM. This 
result supports and opens up additional questions regarding the labelled protein site, 
which may indicate a different location of L7 than in silico predictions. 
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Figure 5.42 MST experiment with ligand L7. Top: The initial raw fluorescence obtained as 
an concentration increase. Bottom: Binding affinity curve with dissociation constant 
(Kd = 4.7 mM) derived from values of the initial fluorescence. 
The binding curves of the most promising ligands are plotted with the reference ligand 
L1, (Figure 5.43). The concentration range varies due to the different ligand solubilities. 
However, the increase in the binding affinity for the proposed ligands can also be seen 
even with the errors of the experiment. This indicates that the initial in silico results were 
valid, and that our design approach was set in the right direction. We have confirmed that 
solubility of the ligands is very important, as a good ligand solubility eases the binding 
assay. In Table 5.5 the most promising ligands are ranked according to their averaged Kd 
values from the MST assay. 
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Figure 5.43 MST experiment, ligands with the best binding affinity toward the hSOD1wt 
protein. 
Table 5.5 The most promissing ligands and the averaged binding constants 
Ligands 
    
L14 L3 L4 L1 
conc. 
[mM] 
0.50 - 1.53e-05 1.00 - 3.05e-05 4.00 - 1.22e-04 7.00 - 2.14e-04 
Kd value 48 µM ±15 µM 182 µM ± 95µM 315 µM ± 115 µM 634 µM ± 235 µM 
S/N 11.38 9.07 10.71 10.89 
Response 
amplitude 
3.42 3.78 4.05 3.67 
 
As previously shown, one of the main problems in microscale thermophoresis is the large 
difference in the results consistency. During the measurements, individual repeats, 
obtained the same day and treated similarly showed different thermophoretic response. 
This was also confirmed for measurements repeated with different batches. On the one 
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hand, we might conclude that some ligands may need to be treated differently and 
optimizing the buffer system may not work for all ligands in the library. On the other 
hand, this poses a problem of comparability among them, and the ranking system 
according to their affinity for the protein cannot be established. Similar problems with 
data reproducibility and inconsistencies with aggregation prone proteins, were already 
reported in the literature, when small molecule interaction on α-synuclein protein was 
studied.[172] Moreover, we have also confirmed the influence of DMSO on the data 
quality. Removing this effect from the measurements could be beneficial for further 
investigation of binding affinities and reproducibility. Like any other biophysical method, 
MST has its advantages and disadvantages. With very small amounts required, it is an 
attractive method, for initial screening and development. With this method, we could 
confirm the binding of the designed ligands. However, in order to obtain more precise 
binding affinities and a better understanding of the investigated system, a combination 
with other methods is required to reach a final conclusion.  
5.4.2 Isothermal Titration Calorimetry (ITC)  
As described in Section 4.4, ITC is a well-established method for analysing binding 
affinities. Another incentive beside confirmation of the MST studies was to obtain 
thermodynamic information of the binding affinity of the ligands and the SOD1 proteins, 
and possibly to be able to evaluate the contribution of different functional groups. In 
addition, the correlation with the in silico design could open up the possibility of 
improving their affinity prior to structural studies. 
Early experimental investigation with reference ligand L1 indicated a binding to 
hSOD1wt, and the fitted binding constant was in the higher micromolar range (104 µM 
± 38.5 µM), as shown in Figure 5.44. At that point we have already observed problems 
of a high DMSO concentration in the control experiment during the titration of the ligand 
into the buffer, yet the effect was not that high, so it was possible to subtract it from the 
protein data, (Figure 9.7). 
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Figure 5.44 Binding affinity in 100 mM hepes buffer, 150 mM NaCl, pH 7.4 including 20% 
DMSO with L1 (8 mM) in syringe and hSOD1 wt (375 µM) concentration in cell (ITC 
experiments performed and evaluated by Lisa-Marie Funk) 
The following attempts to reproduce the data were not successful, as the effect of DMSO 
resulted in a higher signal in the control measurements. Further, experimental 
investigations to find suitable solvents with acceptable ligand solubility for the ITC assay 
confirmed that glycerol (GOL) was a good match. Figure 5.45 shows the high signal in 
the experiment with DMSO and the better baseline obtained with glycerol. 
 
Figure 5.45 Comparison of heat signal produced by titrating ligand L1 into buffer (100 mM 
hepes buffer, 150 mM NaCl, pH 7.4 ) with 20% DMSO (red)or glycerol (green)  
Furthermore, binding experiments with ligand L1 and glycerol as a co-solvent showed no 
binding. Rather, we have confirmed the importance of cell flushing before loading to 
avoid mismatch and reduce the background noise (data not shown). From the data shown 
in Figure 5.46, a higher endothermic signal is observed for the ligand in buffer (shown in 
red). One possibility why the binding with the ITC is undetectable could be the 
L1 in Buffer 20% DMSO 
L1 in Buffer 20% GOL 
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unfavourable desolvation upon binding to the cavity. This effect was confirmed in other 
studies on trypsin and resulted in complete loss of the binding affinity with benzamidines 
derivative.[173] Moreover, the challenge of the ITC binding assay with the SOD1 protein 
has already been recognized, even for soluble ligands that have been structurally 
confirmed to be bound to the Trp32 binding site it was not successful.[69] Recently, a 
group reported the binding affinity of quercitrin to A4V protein with a binding constant 
of ~34 µM, which was obtained from ITC assay measurement. However, prior to the 
assay, the concentration of the DMSO used for the solubility of the ligand was unclear.[166] 
 
Figure 5.46 ITC binding affinity assay; ligand L1 (5 mM) and hSOD1 wt (175 µM) with 
20% glycerol as a co-solvent in buffer M (100 mM hepes buffer, 150 mM NaCl, pH 7.4). 
At this point, further ligand tests in the ITC assay were stopped, mainly because of their 
low solubility even in glycerol, in which the highest concentration was still not sufficient 
to observe weak interactions.  
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5.4.3 Thermal shift assay 
The principle of this method is to determine protein stability by measuring the melting 
temperature of the protein upon thermal denaturation. It is based on the fluorescence 
signal of the SYPRO Orange stain, which is observed upon dye interaction with the 
hydrophobic regions of unfolded protein. To answer the question of ligand influence on 
the hSOD1 protein stability the following assay was conducted as described in Section 
7.2.4.1. 
Initial screening concentration range tests were performed on the hSOD1 holo enzymes. 
Enzymes were tested in the respective concentration range with and without addition of 
DMSO to obtain the protein concentration. The assay with ligands was performed with 
the A4V apo protein; however, high ligand interference with a dye hampered the real 
output, as can be seen from the fluorescence signal (Figure 5.47) even when the respective 
ligand controls were subtracted. Followed by calculation of the 1st and 2nd derivative 
melting temperatures of ligands were obtained in the temperature range of 31- 35°C. 









































Figure 5.47 Fluorescence intensities in thermal shift assay with ligands (1 mM) and hSOD1 
A4V apo protein (1 µM) with 20% DMSO in 50mM sodium phosphate buffer, pH 7.4. 
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Figure 5.48 Linear fit of the thermal shift data as 2nd derivative. 
Table 5.6 Melting temperature obtained from thermal shift assay. Ligand influnce on the 




   
 
L14 L7 L2 L4 L1 L3 
Tm 
(°C) 
32.55±0.12 32.55±0.12 32.55±0.06 32.56±0.10 32.60±0.23 32.70±0.24 
 
From the obtained results it can only be concluded that there might be slight tendency for 
ligand L3, as the difference of 0.03°C between A4V apo protein is the highest. However, 
this would not be enough to stabilize the protein, and more tests should be performed. 
5.4.4 Ligands influence on the SOD1 aggregation 
In order to confirm the influences of the ligands on aggregation processes, aggregation 
assays were conducted as described in Section 7.2.4.4  As already reported in the 
literature, mutations have strong influence on the protein aggregation.[51][61] We have 
confirmed earlier that the apo variant A4V is more unstable and easily prone to 
aggregation. Therefore, the influence of ligands on the apo A4V variant was tested. In the 
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aggregation assay, the A4V apo variant was tested with two different detection reagents, 
the ThT dye and commercially available PROTEOSTAT reagent dye in order to detect 
aggregated protein as amyloid fibrils. In this assay, dyes show an increase in fluorescence 
when bound to the aggregated fibrillar proteins. This structure has been reported as a 
cross-β spine quaternary structure.[174] 
Münch and Bertolotti previously showed the influence of low pH and high temperature 
on the aggregation of the A4V protein.[175] Here, the aggregation of the A4V apo protein 
incubated at different temperatures and times was also confirmed. The amount of 
aggregates was calculated from the aggregated reference IgG standard. Aggregation of 
the A4V protein was confirmed after 48h incubation at 0 °C in both assays, while the 
sensitivity of the PROTEOSTAT dye is approximately two times higher than that of the 
ThT dye at all incubation times. Interestingly, in the aggregation assay with the ThT dye 
less aggregates were detected after 48h incubation at 50 °C than after 24h, a possible 
reason is that the amount of fibrillar aggregates was reduced and not detected due to the 
lower sensitivity of the ThT dye. However, the purpose of the chosen assay setup was to 
confirm the aggregation of the A4V protein and capability of the ThT dye to detect 
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Figure 5.49 Aggregation assays with PROTESOTAT and ThT dye conducted in 50 mM 
sodium phosphate buffer, pH 7.4 with incubation times 24 to 48 h, at 0 °C and 50 °C, with 
20 µM final concentration of A4V apo protein. 
The aggregation assay with the ThT dye was used to determine the aggregation of the 
A4V variant in the presence of the ligands with the best binding affinities (Figure 5.43). 
In the assay, apo A4V protein (20 µM), ligands (1 mM) and the respective controls were 
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incubated in 50 mM sodium phosphate including 20% DMSO for 24h at 50 °C. As it was 
confirmed to be enough time to detect the aggregates. From the results obtained, a strong 
influence of DMSO on the aggregation of the A4V apo variant was observed, as shown 
in Figure 5.50. The amount of A4V aggregated with the addition of DMSO is 
approximately 5% less than hSOD1wt holo protein, which was used as a negative control. 
These results were also confirmed in the assay with the PROTEOSTAT dye, in which the 
amount of aggregates in the presence of DMSO was approximately 25% less than in the 
assay with buffer only, (Figure 9.13). However, it was important to establish the assay 
and obtain the same effect for both tested dyes, because it did not depend on the 
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Figure 5.50 Aggregation assay of hSOD1 proteins with ThT dye; conducted in Buffer 
(50 mM sodium phosphate buffer, pH 7.4) and in DMSO (Buffer + 20% DMSO) at 50 °C 
for 24 h, with a final protein concentration (20 µM). Aggregated and monomeric lysozyme 
was used as a positive and negative control, respectively. 
Additionally, from the data recorded for A4V incubated with the ligands in DMSO, the 
same amount of aggregates was detected with or without ligands (L4, L1 and L14). Yet, 
in the presence of ligand L3, effect on aggregation was different. We observed no 
difference to the A4V variant in buffer, (Figure 9.14). How does DMSO effect the 
aggregation and what really happens with the ligand L3, where this effect is completely 
diminished? It is known that DMSO can have different effects on proteins and can 
stabilize the enzymes by increasing their preferential hydration. Moreover, with thermal 
denaturation, it is unfavourable since more free energy is required for unfolding in a 
system with DMSO as co-solvent.[176][177] Besides, it has been reported that a decrease in 
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protein charge induced by a low concentration of DMSO has a stabilizing effect on 
protein unfolding for lysozyme and myoglobin.[169] This effect was indicated for apo 
SOD1 proteins, but the others showed that an increased concentration of DMSO promotes 
destabilization for the apo SOD1 dimer.[162] 
Different additives were tested in order to obtain a solvent that does not have an effect on 
the aggregation and in which the solubility of the ligands was no longer impaired. Figure 
5.51 shows the data for the aggregation of the apo A4V variant with different additives 
(20%). Again, a lower aggregation with DMSO was confirmed. Importantly we could 
observe that PEG additives did not have an effect on the aggregation as there was no 
significant difference compared with the A4V apo protein in buffer control.  
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Figure 5.51 Aggregation assay screen of hSOD1 proteins with various additives (20%) and 
their influence as co-solvents on aggregation. Samples with a final protein concentration 
20 µM were incubated for 24 h at 50°C in 50 mM sodium phosphate buffer pH 7.4, including 
20% of respective additive.  
In the following, the most promising ligands were tested according to their binding 
affinity, with 20% PEG550. From the data obtained and shown in Figure 5.52, it can be 
seen that the effect of the reference ligand on the aggregation is rather low. Statistically, 
there was no significant difference observed for the ligands L4, L1 and L14, whereas the 
effect on aggregation was confirmed for the ligand L3. If we correlate these results with 
the binding affinity data, we cannot observe an exact similar pattern. L3 had a binding 
constant in the lower µM range compared to the other ligands, L14 had by far the best 
binding constant ~50 µM but it also had the highest error so that the Kd varied from 20-
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100 µM. Moreover, L4 (~315 µM) also showed better binding than L1 (~640 µM), the 
tendency is visible here, but there is no significant difference to the control sample.  
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Figure 5.52 Ligands influence on the aggregation of the hSOD1 A4V apo protein. Assay 
conducted at 50 °C for 24 h with a final protein (20 µM) and ligands (1 mM) concentration 
in 50 mM sodium phosphate buffer, pH 7.4 and 20% PEG550. 
However, we could confirm an effect of the ligands on the aggregation of the A4V apo 
protein. Moreover, the binding affinity does not necessarily need to correlate with the 
aggregation studies, if ligands slow down aggregation by association with undetectable 
aggregates and prolonging time to form insoluble aggregates. Earlier it was shown that 
the aggregation morphology of apo SOD1 protein is kinetically dependent [178], which 
also means that the amount of fibrillar or amorphous aggregates is dependent on the first 
initiated pathway. Additional studies of the most promising ligands with the fluorophore 
attached could provide a clear picture on the aggregation phase and association with the 
ligands. 
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 X-ray crystallographic studies of hSOD1wt and ligands 
For a deeper understanding and confirmation of the real ligand binding site, various 
literature reported conditions were tested for X-ray crystallization; however, these could 
not be reproduced. [69,85] 
In order to find the crystallization conditions for hSOD1 proteins different approaches 
were applied, i.e., (manual screen, additive screen, and automated crystallization screen). 
The manual and additive screens did not give satisfying results; therefore, an automated 
screen was performed. The screen was carried out by Elham Paknia in the group of Prof. 
Holger Stark (Structural Dynamics) at Max Planck Institute for Biophysical Chemistry 
(MPI). For the automated screen, 1µL of the hSOD1wt protein (10 mg/mL) in 20 mM 
Tris buffer pH 8.0 was mixed with 1µL of the kits reservoir solutions on the 96-well plate 
(Intelli - Art Robbins Instruments LLC, Sunnyvale, CA, USA) using crystallization robot 
Crystal Gryphon LCP (Art Robbins Instruments LLC, Sunnyvale, CA, USA). Sitting-
drop diffusion method was used, and the crystallization screen was performed at 20 °C. 
Following, positive screen conditions which revealed bigger crystals, crystal were 
reproduced manually using the sitting and hanging drop vapour diffusion approach. In 
Figure 5.53 first crystals are shown in 0.2 M ammonium sulfate, 0.1 M MES buffer, 
pH 6.5, 20% PEG 8000 as one of the conditions obtained by the hanging-drop method, 
observed after three and ten days incubation time in a well with a precipitant solution of 
0.2 M ammonium sulfate, 0.1 M MES buffer, pH 6.5, 20% PEG 8000 and a final hSOD1 
concentration of 0.04 mg/mL. 
  
Figure 5.53 hSOD1 wt crystals obtained in 0.2 M ammonium sulfate, 0.1 M MES buffer, 
pH 6.5, 20% PEG 8000, after three (left) and ten (right) days. 
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Acquiring crystals itself is a challenging process as even a small change in pH, protein 
concentration, precipitant concentration, or temperature can shift the equilibrium, which 
is not ideal for supersaturation.[179] Furthermore, crystals must be stable and resistant to 
the solvents used in soaking experiments. Here we have also encountered problems with 
DMSO when looking for a good cryoprotectant solution that would not have to affect the 
impact on diffraction. Initially, the crystals burst and broke apart in less than 5s, yet after 
more optimized soaking conditions, we were able to increase the time to 4 min. 
Unfortunately, until now we have not yet been able to structurally confirm any ligands 
bound to the protein sites. One of the reasons could be a short soaking time, Manjula et. 
al. reported much longer ligand soaking time ranging from 3h to 20h.[85] Also, to be able 
to obtain structural information, a higher resolution would be ideal, as our crystals have 
so far been diffracted from 2.3 – 3.2 Å. The entire X-ray data processing, reduction, 
refinement evaluation and building of the hSOD1 model (Figure 5.54) was done by Lisa-
Marie Funk. 
 
Figure 5.54 Refined structure of the obtained crystal structure of hSOD1wt (Evaluation 
was done by Lisa-Marie Funk). 
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 SUMMARY AND OUTLOOK 
In this work, ligands with a binding affinity to hSOD1 and the potential to inhibit the 
aggregation of hSOD1 mutants in amyotrophic lateral sclerosis (ALS) were designed and 
synthesized. The lead ligands were designed after a computational structural investigation 
of the hSOD1 protein cavity Cav(V148) using molecular docking with AutoDock Vina. 
They exhibit two key units, the ligand scaffold unit, through which the stability of the 
protein and the affinity for the cavity was intended to be achieved, and the fluorophore 
unit, which would give a turn-on fluorescence response upon binding to the protein 
The development of the lead ligands required confirmation of the affinity of the ligand 
scaffold to the protein before the fluorophore unit was attached. Putative ligand binders 
were obtained by iterative in silico docking simulation studies. Ligand scaffolds were 
then ranked according to the highest score of the predicted binding energies and 
interactions within the cavity. Ligand L14 with the lowest binding energy is shown in 
Figure 6.1. 
Different synthesis strategies toward the three lead structures A, B and C were performed. 
While the synthesis was successful for two of them, further studies were pursued on the 
variation of lead structure A, which could then be studied in terms of their binding 
properties to hSOD1 and their potential to reduce hSOD1 aggregation. An improved 
modular synthesis strategy granted easier library enlargement. As shown in overall 
Scheme 6.1, it is possible to achieve the main amine compound in two steps, and further 
proceed with a Suzuki coupling or the amide bond reaction formation. The variation of 
the aromatic and aliphatic functional groups on the ligand scaffold enabled a higher 
binding affinity to the protein. A total of 13 ligands bearing H-bond donors and acceptors 
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were synthesized, keeping in mind the overall hydrophobicity required for the cavity, and 
the Lipinski rule[180] of tolerance, (Figure 5.21). 
 
Figure 6.1 Ligand L14 in Cav(V148) obtained from molecular docking with AutoDock 
Vina with an estimated free binding energy of -36.40 kJ/mol. 
 
Scheme 6.1 Modular synthesis approach of improved lead structure A for library 
enlargement. 
Furthermore, to be able to elucidate the affinity of the ligands, hSOD1 proteins were 
expressed and purified. This process already showed a difference between the wild-type 
and the A4V protein. While a high purity could be obtained for both proteins, instability 
of the A4V variant was noted prior to reconstitution with the cofactors, which resulted in 
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a 15% reduced yield of the variant. The instability of the apo variant, the lower activity 
and its prompt aggregation were also confirmed. In size exclusion chromatography 
experiments, the monomer-dimer equilibrium of the variant was not observed, rather high 
molecular weights aggregates indicated an unstable, readily aggregating protein. The 
protein activity assay confirmed a 30-40% lower activity for the apo A4V variant 
compared to the hSOD1wt. The influence of DMSO (20%) as a co-solvent, which was 
needed for further binding studies, was investigated, and the pronounced influence on the 
protein activity was higher for the wt protein than the A4V variant, when compared with 
the buffer controls. The overall influence of DMSO on the protein activity was found to 
be negligible.  
Furthermore, the influence of ligands on the protein was comprehensively studied and 
different assays were developed. It has been shown that various assays would be required 
for a decisive claim of the real binding constants. The development of the microscale 
thermophoresis (MST) assay enabled ligand binding affinity studies, but also indicated 
many pitfalls. The solubility of the ligands turned out to be a significant drawback in the 
assay studies. This was also reflected in the quality of the data and on the reproducibility 
of the binding constants. Yet, the binding affinity studies showed that the rational design 
and ligand scaffold variation were performed in the right direction. 
The obtained ligand binding affinities were also mostly in agreement with the in silico 
predicted ligand binders. However, small differences in the binding affinity energies of 
less than ~ 4 kJ/mol, among the putative ligand binders from in silico simulations cannot 
be decisively used for the ligand synthesis. Ligands with aliphatic groups in their scaffold, 
which were expected to be inferior binders, showed a putative binding affinity of 
~ 30 kJ/mol, while the others with more aromaticity had an increase in affinity for the 
protein of ~ 36 kJ/mol. However, with lower differences (33 kJ/mol - 35kJ/mol) among 
the ligands with an aromatic scaffold and differently positioned H-bond donors and 
acceptor groups, ligands could not precisely be ranked just from putative binding 
affinities. The most promising ligands are shown in Table 6.1.  
First, the ligand L1 was exhaustively studied with different incubation times and DMSO 
concentrations. It was previously elaborated that observed differences in DMSO 
concentration and incubation time had an insignificant influence on the binding constant. 
The best binding affinity was observed for ligands L14 and L3, while L6 performed worst. 
It can be noted that the signal to noise ratio (S/N), response amplitude, and binding 
constant of L6 is the highest and with the lowest error, which represents a good assay. 
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Here, however, the ligand concentration has to be considered; with low solubility of L14 
and L3, the highest concentration was 0.5 and 1.0 mM, respectively, and saturation could 
not be reached, which influenced the fit value. A comparison of the binding constants 
among the ligands L1, L3, L4, and L14 generally showed the tendency for a higher 
affinity, respectively, (Figure 5.43). 
Table 6.1 Ligands with their averaged binding constants obtained from the MST assay, 
and putative free energy obtained as the best score by in silico simulations. 
Ligands 
    
L14 L3 L4 L1 
conc. 
[mM] 
0.50 - 1.53e-05 1.00 - 3.05e-05 4.00 - 1.22e-04 7.00 - 2.14e-04 
Kd value 48 µM ±15 µM 182 µM ± 95µM 315 µM ± 115 µM 634 µM ± 235 µM 
S/N 11.38 9.07 10.71 10.89 
Response 
amplitude 
3.42 3.78 4.05 3.67 
- kJ/mol 36.40 35.98 34.72 33.47 
 
This was complementing the initial in silico putative binders, however, here it is only 
possible to say that these ligands show a binding affinity in the middle micromolar range. 
For a definite binding constant, an additional method like ITC is required, as it could be 
seen from the obtained dissociation binding constants of L3 and L14, which differed 
almost 6-fold just from a different batch measurement. However, these data confirmed 
that the designed ligands have an affinity for the protein and could be improved further 
by rational design.  
From the MST data, the best ligands were tested in an aggregation assay. The obtained 
results showed that L3 has the highest influence on the inhibition of aggregation of the 
apo hSOD1 A4V protein, while the other ligands do not have a significant influence.  
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Figure 6.2 Ligands influence on the aggregation of the hSOD1 A4V apo protein. Assay 
conducted at 50 °C for 24 h with a final protein (20 µM) and ligands (1 mM) concentration 
in 50 mM sodium phosphate buffer, pH 7.4 and 20% PEG550. 
The ligands designed in silico correlate well with the results obtained from the biophysical 
studies. Taken together, designed ligands showed the potential for further development.  
The ligand optimization could be beneficial, especially in terms of solubility. Additional 
attachment of a short PEG-linker could help to increase the solubility. Moreover, the main 
biphenyl ring can also be considered for introducing more overall polarity to the ligands. 
In the MST binding affinity studies, more additives could be tested to reduce the DMSO 
interference. Furthermore, fluorescence studies with the protein should be employed, that 
can be valuable for further aggregation analysis. 
Molecular dynamic studies could be employed to better understand the molecular 
interactions and the cavity. However, structural information from X-ray crystallography 
or NMR would be required in order to improve the understanding of the cavity of interest 
and respective ligands. 
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 EXPERIMENTAL SECTION  
In this chapter, applied methods and performed experiments to obtain previously 
mentioned results are described. It is mainly divided into two parts; biophysical protein 
studies that were done in close collaboration with Lisa-Marie Funk at Schwann-
Schleiden-Forschungszentrum für molekulare Enzymologie, University of Göttingen. The 
second part of the experimental section include synthesis and in silico design, conducted 
at the Center for Biostructural Imaging of Neurodegeneration of the University Medical 
Center Göttingen and the Institute of Organic and Biomolecular Chemistry of the Georg-
August University of Göttingen.   
 Materials 
For the simplicity purpose, the materials, chemicals and other commodities used to 
conduct experiments in the mentioned research groups will be listed together.  
i. Chemicals 
Item Supplier 
Acetic acid Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
Acetonitrile Fisher Scientific (Leicestershire, UK) 
Acrylamide Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
Agar AppliChem GmbH (Darmstadt, Germany) 
Agarose AppliChem GmbH (Darmstadt, Germany) 
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Ammonium sulfate AppliChem GmbH (Darmstadt, Germany) 
APS Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
Bromophenol blue, sodium salt AppliChem GmbH (Darmstadt, Germany) 
Bovine serum albumin (BSA) AppliChem GmbH (Darmstadt, Germany) 
Calcium chloride, hexahydrate  Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
Carbenicillin, disodium salt AppliChem GmbH (Darmstadt, Germany) 
Coomassie Brilliant Blue G250  AppliChem GmbH (Darmstadt, Germany) 
Copper (II) sulfate pentahydrate Sigma-Aldrich (Munich, Germany) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (Munich, Germany) 
Dimethyl sulfoxide (DMSO) ACROS Organics 
Dithiothreitol (DTT) AppliChem GmbH (Darmstadt, Germany) 
Ethanol (denatured) Frau Magerkuth Apotheke (Karlsruhe, Germany) 
Ethanol (purest) 
Nordhäuser Spirituosen GmbH (Nordhausen, 
Germany) 
Ethidium bromide Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
Ethylenediaminotetraacetic acid 
(EDTA) 
AppliChem GmbH (Darmstadt, Germany) 
Glycerol (anhydrous) AppliChem GmbH (Darmstadt, Germany) 
Guanidinium chloride AppliChem GmbH (Darmstadt, Germany) 
2-[4-(2-hydroxyethyl)piperazin-1-
yl] ethanesulfonic acid (HEPES) 
AppliChem GmbH (Darmstadt, Germany) 
Hydrochloric acid (37 %) Th. Geyer GmbH & CoKG (Renningen, Germany) 
IPTG Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
Kanamycin sulfate AppliChem GmbH (Darmstadt, Germany) 
Lithium sulfate monohydrate Thermo Fisher GmbH (Kandel, Germany) 
Magnesium chloride, hexahydrate Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
MES AppliChem GmbH (Darmstadt, Germany) 
b-Mercaptoethanol Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
Methanol Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 




AppliChem GmbH (Darmstadt, Germany) 
Polyethylene glycol (PEG) 400  Sigma-Aldrich (Munich, Germany) 
Polyethylene glycol (PEG) 550 Sigma-Aldrich (Munich, Germany) 
Polyethylene glycol (PEG) 3350 Hampton Research Corp, (CA, USA) 
Polyethylene glycol (PEG) 8000 Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
Polysorbat 20 (TWEEN-20) NanoTemper Technologies GmbH (Munich, Germany) 
di-Potassium hydrogen phosphate 
anhydrous p. A 
AppliChem GmbH (Darmstadt, Germany) 
Potassium di-hydrogen phosphate 
anhydrous 
AppliChem GmbH (Darmstadt, Germany) 
Potassium hydroxide AppliChem GmbH (Darmstadt, Germany) 
SYPRO® Orange protein stain BioRad Laboratories GmbH (Munich, Germany) 
Sodium chloride AppliChem GmbH (Darmstadt, Germany) 
Sodium citrate AppliChem GmbH (Darmstadt, Germany) 
Sodium dodecyl sulfate (SDS) AppliChem GmbH (Darmstadt, Germany) 
Sodium di-hydrogen phosphate AppliChem GmbH (Darmstadt, Germany) 
Sodium di-hydrogen phosphate Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
Sodium hydroxide AppliChem GmbH (Darmstadt, Germany) 




Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
2-Amino-2-hydroxymethyl-
propane-1,3-diol (Tris) 
AppliChem GmbH (Darmstadt, Germany) 
Tryptone Carl Roth GmbH & Co. KG (Karlsruhe, Germany) 
Zinc Sulfate Sigma-Aldrich (Munich, Germany) 
Yeast extract AppliChem GmbH (Darmstadt, Germany) 
 
Furthermore, all commercially obtained reagents used for synthetic purpose that are not 
listed were used as received without further purification if not stated otherwise. Reagents 
were supplied by Thermo Fisher GmbH (Kandel, Germany), Sigma-Aldrich (Munich, 
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Germany), ChemPur GmbH (Karlsruhe, Germany), Fluka GmbH (Ulm, Germany), J&K 
Scientific GmbH (Marbach, Germany), TCI Deutschland GmbH (Eschborn Taunus, 
Germany), Alfa Aesar and Merck (Darmstadt, Germany). Solvents used in the reactions 
were of analytical grade. Anhydrous solvents were from Acros Organics (Thermo Fisher 
Scientific brand), stored over molecular sieves under a nitrogen atmosphere and used 
without further purification. 
ii. Enzymes 
Item Supplier 
DNase I  AppliChem GmbH (Darmstadt, Germany) 
Lysozyme AppliChem GmbH (Darmstadt, Germany) 
Phusion polymerase 
Thermo Fisher Scientific (Braunschweig, 
Germany) 
 
iii. Bacterial strains 
Item Supplier 
E. coli-BL21 (DE3) Invitrogen TM (Karlsruhe, Germany) 
E. coli-BL21 Star™ (DE3) Invitrogen TM (Karlsruhe, Germany) 





provided by Prof. Samar Hasnain (University 
Liverpool) 
 
v. Kits and solutions 
Item Supplier 
dNTP mix (10 mM) 
Thermo Fisher Scientific (Braunschweig, 
Germany) 
NucleoSpin™ Plasmid Kit Macherey Nagel (Düren, Germany) 
NucleoSpin™ Gel and PCR 
Macherey Nagel (Düren, Germany) Clean-
Up Kit 
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Bradford reagent, 5x concentrate 
SERVA Electrophoresis GmbH (Heidelberg, 
Germany) 
Gel Filtration Standard  
Bio-Rad Laboratories GmbH (Munich, 
Germany) 
Pierce™ Unstained Protein MW Marker 
Thermo Fisher Scientific (Braunschweig, 
Germany) 
GeneRuler DNA Ladder Mix 0.5µg/µL 
Thermo Fisher Scientific (Braunschweig, 
Germany) 
6x DNA Loading Dye 
Thermo Fisher Scientific (Braunschweig, 
Germany) 
Monolith Protein Labeling Kit RED-NHS 
2nd Generation (MO-L011) 
NanoTemper Technologies GmbH (Munich, 
Germany) 
SOD Assay Kit (19160-1KT-F) 
Sigma-Aldrich Chemie GmbH (Munich, 
Germany) 
 
vi. Crystallization screens 
Item Supplier 
Additive Screen™ HR-418 Hampton Research Corp, (CA, USA) 
The AmSO4 Suite QIAGEN (Hilden, Germany) 
Classic Lite QIAGEN (Hilden, Germany) 
Classics QIAGEN (Hilden, Germany) 
Classic II QIAGEN (Hilden, Germany) 
Compass QIAGEN (Hilden, Germany) 
Index Hampton Research 
MBclass QIAGEN (Hilden, Germany) 
MBclassII QIAGEN (Hilden, Germany) 
PACT QIAGEN (Hilden, Germany) 
PEGs QIAGEN (Hilden, Germany) 
pHCLear QIAGEN (Hilden, Germany) 
Protein Complex QIAGEN (Hilden, Germany) 
Wizard Classic 1+2 Rigaku 
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vii. Commodities  
Item Supplier 
Cover plates, 18 mm (siliconized) Jena Bioscience GmbH, (Jena, Germany) 
Cryoloops (0.05 - 0.5 mm) Hampton Research Corp, (CA, USA) 
Crystallization plates, greased Hampton Research Corp, (CA, USA) 
Spin-X UF® 6, 20 mL (5 kDa – 50 kDa 
MWCO) 
Corning GmbH (Berlin, Germany) 
ZelluTrans/Roth® dialysis membrane (3.5 
kDa MWCO) 




LB medium LB agar plates 
Yeast extract 0.5% (w/v) Yeast extract 0.5% (w/v) 
Tryptone 1% (w/v) Tryptone 1% (w/v) 
NaCl 0.5% (w/v) NaCl 0.5% (w/v) 
  Agar 2% (w/v) 
 
7.1.1 Utilized Primers 
i. Mutagenesis primers 
Name Sequence 
hSOD1A4V Fwd 5’ – GCGACGAAGGTCGTGTGCGTG - 3’ 
hSOD1A4V Rev 5’ – CACGCACACGACCTTCGTCGC – 3’ 
hSOD1C6F Fwd 5’ – GACGAAGGCCGTGTTCGTGCTGAAGG – 3’ 
hSOD1C6F Rev 5’ - CCTTCAGCACGAACACGGCCTTCGTC - 3’ 
hSOD1D90A Fwd 5’ – CAATGTGACTGCTGCCAAAGATGGTGTGG – 3’ 
hSOD1D90A Rev 5’ – CCACACCATCTTTGGCAGCAGTCACATTG -3’ 
hSOD1G93C Fwd 5’ – CTGACAAAGATTGCGTGGCCGATGTGT – 3’ 
hSOD1G93C Rev 5’ – ACACATCGGCCACGCAATCTTTGTCAG – 3’ 
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ii. Sequencing primers 
T7 promotor 5’ – TAATACGACTCACTATAGGG – 3’ 
T7 terminator 5’ – AGCTAGTTATTGCTCAGCGG – 3’ 
 
7.1.2 Devices 
i. Cell cultivation and disruption 
Item Supplier 
Biofermenter, Biostat C Sartorius AG (Göttingen, Germany) 
Incubation shaker, Unitron Infors AG (Bottmingen, Switzerland) 
Microfluidizer, M-110S Microfluidics (Newton, MA, USA) 
Multifuge 1S-R Thermo Scientific 
 
ii. Centrifuges and rotors 
Item Supplier 
Avanti™ HP-30I Beckmann Coulter GmbH (Krefeld, Germany) 
Rotor JA-10 Beckmann Coulter GmbH (Krefeld, Germany) 
Rotor JA-30.50 Ti Beckmann Coulter GmbH (Krefeld, Germany) 
Avanti™ J-20XPI Beckmann Coulter GmbH (Krefeld, Germany) 
Rotor JLA-8.1000 Beckman Coulter GmbH (Krefeld, Germany) 
Centrifuge tubes Beckman Coulter GmbH (Krefeld, Germany) 
Eppendorf 5810R Eppendorf AG (Wesseling-Berzdorf, Germany) 
Rotor A-4-81 Eppendorf AG (Wesseling-Berzdorf, Germany) 
Mikro 200 Hettich GmbH & Co. KG (Tuttlingen, Germany) 
Rotor 2424 B Hettich GmbH & Co. KG (Tuttlingen, Germany) 
OptimaTM L-90K Ultracentrifuge Beckman Coulter GmbH (Krefeld, Germany) 
Rotor SW40 Ti  Beckman Coulter GmbH (Krefeld, Germany) 
Rotor SW60 class GH Beckman Coulter GmbH (Krefeld, Germany) 
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Universal 320R Hettich GmbH & Co. KG (Tuttlingen, Germany) 
Rotor 1420 A/B Hettich GmbH & Co. KG (Tuttlingen, Germany) 
Rotor 1617 A Hettich GmbH & Co. KG (Tuttlingen, Germany) 
Rotor 1620 A Hettich GmbH & Co. KG (Tuttlingen, Germany) 
 
iii. Liquid chromatography 
Item Supplier 
ÄKTAprime plus GE Healthcare Europe (Munich, Germany) 
ÄKTApurifier  GE Healthcare Europe (Munich, Germany) 
HiPrep™ 26/10 desalting (50 mL) GE Healthcare Europe (Munich, Germany) 
HiTrap™ 26/10 desalting (5 mL) GE Healthcare Europe (Munich, Germany) 
Superdex™ 200 HiLoad™ 16/60 GE Healthcare Europe (Munich, Germany) 
Fractogel® EMD TMAE 650 (S) Merck KGaA (Darmstadt, Germany) 
Superdex™ 75 10/300 GL GE Healthcare Europe (Munich, Germany) 
Superdex™ 200 10/300 GL GE Healthcare Europe (Munich, Germany) 
Superdex® 200 Increase 10/300 GL GE Healthcare Europe (Munich, Germany) 




AV401 NMR spectrometer Bruker, USA 
Avance III 300 Bruker, USA 
Avance III HD 500 Bruker, USA 
Fluoromax 4 spectrofluorometer HORIBA Europe GmbH, Oberursel 
NanoDropOne Thermo Scientific, USA 
UV-Vis spectrometer, V-650 Jasco GmbH, (Groß-Umstade, Germany) 
UV-Vis spectrometer, V-630 Jasco GmbH, (Groß-Umstade, Germany) 
UV-Vis spectrophotometer, V-750 Jasco GmbH, (Groß-Umstade, Germany) 
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Spectrofluorometer, FP-8500 Jasco GmbH, (Groß-Umstade, Germany) 
Black quartz glass cuvettes Hellma GmbH & Co.KG (Mühlheim, Germany) 
Precision cuvettes, suprasil Hellma GmbH & Co.KG (Mühlheim, Germany) 
JASCO FT/IR-4100 type A Jasco GmbH, (Germany) 








Arium®proVF  Sartorius AG (Göttingen, Germany) 
C1000 thermal cycler BioRad Laboratories GmbH (Munich, Germany) 
CFX96™ Optical Reaction Module BioRad Laboratories GmbH (Munich, Germany) 
Thermocycler TProfessional Biometra (Göttingen, Germany) 
pH-electrode Minitrode Hamilton Mettler Toledo GmbH (Giessen, Germany)  
Monolith NT.115Pico 
NanoTemper Technologies GmbH (Munich, 
Germany) 
Melting point meter (M5000) A. KRÜSS Optronic GmbH (Hamburg, Germany) 
pH-electrode Mettler-Toledo GmbH (Giessen, Germany) 
 
 Methods 
7.2.1 Molecular Biology 
7.2.1.1 Plasmid Transformation 
Plasmid pET303C-hSOD1wt was obtained from Prof. Samar Hasnain, university of 
Liverpool. The plasmid was introduced into various chemical competent E. coli-strains, 
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for a different downstream process: multiplication of plasmid (XL1-Blue), and the 
recombinant protein expression (BL21 (DE3), BL21 Star™ (DE3)). The chemical 
competent cells were purchased (see Section 7.1). 
The chemical competent cells (50 µL) were thawed on ice for 15 min; 1 ng plasmid was 
added and mixed by flicking. The cells were incubated on ice for 25 min. The 
transformation was done by heat shock (20 s, 42 °C) according to Inoue et all[181] followed 
by incubation on ice for 5 min. The cells were supplied with 1 mL preheated super optimal 
broth with catabolite repression (SOC) medium, and they were grown for 70 min at 37 °C, 
800 rpm. 
The transformed cells, containing plasmid of interest, were transferred onto LB-agar 
plates (see page 118), enriched with appropriate antibiotic carbenicillin (100 μg/mL) and 
incubated overnight at 37 °C. 
7.2.1.2 Isolation of Plasmid DNA 
As a preparation step for the isolation of the plasmid DNA, (6 x 10 mL) of LB medium 
containing carbenicillin (100 μg/mL) were inoculated with single colonies of previously 
with pET303C-hSOD1wt transformed XL1-Blue cells. The preculture was grown 
overnight at 37 °C, 200 rpm. Cell culture with (OD600 = 3.0 - 3.5) was centrifuged (4 °C, 
9000 rpm, 5 min), the pellet was used for plasmid isolation following the High Copy 
protocol from (Macherey Nagel, Germany) and using NucleoSpin™ Plasmid Kit. 
7.2.1.3 Determination of DNA Concentration 
The DNA concentration was determined using a Nanodrop One™ device. The 
absorbance (A260) values were measured at 260 nm using baseline correction at 340 nm. 
The DNA concentration (c) was calculated according to the Beer-Lambert Equation 7.1 
with the extinction coefficient of  = 50 ng/µL cm, and the path length of d = 1 cm.  
𝐴260 = 𝑐 ∗ 𝑑 ∗ 𝜀 
7.1 
7.2.1.4 DNA Sequencing 
The sequence of the isolated plasmid constructs was done by GATC Biotech AG 
(Constance, Germany). The T7 primers used for sequencing reaction are listed under 
Section 7.1.1. 
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7.2.1.5 Polymerase Chain Reaction 
As firstly described site-directed mutagenesis Polymerase Chain Reaction (PCR) from 
Mullis in 1986 [182] was used to exchange desired bases by using partially mismatching 
oligonucleotides for directed mutagenesis. The PCR conditions were adjusted for the 
respective variants, primers are listed, see Section 7.1.1. To obtain designed variants, 
QuikChange (Stratagene, La Jolla, USA) protocol was adapted for Phusion® DNA- 
polymerase. After the PCR, template DNA with unmodified sequence was digested by 
adding 5 units DpnI and incubated at 37 °C overnight. The digestion was then heat-
inactivated at 80 °C for 20 min. 
7.2.1.6 Horizontal Agarose Gel Electrophoresis 
DNA fragments were separated by their sequence length using agarose gel 
electrophoresis. DNA samples were mixed with 6x DNA loading dye and loaded onto a 
1% agarose gels, containing 1 x TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM 
EDTA, pH 7.0). The gels were stained in a 2 µg/mL ethidium bromide solution for 
15 min, following visualization with UV-light. DNA fragments size was determined 
using 1kb DNA-Ladder as a size standard. 
7.2.2 Protein preparation 
7.2.2.1 Expression of hSOD1 and variants 
For expression of the hSOD1 wt and variants, a preculture of 200 mL of sterilized LB 
medium (10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl) with 100 μg/mL carbenicillin 
was inoculated with two to three colonies of E. coli BL21 Star™ (DE3), carrying a 
specific hSOD1 plasmid. The preculture was incubated overnight at 30 °C with a constant 
shaking of 200 rpm. The preculture at the final (OD600 = 0.1) was aliquoted and 
centrifuged (9000 rpm, 10 °C, 15 min), the supernatant was discarded, and the cell pellets 
were dissolved again in 4 mL fresh LB medium per 50 mL of preculture. The prepared 
preculture was used to inoculate the main cultures to an OD600 of 0.1 (LB medium was 
containing the respective antibiotic). The main culture was incubated at 37 °C while 
shaking at 200 rpm. At OD600 of (0.6 - 0.8), expression was induced by addition of 
200 mM IPTG (2 mL), and 500 mM ZnSO4 (1 mL) was added. After induction, it was 
incubated overnight at 25 °C with constant shaking at 200 rpm. The expression of hSOD1 
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protein and variants was confirmed via SDS-PAGE. The cells were transferred into 1 L 
beakers and harvested by centrifugation (20 min, 4800 rpm, 4 °C). The cell pellets were 
resuspended in approximately 5-10 mL of buffer A(20 mM Tris, pH 8.0) per beaker, 
transferred to 50 mL falcon tubes and centrifuged for 20 min at 4000 rpm and 4 °C. The 
cell pellets were flash-frozen in liquid nitrogen and stored at -80 °C for long term storage, 
or -20 °C for short term storage. 
7.2.2.2 Purification of the hSOD1 proteins 
Purification of the hSOD1 proteins was done based on the protocol received from Dr. 
Michael Capper (University of Liverpool), which was further optimized by Lisa-Marie 
Funk. The cell pellets (approx. 10 g) were resuspended in the loading buffer A (20 mM 
Tris, pH 8.0), using 4 mL per gram of pellet. While kept on ice it was supplemented with 
0.5 mM PMSF, 5 µg/mL DNase I, 5 mM MgCl2, and a tip of spatula of lysozyme. The 
cell suspension was stirred for 45 min at 6 °C. Lysis of the homogenous cell suspension 
was performed using three to five cycles on the Microfluidizer device at 15000 psi. 
Afterwards, the cells debris were removed by centrifugation (30 min, 75 000 x g, 10 °C). 
The supernatant was dialyzed twice against 2 L buffer A (20 mM Tris, pH 8.0) for 16 h 
at 4 °C. Prior to anion-exchange chromatography protein solution was centrifuged for 
20 min at 75 000 x g, and 10 °C. The supernatant was loaded onto a TMAE column which 
was equilibrated with buffer A (20 mM Tris, pH 8.0). Chromatography was performed 
on the room temperature of approximately 20 °C. The column was washed with buffer A 
until the baseline was reached and flow-through did not contain any visible amount of 
unspecific bound proteins. The hSOD1 proteins were eluted in buffer B (20 mM Tris, 
500 mM NaCl, pH 8.0) with a gradient of 20% over 3 column volumes (150 mL). 
Afterwards, the gradient was increased to 100% to elute remaining proteins from the 
column. SDS-PAGE was used to confirm the purified proteins. Pure fractions of the 
hSOD1 proteins were pooled together and concentrated via ultrafiltration using 
concentrator (Corning Spin-X UF,10K MWCO) up to 5-10 mL. The proteins were then 
either loaded onto HiPrep 26/10 desalting column equilibrated with the chosen buffer M 
(100 mM HEPES, 150 mM NaCl, pH 7.4), and stored at -80 °C or utilized further without 
desalting for dialysis and cofactors reconstitution. 
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7.2.2.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a method 
used to separate denatured proteins by molecular weight and confirm their purity.[183] To 
assign a molecular weight to a different band detected on the gel, protein molecular 
weight marker was used. The gels were prepared as following: stacking gel (5% 
acrylamide, 125 mM Tris, 0.1% (w/v) SDS, pH 6.8), and a separating gel (15% 
acrylamide, 375 mM Tris, 0.1% (w/v) SDS, pH 8.0). Samples for the SDS-PAGE were 
mixed with the sample buffer (0.1 M Tris, 25% (v/v) glycerol, 2% (w/v) SDS, 0.02% (w/v) 
bromophenol blue, 2.5% -mercaptoethanol, pH 6.8) and incubated for 5 minutes at 
95 °C. The gels were run at 35 mA, 150 W, and 300 V for 30 min. Afterwards, the gels 
were stained with solution of (0.25% (w/v) Coomassie Brilliant Blue G250, 30% (v/v) 
ethanol, and 6% (v/v) acetic acid). Non-protein bound dye was removed by washing with 
a destaining solution (30% (v/v) ethanol, 10% (v/v) acetic acid). 
7.2.2.4 Protein concentration determination 
The protein concentrations were determined spectroscopically by measuring the intrinsic 
absorbance of the Trp amino acid at 280 nm, using the Beer-Lambert Equation (7.1). It 
was measured on NanoDrop One device using molar extinction coefficients of 
( = 5500 M-1 cm-1) and molecular weight (Mw = 15936 kDa) calculated with the 
ProtParam online-tool. [184] Additionally, the protein concentrations were determined 
using an assay based on the Bradford method.[185] Calibrations of the Bradford reagent 
were done using known concentration (0.1 - 0.9 mg/mL) of bovine serum albumin 
solutions. Both described methods gave statistically similar values for the protein 
concentrations. Therefore, we pursued using the intrinsic absorption signal of Trp to 
determine the hSOD1 protein concentrations. 
7.2.2.5 Reconstitution of hSOD1 with Cofactors 
Preparation of the apo proteins and further reconstitution with metals was performed after 
the purification step, as in Section 7.2.2.2. For demetallation of the Zn metal introduced 
in the expression step, purified proteins were dialyzed for 16 h against 2 L of buffer D1 
(100 mM sodium acetate, 5 mM EDTA, pH 3.8) at 4 °C. Additionally, a second dialysis 
step was done against 2 L of buffer D2 (100 mM sodium acetate, 150 mM NaCl, pH 3.8) 
for 4 h at 4 °C. Reconstitution of the hSOD1wt protein was performed at room temperature 
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firstly by incubation of the protein with 10 mM CuSO4 for 15 min, followed by another 
15 min incubation with 10 mM ZnSO4. Reconstitution process of the hSOD1A4V variant 
was done on ice. The proteins were then loaded onto HiPrep 26/10 desalting column 
equilibrated with different buffers for each use, i.e., (20 mM Tris, pH 8.0) for 
crystallization, and (50 mM sodium phosphate pH 7.4) or (100 mM HEPES, 150 mM 
NaCl, pH 7.4) for biophysical assays. Protein fractions were pooled together, 
concentrated via ultrafiltration, as explained before, and stored at -80 °C. 
7.2.2.6 Activity assay of the SOD1 proteins 
The activity assay of the SOD1 protein, as elaborated in Section 5.3.2 was measured using 
a Superoxide Dismutase Activity Assay kit (Sigma Aldrich).[157] The reaction mixture 
(260 µL) contained 200 µL of WST working solution and 20 µL of a sample (buffer, 
hSOD1 proteins or ligand and protein) it was incubated for 2 min at 25 °C. The reaction 
was started by addition of the 40 µL xanthine oxidase to the reaction mixture, and it was 
measured in the time span of 2 min. Final concentrations of the hSOD1 proteins were in 
the range of 0.04 µg/mL to 2 µg/mL, in the experiments with the ligand final 
concentration was 0.5 mM to 1 mM with a maximum of 20% DMSO.  
The average triplicate absorbance values at 440 nm were plotted against time. To 
determine the rate of change in absorbance, the slope from each curve was taken in the 
time of 0-50s. The % inhibition of the SOD1 proteins was determined as shown in 
Equation 7.2 where the slope in the absence of the SOD1 protein was the control 






7.2.2.7 Size exclusion chromatography (SEC) 
To analyse and separate the oligomerization state of the holo and apo hSOD1 proteins, 
size exclusion chromatography was performed. The Superdex Increase 200 10/300 GL 
column was equilibrated with 50 mM sodium phosphate buffer pH 7.4 and 150 µL 
hSOD1 sample (0.1 mg/mL – 5 mg/mL) was loaded onto the column. The experiment 
was performed at 4 °C with a flow rate of 0.5 mL/min. Fractions of interest were 
collected, analysed, and processed for further use. To obtain a calibration curve, gel 
filtration standard (Bio-Rad Laboratories) was used as in the previously described 
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experimental setup of the sample. Using Equation 7.3 partition coefficient (𝐾𝑎𝑣) was 
calculated, where 𝑉𝑒  is elution volume, 𝑉𝑐  geometric column volume and 𝑉0  is void 
column volume. The calibration curve was plotted using calculated 𝐾𝑎𝑣  versus 
logarithmic molecular weight values of the BioRad standard. (Figure 9.5). 
The molecular weight of the hSOD1 proteins and oligomers was determined from the 
elution volume of the samples and the calibration curve of the standard.  
𝐾𝑎𝑣 =  
𝑉𝑒 −  𝑉0
𝑉𝑐 −  𝑉0
 
7.3 
7.2.3 X-Ray Crystallography 
7.2.3.1 Crystallization conditions for hSOD1 proteins 
Prior to the crystallization of hSOD1wt, the protein was thawed on ice, centrifuged for 
15 min at 4 °C and 13 000 x g, further the protein stocks, concentration (5 - 20 mg/mL, 
20 mM Tris buffer, pH 8.0) were prepared. The well solution consisted of 18-22% (w/v) 
PEG 8000, 0.2 M ammonium sulfate, 0.1 M MES buffer, pH 6.5 with a total volume of 
500 µL. For the crystallization, hanging drop diffusion method was used, two drops were 
set up per each well, 2 µL of the protein stock (10 mg/mL) were mixed with 2 µL of the 
well solution, and the plates were stored at 20 °C. Crystals grew over a period of 3-10 
days. Crystals were incubated with a total time of 1-4 min, the sequentially increasing 
amount of PEG 8000 50% (w/v) by 5% in cryoprotectant solution with 20% (w/v) DMSO, 
0.2 M ammonium sulfate, 0.1 M MES buffer, 1 mM ZnSO4, 1 mM CuSO4. Soaking of 
crystals with ligands L3 (10 mM), L4 (15 mM), L1 (20 mM), L7 (20 mM) and L14 
(5 mM) was performed using cryoprotectant solution and soaking them for 1-5 min in the 
last step. 
7.2.3.2 X-ray Data Collection and Refinement 
Diffraction data collection was performed using synchrotron radiation at the P14 
beamLine at DESY (Hamburg, Germany) under cryogenic conditions (100 K). 
Diffraction patterns were indexed, integrated and scaled with the XDS package (Kabsch, 
2010).[186] Processing data collection and refinement was done by Lisa-Marie Funk. 
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7.2.4 Biophysical studies 
7.2.4.1 Thermal shift assay 
In order to test thermal stability and protein unfolding, thermal shift assay was performed. 
The concentration range of the hSOD1wt protein and A4V variant were investigated to 
obtain the concentration for further assays with the target molecules. Typically, the 
reaction mixture consisted of 50 mM sodium phosphate buffer pH 7.4, with or without 
20% of DMSO, 1x SYPRO® Orange protein stain (1:50 dilution of the supplied stock 
solution), and 1-20 µM of the hSOD1 protein concentration.  
Furthermore, to confirm the interaction, and understand the influence of the ligands 
(Figure 5.21) on the hSOD1 proteins, the experiment was performed with previously 
established conditions, with a final ligand concentration of 1 mM, and protein 
concentration of 1 µM. Ligands were dissolved in 100% DMSO, with the final DMSO 
concentration of 20%.  
The measurements were performed using a C1000 thermal cycler in the department of 
Molecular Structural Biology (Institute for Microbiology and Genetics, Georg-August-
University Göttingen). The thermal protein unfolding was monitored using a CFX96™ 
Optical Reaction Module (excitation: 515 – 535 nm, detection: 560 – 580 nm). The 
temperature range was 20-95 °C with the temperature increment of (1 °C/30 s). Recorded 
raw data across 96 well plate, was exported and processed with OriginPro 8.5.0 SR1 
(OriginLab Corporation, Northampton, Massachusetts, USA). 
Melting curves were obtained by plotting data of fluorescence intensity against time. 
Fluorescence data of the sample triplicates were averaged, and the respective reference 
sample was subtracted. Analysis of the obtained fluorescence transition signals was done 
by investigation of the first derivative for a peak maximum, where it represents Tm value. 
In the case of our measurement, the difference in Tm values was < 1°C, therefore, to 
confirm the Tm values for different ligands, calculations with a second derivative were 
done. Linear regression curves were fitted for the specified temperature range, further, 
the Tm values were calculated from the obtained fit, as x-intercept, when y=0. 
7.2.4.2 Microscale Thermophoresis 
To perform binding studies of the hSOD1 proteins and respective ligands by Microscale 
Thermophoresis (MST) it was necessary to label the protein. As a labelling strategy, NHS 
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ester chemistry was used. Protein was labelled using Monolith Labeling Kit 
(NanoTemper Technologies).[187] In our case, it was Red dye-NHS 2nd Generation which 
contains reactive NHS-ester group that can react with the primary amines in the protein 
(n-terminus or ɛ-amino group of lysine) at pH 7-9, and form an amide bond. Before the 
labelling, proteins were prepared in sodium phosphate buffer, as shown previously in 
Section 7.2.2.5 and the stock concentration was adjusted to 2-fold of the final 
concentration (200 µM). The dye was dissolved in 100% DMSO to a stock concentration 
of 600 µM. For the labelling reaction, final concentration of the protein and dye was 
adjusted to the 1:1 ratio, it was mixed shortly by pipetting, and incubated for 1.5 h in the 
dark at room temperature. Following, the unreacted free dye was removed via Superdex 
200 10/300 GL column as described in Section 7.2.2.7. 
Afterwards, protein concentration and degree-of-labelling (DOL) were calculated. 
Absorbance spectrum was measured using UV/Vis spectrophotometer (see Section 7.1.2). 
Protein absorbance values at a wavelength of 280 nm (A280) and the maximum 
wavelength at 650 nm (A650) were used for concentration determination. Protein 
concentration was calculated using the adjusted Beer-Lambert Equation 7.4. where: 
𝜀𝑃𝑟𝑜𝑡 = 10 800 𝑀
−1𝑐𝑚−1  is the extinction coefficient of the hSOD1 dimer [70], 
absorbance value at 650 nm (A650) is the maximum wavelength observed which is 
characteristic of the red dye, 𝑐𝑓 = 0.04 is the correction factor of the dye for absorbance 
at 280 nm, and 𝑑 = 1 cm is the instrument path length. 
𝑐𝑃𝑟𝑜𝑡 =
𝐴𝑃𝑟𝑜𝑡
𝜀𝑃𝑟𝑜𝑡  .  𝑑
=
𝐴280 −  (𝐴650  .  𝑐𝑓280)
𝜀𝑃𝑟𝑜𝑡 .  𝑑
  
7.4 
The concentration of the dye was calculated using the Beer-Lambert Equation with the 
extinction coefficient of the dye 𝜀𝑑𝑦𝑒 = 195 000 𝑀
−1𝑐𝑚−1 . Calculation of the labelling 
efficiency; DOL was obtained as dye/protein concentration ratio.[187] A degree of 
labelling between 0.3 - 1.1 was achieved.  
Binding experiments with the ligands explained in Section 5.4.1 were performed as 
follows. The concentration of the labelled hSOD1wt protein was adjusted to 10 nM with 
the assay buffer, it consisted of 50 mM sodium phosphate pH 7.4, 20% DMSO and 0.05% 
Tween 20. Following, sixteen ligands concentrations were prepared in the range from 
30.4 nM to 20 mM using ligand buffer (50 mM sodium phosphate buffer, pH 7.4 and 20% 
DMSO) with 1:1 dilution series. Thus, prepared ligand dilution series was mixed with a 
labelled protein, producing final concentrations i.e., (5 nM of hSOD1wt NHS labelled 
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protein and ligand concentrations ranging from 15.2 nM to 10 mM). Samples were 
centrifuged at 10 000 × g for 2 - 5 min. After 2 h incubation at room temperature samples 
were loaded into Monolith NT.115 Premium Capillaries (NanoTemper Technologies). 
MST experiment was performed using a Monolith NT.115 Pico instrument (NanoTemper 
Technologies) with 10% LED power and medium MST power at 22 °C. Data of three 
independently pipetted measurements were analysed with MO. Affinity Analysis 
software version 2.3 (NanoTemper Technologies) using the signal from an MST-on time 
of 1.5 s. The dissociation constant (𝐾𝑑) was estimated from the law of mass action by 
fitting function with Equation 7.5. 
 
𝑓(𝑐𝐿) = 𝐹𝑛𝑜𝑟𝑚 𝑇 + (𝐹𝑛𝑜𝑟𝑚 𝐿𝑇 − 𝐹𝑛𝑜𝑟𝑚 𝑇) .




Where the f(cL) is the fraction bound at a given ligand concentration 𝑐𝐿 ; 𝐹𝑛𝑜𝑟𝑚  is 
normalized MST trace value, it is calculated by dividing the average fluorescence signal 
in the heated state when the laser is turned on (F hot) by the average fluorescence signal 
when the IR laser is turned off (F cold). L, T, LT represent ligand, target protein, and ligand-
protein complex, respectively.  
7.2.4.3 Isothermal titration calorimetry (ITC) 
For an ITC experiment, hSOD1wt was reconstituted with Cu2+ and Zn2+ in 100 mM hepes, 
150 mM NaCl buffer, pH 7.4, ligands were dissolved in the same buffer with 20% DMSO 
or glycerol. Before the experiment protein and ligands were degassed for 2 min and the 
measurement cell was flushed with 50 – 200 µL of the sample before loading. In the 
experiment at 25 °C, 10 mM ligand in hepes buffer with 20% of respective additive was 
titrated into hSOD1 dimer (175 µM) with the same additive concentration in the cell as 
in syringe at the rate of 2 µL every 2 min. Experiments were conducted on MicroCal 
PEAQ-ITC (Malvern), and ITC data were obtained from analysis software. (Experiments 
were performed and evaluated by Lisa-Marie Funk). 
7.2.4.4 Aggregation assay 
In order to analyse the influence of the ligands to the proteins, aggregation assays were 
conducted. To confirm and determine a low level of aggregated protein PROTESOTAT® 
Protein Aggregation assay kit ENZ-51023-KP050 [188] was tested, with slightly modified 
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protocol, the assay was adjusted and aggregation was monitored with the use of a ThT 
dye (extinction coefficient used for concentration determination was 31600 M-1cm-1).[189] 
hSOD1 proteins (20 µM) were incubated for up to 48 h at temperatures between 0 °C to 
50 °C in 50 mM sodium phosphate buffer, pH 7.4 with or without ligands (1 mM) in 
presence of 20% DMSO, PEG550, or other additives where indicated. After respective 
incubation time, PROTESOSTAT® detection dye was added with a final concentration 
of 1000-fold dilution in the assay, while in the assay with the ThT dye final concentration 
was 15 µM. The aggregation experiment was monitored using a Cytation3 instrument, 
and fluorescence was read at 25 °C, with an optics set to be measured from the bottom, 
and the gain value set to 100. Excitation and emission were set to 550 nm and 600 nm for 
PROTEOSTAT® detection dye, and at 440 nm and 480 nm for the assay with the ThT 
dye, respectively. Aggregated and monomeric lysozyme controls were used in the assay 
and had the final concentration of (15 or 20 µM). For a quantitative result of the 
aggregates in the solution, the reference sample of aggregated IgG protein, 
PROTEOSTAT® aggregation standard was used.[190] From the linear regression fit of the 
standard curve, the slope coefficient was obtained and was used for the calculation of 
aggregates % in the sample, respective blanks RFU values were subtracted. Data was 
exported, evaluated, and plotted with OriginPro 8.5.0 SR1 (OriginLab Corporation, 
Northampton, Massachusetts, USA), see Section 5.4.4. 
 In silico design and molecular docking 
7.3.1 Preparation of protein and ligands structure for docking 
The crystal structures of the hSOD1wt protein with a PDB codes 2V0A, 2C9U were 
obtained from the RCSB protein data bank.[191] They were compared and 2V0A was used 
for in silico docking. All water molecules were removed, polar hydrogen atoms and 
charges were added with AutoDock Tools (ADT) software version 1.5.6 as shown by 
Forli et all. [192] Additionally, so prepared protein structure was converted from the PDB 
file format to the PDBQT format that is needed for the AutoDock Vina 1.1.2 docking 
software. [106,193] 
Ligands structures were prepared using Chem3D software version 15.1 and saved as a 
PDB file format. The ligands were further prepared with AutoDock tools by assigning 
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and confirming rotatable bonds, all functional groups were assigned as flexible except for 
amide bonds. Prepared ligands were saved in PDBQT format for docking analysis. 
7.3.2 Docking procedure with AutoDock Vina 
Molecular docking was performed using the AutoDock Vina 1.1.2 software. Protein and 
ligands were prepared as described. Ligands were docked individually to the protein 
receptor. The big grid-box was set to the size of 38 x 30 x 42 Å in x, y and z dimensions 
with the centre at 20.41, -0.008, and 13.315, respectively, and a grid spacing of 1000 Å. 
Small grid-box was centred at x = 14.383, y = 0.003, and z = 13.503 with a size of 
26 x 24 x 24. A total exhaustive search was set to 200. Docking parameters were set as 
default, with a total of nine output conformations without randomization of the ligand 
prior docking. Ligand-binding affinities were predicted as a negative Gibs energy in 
kcal/mol using a scoring function from AutoDock Vina and RMSD cut off at 4Å.[106] 
Visualization of ligands and proteins was performed using UCSF Chimera visualization 
modelling software.[44] 
 Synthesis of ligand molecules 
7.4.1 Analytics 
i. NMR Spectroscopy 
NMR spectra were recorded on one of the following devices: BRUKER Avance III 300 
or BRUKER Avance III HD 500. Coupling constants are given in Hertz (Hz). 
Multiplicities are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), 
doublet of doublets (dd), doublet of triplets (dt), triplet of doublets (td), doublet of doublet 
of triplets (ddt), triplet of doublet of doublets (tdd). The chemical shifts of the deuterated 
solvents  acetone-d6 (2.05ppm; 29.84 ppm, 206.26 ppm), (CDCl3 (7.26 ppm; 77.16 ppm), 
MeOD d4 (3.31 ppm; 49.00 ppm), DMSO d6 (2.50 ppm; 39.52 ppm), CD2Cl2 (5.32 ppm; 
53.84 ppm), THF d8 (1.72 ppm; 3.58 ppm, 25.31 ppm, 67.21 ppm), D2O (4.79 ppm) were 
used as an internal standard for (1H NMR; 13C NMR), respectively.[194] 
ii. Mass Spectrometry 
Mass spectra were recorded using a microTOF mass spectrometer manufactured by 
BRUKER DALTONICS. For ionisation, electron ionisation (EI) or electrospray 
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ionization (ESI) was applied and detection was conducted using a time-of-flight (TOF) 
detector. All data is given in m/z values and the peak intensities are normalized in EI to 
the intensity of the respective mol peak. 
iii. UV/Vis Spectroscopy 
UV absorption of a sample was measured on a V-750 spectrometer from JASCO using 
the Spectra Manager software provided by the manufacturer. Black quartz glass cuvettes 
from Hellma Analytics 104 (Müllheim, Germany) with 10 mm light path were used. The 
sample volume was 120 μL. The temperature was set to 25 °C, the scanning speed to 200 
nm/min with fast response and the bandwidth to 2.0 nm. Typically, the absorption was 
monitored over 30 s and the mean value was calculated. 
iv. IR spectroscopy 
IR spectra were measured from the solid or oil compounds using a JASCO FT/IR 4100 
type A spectrometer. Wavenumbers ν are given in cm-1. 
v. Melting point analysis 
Melting points were measured using a Krüss melting point meter (M 5000) and capillary 
tubes for melting point determination. 
vi. Reactions under anhydrous and/or oxygen-free conditions 
Standard Schlenk techniques were applied for conversions under anhydrous and/or 
oxygen-free conditions. Argon (99.999 %) was used as a protective gas, and all glassware 
was flame dried in vacuo and vented with argon. This was repeated three times in total.  
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7.4.2 Synthetic procedures 
7.4.2.1 3-Iodo-4-nitrophenol (1) 
 
Over 15 min, fuming nitric acid (730 µL, 17.5 mmol, 1.00 eq), which was dissolved in 
glacial acetic acid (3 mL) was added to a cooled solution of 3-iodophenol (3.50 g, 
15.9 mmol, 0.91 eq) dissolved in glacial acetic acid (15 mL). The reaction mixture was 
allowed to warm up to room temperature and was stirred for 30 min, the solution was 
poured on ice and concentrated in vacuo. The mixture was dissolved in water (40 mL) 
and extracted with DCM (3 x 70 mL). The combined organic layers were dried over 
anhydrous magnesium sulfate and the solvent was removed in vacuo. Afterwards a flash 
chromatography on silica gel (n-hexane/EtOAc, 9:1 + 0.5% AcOH) was performed. The 
product was obtained as a yellow solid (1.54 g, 5.80 mmol, 37%). 
TLC: Rf = 0.05 (n-hexane/ EtOAc, 9:1 + 0.5% AcOH). 
1H NMR (400 MHz, DMSO): δ (ppm) 11.08 (s, 1H, OH), 7.94 (dd, J = 9.0, 0.6 Hz, 1H, 
H-5), 7.45 (d, J = 0.5 Hz, 1H, H-2), 6.92 (dd, J = 9.0, 2.6 Hz, 1H). 
13C NMR (76 MHz, DMSO) δ (ppm) 161.83 (1C, C-1), 149.45 (C1, C-4), 143.89 (C1, 
C-5), 127.94 (1C, C-2), 115.67 (1C, C-6), 90.46 (1C, C-3). 
MS (ESI-): 263.9 ([M-H]-). 
HR-MS (ESI-): calc. for C6H4NO3I ([M-H]
-): 263.9163, found: 263.9166. 
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7.4.2.2 Tert-butyl(3-iodo-4-nitrophenoxy)diphenylsilane (2) 
 
In a schlenk flask under an argon atmosphere, 3-iodo-4-nitrophenol (1.00 g, 3.77 mmol, 
1.0 eq) was dissolved in anhydrous DCM (11 mL), Et3N (1.0 mL, 7.5 mmol, 2.0 eq) was 
added, and the reaction mixture was stirred for 5 min. Then, TBDPSCl (1.96 mL, 
7.55 mmol, 2.0 eq) was added, and the reaction mixture was stirred for 48 h, and 
monitored by TLC (n-hexane/EtOAc, 19:1). The reaction mixture was washed with sat. 
aq. NaHCO3 solution (20 mL), extracted with DCM (3 x 25 mL). Organic layers were 
washed with sat. aq. NaCl solution (50 mL), dried over MgSO4 and concentrated in 
vacuo. The title compound was obtained as a yellow oil (1.77 g, 3.51 mmol, 93%), after 
purification by flash column chromatography (n-hexane/EtOAc, 19:1). NMR analysis 
confirmed that only ~50% is a product, hence the portion of the title compound was 
purified via HPLC in a gradient 80% to 100%, so the total final yield cannot be given. 
TLC: Rf = 0.34 (n-hexane/EtOAc, 19:1) 
1H NMR (300 MHz, DMSO) δ (ppm)7.68 – 7.62 (m, 4H, H-8, H-8’, H-12, H-12’), 7.59 
– 7.34 (m, 7H, H-2, H-9, H-9’, H-10, H-13, H-13’, H-14), 6.96 (t, J = 8.2 Hz, 1H, H-6), 
6.44 (dd, J = 8.4, 1.0 Hz, 1H, H-5), 0.95 (s, 9H, H-16, H-17, H-18). 
13C NMR (76 MHz, DMSO) δ (ppm)146.12 (1C, C-1), 134.81 (4C, C-8, C-8’, C-12, C-
12’), 131.48 (1C, C-5), 130.81 (1C, C-2), 128.40 (6C, C-7, C-11, C-9, C-9’, C-13, C-
13’), 119.31 (1C, C-6), 87.40 (1C, C-3), 25.67 (3C, C-16, C-17, C-18), 18.78 (1C, C-15). 
MS (ESI+): 526.0 ([M+Na]+) 
HR-MS (ESI+): calc. for C22H22INO3Si ([M+Na]
+): 526.0306, found: 526.0292 calc. for 
C22H22INO3Si ([M+K]
+): 542.0056, found: 542.0027 
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7.4.2.3 1-Bromo-4-(tert-butoxy) benzene (4) 
 
In a one-neck flask under an argon atmosphere, 4-bromophenol (15.0 g, 86.7 mmol, 
10 eq) was mixed with pyridine (701 µl, 8.67 mmol, 1.0 eq). The reaction mixture was 
stirred for 5 min, and tert-butyl bromide (973 µl, 8.67 mmol, 1.0 eq) was added. The clear 
reaction mixture was stirred for 6 h. The yellowish reaction mixture was poured into a 
water-ethylene glycol (8/1) mixture (30 mL) and extracted with n-pentane (3 x 40 mL). 
The organic layer was washed with 5% aq. NaOH solution (40 mL), water (2 x 40 mL), 
and dried over MgSO4. The title compound was isolated as a colourless liquid (980 mg, 
4.27 mmol, 49%) after purification by flash column chromatography (n-hexane/ EtOAc, 
95:5). 
TLC: Rf = 0.51 (n-hexane/EtOAc, 95:5) 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 7.43 (d, J = 8.9 Hz, 2H, H-2, H-2’), 6.92 (d, J 
= 8.9 Hz, 2H, H-3, H-3’), 1.28 (s, 9H, -tBu). 
13C NMR (75 MHz, DMSO-d6): δ (ppm) 154.18 (1C, C-4), 131.49 (2C, C-2, C-2’), 
125.40 (2C, C-3, C-3’), 114.77 (1C, C-1), 78.30 (1C, -tBu),  28.31 (3C, -tBu). 
MS (EI+): m/z (%) calc. for C10H13BrO found: 228.0157 (80), 230.0170. 
7.4.2.4 4-(Tert-butoxy)phenyl)boronic acid (5) 
  
In a three-neck Schlenk flask, equipped with a reflux condenser under an argon 
atmosphere Mg (331.2 mg, 13.62 mmol, 3.0 eq) and LiCl (240.67 mg, 5.67 mmol, 
1.25 eq) were dissolved in anhydrous THF (6 mL). The solution of 4-bromophenol t-butyl 
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ether (1.05 g, 4.54 mmol, 1.0 eq) in anhydrous THF (5 mL) was added. The reaction 
mixture was heated up until reflux, and the colour turned dark grey/black, further it was 
stirred for 1 h at room temperature. Afterwards, the reaction mixture was transferred with 
a cannula to a one-neck flask under argon, B(OEt)3 (2.30 mL, 13.6 mmol, 3.0 eq), and 
anhydrous THF (15 mL) were added. The reaction was stirred for 90 min, and then HCl 
(1 M, 15 mL, 3.3 eq) was added, stirred for 30 min, and extracted with EtOAc (3 x 60 
mL). The organic layer was washed with sat. aq NaCl solution (30 mL), dried over 
MgSO4 and concentrated in vacuo. The title compound was obtained as a white solid 
(208 mg, 1.07 mmol, 23%) after purification by flash column chromatography 
(DCM/MeOH, 19:1). 
TLC: Rf = 0.6 (DCM/MeOH, 19:1) 
1H NMR (300 MHz, DMSO-d6) δ (ppm) 7.81 – 7.76 (m, 2H, H-2, H-2’), 6.97 – 6.90 (m, 
2H, H-3, H-3’), 1.31 (s, 9H, H-6, H-7, H-8). 
13C NMR (75 MHz, DMSO-d6) δ (ppm) 156.52 (1C, C-4), 134.41 (2C, C-2, C-2’), 122.41 
(2C, C-3, C-3’), 77.80 (1C, C-5), 28.67 (3C, C-6, C-7, C-8). 
FT-IR (Diamond-ATR): ν (cm-1) 2978, 1743, 1602, 1561, 1362, 1338, 1238, 1153, 895. 
HR-MS (ESI-): calc. for C10H15O3Br ([M-H]




In a one-neck flask under argon, tert-butyl(3-iodo-4-nitrophenoxy)diphenyl silane 
(79.0 mg, 0.160 mmol, 1.0 eq), 4-(tert-butoxy)phenyl)boronic acid (68.0 mg, 
0.350 mmol, 2.2 eq), barium hydroxide (76.1 mg, 0.44 mmol, 2.8 eq), and Pd(PPh3)4 
(20.0 mg, 0.016 mmol, 10 mol%) were dissolved in 5 mL of dioxane/water (4:1 v/v) 
mixture, which was previously degassed in an argon stream. The reaction mixture was 
stirred at 75 °C for 24 h. Afterwards, the TLC analysis (n-hexane/EtOAc, 9:1) still 
showed starting material, therefore it was stirred for 24 h more at 100 °C. The reaction 
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mixture was washed with sat. aq. NH4Cl (40 mL) and extracted with EtOAc (3 x 50 mL). 
The organic layers were washed with sat. aq. NaCl (2 x 50 mL), dried over MgSO4 and 
concerted in vacuo, as a yellow/orange crude solid (126 mg). The title compound was not 
confirmed with mass analysis of the crude solid. 
7.4.2.6 4'-(Benzyloxy)-6-nitro-[1,1'-biphenyl]-3-ol (18) 
 
In a dry 100 mL two-neck Schlenk flask, which was equipped with a reflux condenser, 
and in an argon atmosphere, 3-iodo-4-nitrophenol (1.50 g, 5.66 mmol, 1.0 eq), 
(4-(benzyloxy)phenyl)boronic acid (1.94 g, 8.49 mmol, 1.5 eq), TBAI (167.25 mg, 
0.45 mmol, 0.08 eq), K2CO3 (3.52 g, 25.47 mmol, 4.5 eq) and Pd(PPh3)4 (170 mg, 
0.147 mmol, 2.6 mol%) were dissolved in MeOH/H2O (4/1) mixture (20 mL), which was 
previously degassed under an argon stream for 1.5 h. The mixture was refluxed for 6 h, 
while the reaction was monitored by TLC (DCM/MeOH 50:1). As the 3-iodo-4-
nitrophenol has the same Rf value, as the title compound, the reaction mixture was stirred 
for an additional 12 h at room temperature. The mixture was filtered, washed with EtOAc 
(30 mL), and the filtrate was concentrated in vacuo. The residue was dissolved in H2O 
(60 mL) and sat. aqueous NaHCO3 solution (40 mL) and extracted with EtOAc (3 x 
50 mL). The combined organic layers were washed with sat. aqueous NaCl solution 
(60 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The title 
compound was obtained after flash column chromatography (DCM/MeOH, 50:1) as a 
yellow solid (1.63 g, 5.09 mmol, 90 %). 
TLC: Rf = 0.47 (DCM/MeOH 50:1). 
mp.: 130 °C - 131 °C  
1H NMR (400 MHz, DMSO) δ (ppm) 10.85 (s, 1H, -OH), 7.90 (d, J = 8.9 Hz, 1H, H-5), 
7.51 – 7.44 (m, 2H, H-13, H-13’), 7.44 – 7.37 (m, 2H, H-14, H-14’), 7.41 – 7.30 (m, 1H, 
H-15), 7.26 – 7.17 (m, 2H, H-8, H-8’), 7.10 – 7.02 (m, 2H, H-9, H-9’), 6.88 (dd, J = 8.9, 
2.7 Hz, 1H, H-4), 6.74 (d, J = 2.6 Hz, 1H, H-2), 5.14 (s, 2H, H-11). 
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13C NMR (101 MHz, DMSO) δ (ppm) 161.29 (1C, C-3), 158.18 (1C, C-10), 140.38 (1C, 
C-6), 138.38 (1C, C-1), 136.94 (1C, C-12), 130.29 (2C, C-8, C-8’), 128.88 (2C, C-13, C-
13’), 128.46 (2C, C-14, C-14’), 127.89 (1C, C-7), 127.76 (1C, C-5), 127.35 (1C, C-15), 
117.99 (1C, C-4), 114.78 (2C, C-9, C-9’), 114.45 (1C, C-2), 69.29 (1C, C-11). 
MS (ESI-): 320.1 ([M-H]-), 641.2 ([2M-H]-). 
HR-MS (ESI-): calc. for C19H15NO4 ([M-H]
-): 320.0928, found: 320.0925. 
FT-IR (Diamond-ATR): ν (cm-1) 3750.87, 3398.92, 1734.66, 1588.09, 1505.17, 
1324.86, 1001.84. 
7.4.2.7 6-Nitro-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-ol (19) 
 
In a dry 100 mL two-neck Schlenk flask, which was equipped with a reflux condenser, 
and under an argon atmosphere, 3-iodo-4-nitrophenol (1.60 g, 5.66 mmol, 1.0 eq), 
(4-(trifluoromethyl)phenyl)boronic acid (1.63 g, 8.49 mmol, 1.5 eq), TBAI (167.25 mg, 
0.450 mmol, 0.08 eq), K2CO3 (3.52 g, 25.5 mmol, 4.5 eq) and Pd(PPh3)4 (170 mg, 
0.147 mmol, 2.6 mol%) were dissolved in MeOH/H2O (4/1) solvent mixture (20 mL), 
which was previously degassed under an argon stream for 1.5 h. The mixture was refluxed 
for 30 h, and the reaction was monitored by TLC (DCM/MeOH, 50:1). The brown/orange 
mixture was filtered, the precipitate washed with EtOAc (30 mL) and the filtrate 
concentrated in vacuo. The residue was suspended in H2O (60 mL) and sat. aqueous 
NaHCO3 solution (40 mL) and extracted with EtOAc (3 x 50 mL). The combined organic 
layers were washed with sat. aqueous NaCl solution (60 mL), dried over anhydrous 
MgSO4, filtered, and the solvent was removed in vacuo. The title compound was obtained 
after purification by flash column chromatography (DCM/MeOH, 100:1) as a yellow 
solid (962 mg, 3.40 mmol, 60 %). 
TLC: Rf = 0.5 (DCM/MeOH, 100:1) 
mp.: 113 °C – 114 °C 
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1H NMR (300 MHz, cd2cl2) δ (ppm) 8.02 (dd, J = 9.0, 0.3 Hz, 1H, H-5), 7.75 – 7.64 (m, 
2H, H-8, H-8’), 7.50 – 7.38 (m, 2H, H-9, H-9’), 7.04 – 6.88 (m, 1H, H-2), 6.85 – 6.77 (m, 
1H, H-2). 
13C NMR (126 MHz, cd2cl2) δ (ppm)159.64 (1C, C-3), 142.36 (1C, C-6), 138.72 (1C, C-
7), 128.25 (4C, C-8, C-8’, C-5, C-7), 127.95 (3C, C-9, C-9’, C-10), 125.67 (1C, C-11), 
118.84 (1C, C-4), 115.65 (1C, C-2). 
19F NMR (282 MHz, cd2cl2) δ (ppm) -60.62 
MS (ESI-): 282.0 ([M-H]-), 565.0 ([2M-H]-) 
HR-MS (ESI-): calc. for C13H8F3NO3 ([M-H]
-): 282.0384, found: 282.0380. 
FT-IR (Diamond-ATR): ν (cm-1) 3422.06, 1589.06, 1512.88, 1319.07, 1109.83, 
850.454, 702.926. 
7.4.2.8 6-Nitro-[1,1'-biphenyl]-3-ol (21) 
 
To a solution of 3-phenylphenol (2.50 g, 14.6 mmol, 1.0 eq) in acetic acid (15 mL), HNO3 
(3 mL, 6 M, 18.0 mmol) was added dropwise within 15 min, while cooling on an ice bath. 
Afterwards, the reaction mixture was stirred for 2.5 h at ambient temperature. To the dark 
brown reaction mixture water (60 mL) was added, and the mixture was extracted with 
DCM (4 x 60 mL). The organic phase was washed with sat. aq. NaCl solution (100 mL), 
dried over Na2SO4, filtered, and the solvent was removed in vacuo. The residue was 
purified by flash column chromatography using a gradient of (n-hexane/EtOAc, 10:1 to 
1:1) as an eluent to give 4-nitrobiphenyl-3-ol (822 mg, 3.82 mmol, 26%) as a yellow solid 
and a mixture of 2-nitrobiphenyl-3-ol and 6-nitrobiphenyl-3-ol as a brown oil. The brown 
oily mixture was purified by silica gel flash column chromatography using (DCM/MeOH, 
50:1) as eluent to give 2-nitrobiphenyl-3-ol (443 mg, 2.05 mmol, 14%) as a brown solid, 
and the title compound (1.29 g, 5.99 mmol, 41%) as a brown oil. 
TLC: Rf = 0.47 (DCM/MeOH, 50:1) 
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1H NMR (600 MHz, CDCl3) δ (ppm) 7.79 (d, J = 9.0 Hz, 1H, H-5), 7.30 – 7.22 (m, 2H, 
H-8, H-8’), 7.17 – 7.10 (m, 3H, H-9, H-9’,H-10), 6.73 (dd, J = 8.9, 2.7 Hz, 1H, H-4), 6.67 
(d, J = 2.7 Hz, 1H, H-2). 
13C NMR (126 MHz, CDCl3) δ (ppm) 159.28 (1C, C-3), 139.66 (1C, C-1), 137.87 (1C, 
C-6), 128.41 (2C, C-8, C-8’), 127.99 (1C, C-7), 127.61 (2C, C-9, C-9’), 127.17 (1C, C-
10), 118.48 (1C, C-4) , 114.52 (1C, C-2). 
MS (ESI+): 238.1 ([M+Na]+) 
HR-MS (ESI+): calc. for C12H9NO3 ([M+H]
+): 216.0655, found: 216.0658. calc. for 
C12H9NO3 ([M+Na]
+): 238.0475, found: 238.0478 
7.4.2.9 6-Nitro-[1,1'-biphenyl]-3-yl propionate (22) 
 
In a dry 100 mL schlenk flask, and in an argon atmosphere, 6-nitro-[1,1'-biphenyl]-3-ol 
(390 mg, 1.81 mmol, 1.0 eq) was dissolved in anhydrous DCM (10 mL). To this solution 
propionic acid (0.270 mL, 3.62 mmol, 2.0 eq), and DMAP (22.1 mg, 0.18 mmol, 0.1 eq) 
were added. The mixture was stirred for 15 min. In a second dry 50 mL Schlenk flask, 
and under argon, EDC-HCl was dissolved in anhydrous DCM (20 mL) and added to the 
reaction mixture. After complete addition of EDC-HCl, the flask was rinsed with 
additional 10 mL of anhydrous DCM. The reaction mixture was stirred at ambient 
temperature for 12 h. The yellowish reaction mixture was washed with aq. HCl solution 
(1M, 30 mL), water (30 mL), sat. aq. NaHCO3 solution (50 mL) and sat. aq. NaCl solution 
(50 mL). The organic layer was dried over MgSO4, filtered, and the solvent was removed 
in vacuo to give a yellow oil (500 mg). The title compound was isolated as a yellow solid 
(420 mg, 1.56 mmol, 85%) after purification by flash column chromatography 
(n-hexane/EtOAc, 4:1). 
TLC: Rf = 0.40 (n-hexane/EtOAc, 4:1) 
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1H-NMR (300 MHz, cd2cl2): δ (ppm) 7.92 (dd, J = 8.8, 0.4 Hz, 1H, H-5), 7.48 – 7.40 (m, 
3H, H-8, H-8’, H-2), 7.34 – 7.28 (m, 2H, H-9, H-9’), 7.26 – 7.18 (m, 2H, H-10, H-4), 
2.62 (q, J = 7.5 Hz, 2H, H-12), 1.32 – 1.16 (m, 3H, H-13). 
13C-NMR (126 MHz, cd2cl2) δ (ppm) 172.23 (1C, C-11), 153.51 (1C, C-3), 146.36 (1C, 
C-6), 138.45 (1C, C-1), 137.21 (1C, C-7), 128.86 (2C, C-9, C-9’), 128.63 (1C, C-10), 
128.01 (2C, C-8, C-8’), 126.00 (1C, C-5), 125.26 (1C, C-4), 121.59 (1C, C-2), 28.02 (1C, 
C-12), 9.04 (1C, C-13). 
MS (ESI+): 294.1 ([M+Na]+) 
HR-MS (ESI+): calc. for C15H13NO4 ([M+Na]
+): 294.0737, found: 294.0736. 
7.4.2.10 6-Amino-[1,1'-biphenyl]-3-yl propionate (23) 
 
In a hydrogen atmosphere, 6-nitro-[1,1'-biphenyl]-3-yl propionate (728 mg, 2.66 mmol, 
1.0 eq) was dissolved in a mixture of ethyl acetate (15 mL) and acetic acid (10 mL). Then, 
Pd/C (10%, 100 mg) was added and the pressure vessel was purged with hydrogen and 
set to 2 bar. The reaction mixture was stirred for 5 h at ambient temperature until no 
starting material was observed by TLC analysis (n-hexane/EtOAc, 4:1). The reaction 
mixture was filtered and concentrated under reduced pressure. The title compound was 
isolated after gradient flash column chromatography (n-hexane/EtOAc, 4:1 to n-
hexane/EtOAc, 1:1) as an off-yellow oil (398.4 mg, 1.65 mmol, 62%). 
TLC: Rf = 0.26 (n-hexane/EtOAc, 4:1) 
1H NMR (300 MHz, cd2cl2) δ (ppm) 7.51 – 7.28 (m, 5H, H-8, H-8’, H-9, H-2, H-4), 6.89 
– 6.78 (m, 2H, H-7, H-7’), 6.78 – 6.67 (m, 1H, H-5), 3.77 (s, 2H, H-NH2), 2.53 (q, J = 
7.5 Hz, 2H, H-11), 1.29 – 1.14 (m, 3H, H-12). 
13C NMR (126 MHz, cd2cl2) δ (ppm) 173.57 (1C, C-10), 143.06 (1C, C-6), 141.74 (1C, 
C-3), 138.96 (1C, C-1’), 129.11 (2C, C-8, C-8’), 129.06 (2C, C-7, C-7’), 128.13 (1C, C-
9), 127.63 (1C, C-1), 123.27 (1C,  C-4), 121.63 (1C, C-2), 116.02 (1C, C-5), 27.93 (1C, 
C-11), 9.27 (1C, C-12). 
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MS (ESI+): 242.1 ([M+H]+) 
HR-MS (ESI+): calc. for C15H15NO2 ([M+H]
+): 242.1176, found: 242.1178 
calc. for C15H15NO2 ([M+Na]
+): 264.0995, found: 264.0996 
7.4.2.11 2-(4-(Benzyloxy)phenyl)acetic acid (26) 
 
In a 500 mL one-neck flask, which was equipped with a reflux condenser, 2-(4-
(benzyloxy)phenyl)acetic acid (5.00 g, 32.9 mmol. 1.0 eq), (bromomethyl)benzene 
(4.10 mL, 34.5 mmol, 1.1 eq), KOH (4.60 g, 82.3 mmol, 2.5 eq) and NaI (99.0 mg, 
0.66 mmol, 0.02 eq) were dissolved in EtOH (150 mL) and refluxed for 24 h. The reaction 
mixture was allowed to cool down to room temperature, and upon addition of 3 M HCl 
(150 mL) product precipitated. The precipitate was filtered, washed with water (100 mL), 
and dried in vacuo. The title compound was obtained as a white powder (4.60 g, 
18.98 mmol, 60%). 
TLC: Rf = 0.5 (cyclohexane/EtOAc, 1:1) 
mp.: 122.6 °C 
1H NMR (300 MHz, DMSO) δ (ppm)12.24 (s, 1H, -OH) 7.49 – 7.36 (m, 5H, H-10, H-
10’, H-11, H-9, H-9’), 7.17 (d, J = 8.1 Hz, 2H, H-4, H-4’), 6.95 (d, J = 8.1 Hz, 2H, H-5, 
H-5’), 5.09 (s, 2H, H-7), 3.49 (s, 2H, H-2). 
13C NMR (75 MHz, DMSO) δ (ppm)173.43 (1C, C-1), 157.57 (1C, C-6), 137.65 (1C, C-
8), 130.85 (2C, C-4, C-4’), 128.89 (2C, C-10, C-10’), 128.24 (1C, C-3), 128.08 (2C, C-
9, C-9’), 127.67 (1C, C-11), 115.03 (2C, C-5, C-5’), 69.61 (1C, C-7), 40.31 (1C, C-2). 
FT-IR (Diamond-ATR): ν (cm-1) 2360.44 ,1685.48, 1508.06, 1012.45. 
MS (ESI+): 265.1 ([M+Na]+) 
HR-MS (ESI+): calc. for C15H14O3 ([M+Na]
+): 265.0846, found: 265.0846 
MS (ESI-): 241.1 ([M-H]-) 
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HR-MS (ESI-): calc. for C15H14O3 ([M-H]
-): 241.0870, found: 241.0869 
7.4.2.12 2-(4-((Tetrahydro-2H-pyran-2-yl)oxy)phenyl)acetic acid (27) 
 
Methyl 2-(4-hydroxyphenyl)acetate (2.50 g, 15.0 mmol, 1.0 eq) and 3,4-dihydro-2H-
pyran (1.5 mL, 16.5 mmol, 1.1 eq) were dissolved in DCM (65 mL). Pyridinium 4-
methylbenzenesulfonate (57.7 mg, 0.15 mmol, 0.01 eq.) was added and the solution was 
stirred at room temperature for 12 h and poured into saturated aqueous NaHCO3 solution 
(50 mL). The aqueous phase was extracted three times with methylene chloride (50 mL). 
The combined organic phases were extracted with brine (100 mL) and dried over 
anhydrous Na2SO4. After the removal of the solvent under reduced pressure, 3.91 g of a 
yellow-green oil (methyl 2-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)acetate) was 
isolated and directly used without further purification. The crude methyl ester was 
dissolved in THF/methanol/water (2:2:1, 75 mL) and lithium hydroxide monohydrate 
(930 mg, 22.5 mmol) was added. The clear solution was stirred at room temperature for 
12 h, after which 1 M hydrochloric acid was added to adjust the pH to 7. The mixture was 
extracted with ethyl acetate (3 x 50 mL); the aqueous phase was stored. The combined 
organic phases were washed with brine (2x 50 mL) and dried over anhydrous MgSO4 to 
yield 436 mg of a reddish oil, which solidified in the fridge. 1 M hydrochloric acid was 
added to the remaining aqueous solution until no new white precipitate appeared. The 
suspension was then treated as described above yielding white powder (2.72 g, 
11.0 mmol, 77%). 
1H NMR (300 MHz, CDCl3) δ (ppm) 11.09 (s, 1H, H-COOH), 7.19 (d, J = 8.6 Hz, 2H, 
H-4, H-4’), 7.01 (d, J = 8.6 Hz, 2H, H-5, H-5’), 5.40 (t, J = 3.3 Hz, 1H, H-7), 3.68 - 3.55 
(m, 4H, H-2, H-8), 2.09 - 1.92 (m, 2H, H-10), 1.91 - 1.49 (m, 4H, H-9, H-11). 
13C NMR (75 MHz, CDCl3) δ (ppm) 177.39 (1C, C-1), 156.48 (1C, C-6), 130.46 (2C, C-
4, C-4’), 126.39 (1C, C-3), 116.78 (2C, C-5, C-5’), 96.52 (1C, C-7), 62.14 (1C, C-8), 
40.27 (1C, C-2), 30.49 (1C, C-10), 25.35 (1C, C-9), 18.88 (1C, C-11). 
HR-MS (ESI-) calc. for C13H16O4 ([M-H]
-): 235.0976, found: 235.0977. 
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HR-MS (ESI+) calc. for C13H16O4 ([M+Na]




In a dry 50 mL Schlenk flask, under an argon atmosphere, 2-(4-(benzyloxy)phenyl)acetic 
acid (450 mg, 1.85 mmol, 1.0 eq) was dissolved in anhydrous DCM (10 mL) with 
catalytic amounts of  DMF. To the reaction mixture, oxalyl chloride (0.2 mL, 2.78 mmol, 
1.5 eq) was added slowly, and the reaction was stirred under an argon atmosphere for 2 h. 
Afterwards, excess oxalyl chloride was removed under reduced pressure. The obtained 
yellow solid was dissolved in anhydrous toluene (10 mL), and K2CO3 (978 mg, 
7.20 mmol, 4.0 eq) was added to the reaction mixture. In a second dry Schlenk flask under 
an argon, 6-amino-[1,1'-biphenyl]-3-yl propionate (644 mg, 2.68 mmol, 1.5 eq) was 
dissolved in anhydrous toluene (5 mL) and added to the reaction mixture. The flask was 
rinsed with an additional 5 mL of anhydrous toluene. The reaction mixture was stirred for 
20 h in an argon atmosphere. The yellow suspension was filtered, washed with water 
(20 mL), sat. aq. NaHCO3 solution (40 mL) and sat. aq. NaCl solution (50 mL). The 
organic phase was dried over MgSO4 and concentrated in vacuo to give a crude brownish 
solid (714 mg). The title compound was purified by flash column chromatography 
(n-hexane/EtOAc, 5:1), and isolated as a brownish solid (340 mg, 0.73 mmol, 40%). 
TLC: Rf = 0.22 (n-hexane/EtOAc, 3:1) 
1H NMR (500 MHz, CD3CN) δ (ppm) 7.97 (d, J = 8.8 Hz, 1H, H-7), 7.60 (s, 1H, H-NH), 
7.48 (ddt, J = 7.6, 1.4, 0.7 Hz, 2H, H-22, H-22’), 7.45 – 7.38 (m, 2H, H-11, H-24), 7.38 
– 7.29 (m, 4H, H-10, H-10’, H-23, H-23’), 7.22 – 7.15 (m, 2H, H-17, H-17’), 7.09 – 7.01 
(m, 3H, H-9, H-9’, H-6), 6.97 (d, J = 2.7 Hz, 1H, H-4), 6.89 – 6.82 (m, 2H, H-18, H-18’), 
5.08 (s, 2H, H-20), 3.46 (s, 2H, H-15), 2.56 (q, J = 7.5 Hz, 2H, H-13), 1.17 (t, J = 7.5 Hz, 
3H, H-14). 
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13C NMR (126 MHz, CD3CN) δ (ppm) 174.08 (1C, C-12), 170.64 (1C, C-1), 158.76 (1C, 
C-19), 148.57 (1C,  C-5), 138.26 (1C, C-8), 136.48 (1C, C-21), 133.48  (1C, C-2) , 131.45  
(2C, C-22, C-22’), 129.83 (2C, C-17, C-17’), 129.72 (2C, C-10, C-10’), 129.51 (1C, C-
16), 128.88 (1C, C-3), 128.78 (2C, C-11, C-24), 128.64 (2C, C-23, C-23’), 128.05 (2C, 
C-9, C-9’), 125.28 (1C, C-7), 124.19 (1C, C-6), 122.14 (1C, C-4), 116.01 (2C, C-18, C-
18’), 70.54 (1C, C-20), 43.67 (1C, C-15), 28.08 (1C, C-13), 9.23  (1C, C-14). 
MS (ESI+): 488.2 ([M+Na]+), 466.2 ([M+H]+). 
HR-MS (ESI+): calc. for C30H27NO4 ([M+H]
+): 466.2013, found 466.2016 
7.4.2.14 4'-(Benzyloxy)-6-nitro-[1,1'-biphenyl]-3-yl propionate (29) 
 
In a dry 250 mL Schlenk flask under an argon atmosphere, 4'-(benzyloxy)-6-nitro-[1,1'-
biphenyl]-3-ol (1.55 g, 4.85 mmol, 1.0 eq) was dissolved in anhydrous DCM (50 mL). 
To this solution propionic acid (0.7 mL, 9.70 mmol, 2.0 eq), and DMAP (63.0 mg, 
0.50 mmol, 0.1 eq) were added. The mixture was stirred for 15 min. In a second dry 
50 mL Schlenk flask, and under argon, EDC-HCl (929.75 mg, 4.85 mmol, 1.0 eq) was 
dissolved in anhydrous DCM (20 mL) and added to the reaction mixture. After complete 
addition of EDC-HCl, the flask was rinsed with an additional 10 mL of anhydrous DCM. 
The reaction mixture was stirred at ambient temperature for 12 h. Then, the reaction 
mixture was washed with aq. HCl (1M, 50 mL), water (50 mL), sat. aq. NaHCO3 solution 
(50 mL) and sat. aq. NaCl solution (50 mL). The organic phase was dried over MgSO4, 
filtered, and the solvent was removed in vacuo to give a yellow oil (1.71 g). The title 
compound was isolated as a yellow solid (1.57 g, 4.17 mmol, 86%) after purification by 
flash column chromatography (n-hexane/EtOAc, 4:1). 
TLC: Rf = 0.45 (n-hexane/EtOAc, 4:1) 
mp.: 76.1 °C 
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1H NMR (300 MHz, cd2cl2) δ (ppm) 7.87 (dd, J = 8.6, 0.5 Hz, 1H, H-5), 7.51 – 7.28 (m, 
5H, H-4, H-13, H-13’, H-14, H-14’), 7.32 – 7.13 (m, 4H, H-8, H-8’, H-15, H-2), 7.09 – 
6.98 (m, 2H, H-9, H-9’), 5.10 (s, 2H, H-11), 2.62 (q, J = 7.5 Hz, 2H, H-17), 1.24 (t, J = 
7.5 Hz, 3H, H-18). 
13C NMR (126 MHz, cd2cl2) δ (ppm) 172.24 (1C, C-16), 159.31 (1C, C-10), 153.37 (1C, 
C-3), 146.44 (1C, C-6), 137.92 (1C, C-1), 137.05 (1C, C-12), 129.47 (1C, C-7), 129.31 
(2C, C-8, C-8’), 128.74 (1C, C-5), 128.23 (2C, C-14, C-14’), 127.80 (2C, C-13, C-13’), 
125.90 (1C, C-15), 125.15 (2C, C-9, C-9’), 121.18 (1C, C-4), 115.21 (1C, C-2), 70.37 
(1C, C-11), 28.00 (1C, C-17), 9.03 (1C, C-18). 
MS (ESI+): 400.1 ([M+Na]+) 
HR-MS (ESI+): calc. for C22H19NO5 ([M+Na]
+): 400.1155, found 400.1148 
FT-IR (Diamond-ATR): ν (cm-1) 1759.73, 1516.74, 1345.11, 1177.33, 1132.01. 
7.4.2.15 6-Amino-4'-(benzyloxy)-[1,1'-biphenyl]-3-yl propionate (30) 
 
In a one-neck flask, 4'-(benzyloxy)-6-nitro-[1,1'-biphenyl]-3-yl propionate (1.58 g, 
4.19 mmol, 1.0 eq) was dissolved in EtOH (50 mL). Then, tin (II) chloride (4.21 g, 
22.2 mmol, 5.3 eq) was added and the reaction mixture was refluxed for 4 h. After the 
completion of the reaction ice-cold water (100 mL) was added, and the tin hydroxide 
precipitate was dissolved with 20 mL of NaOH (20%). The aqueous layer was extracted 
with EtOAc (3 x 60mL), dried over anhydrous Na2SO4, and concentrated in vacuo. The 
title compound was isolated, after purification by gradient flash column chromatography 
(n-hexane/EtOAc, 3:1→ 2:1) as a brown oil (557 mg, 1.60 mmol, 40%). 
TLC: Rf = 0.43 (n-hexane/EtOAc, 2:1) 
1H NMR (300 MHz, dmso) δ (ppm)7.50 – 7.30 (m, 7H, H-2, H-4, H-13, H-13’, H-14, H-
14’, H-15), 7.12 – 7.05 (m, 2H, H-8, H-8’), 6.80 – 6.68 (m, 3H, H-9, H-9’, H-5), 5.13 (s, 
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2H, H-11), 4.67 (s, 2H, H-NH2), 2.56 – 2.47 (m, 2H, H-17), 1.11 (t, J = 7.5 Hz, 3H, H-
18). 
13C NMR (126 MHz, dmso) δ (ppm)172.79 (1C, C-16), 157.24 (1C, C-10), 142.59 (1C, 
C-6), 141.18 (1C, C-3), 136.92 (1C, C-12), 131.03 (1C, C-7), 129.52 (2C, C-8, C-8’), 
128.28 (2C, C-14, C-14’), 127.66 (1C, C-15), 127.50 (2C, C-13, C-13’), 125.59 (1C, C-
4), 122.46 (1C, C-2), 120.68 (1C, C-1), 115.27 (1C, C-5), 114.93 (2C, C-9, C-9’), 69.18 
(1C, C-11), 26.84 (1C, C-17), 8.95  (1C, C-18). 
MS (ESI+): 348.2 ([M+H]+), 370.1 ([M+Na]+). 
HR-MS (ESI+): calc. for C22H21NO3 ([M+H]
+): 348.1594, found: 348.1592; calc. for 
C22H21NO3 ([M+Na]
+): 370.1414, found: 370.1411. 
7.4.2.16 4'-(Benzyloxy)-6-(2-(4-(benzyloxy)phenyl)acetamido)-[1,1'-
biphenyl]-3-yl propionate (31) 
 
In a dry Schlenk flask, 2-(4-(benzyloxy)phenyl)acetic acid (698 mg, 2.88 mmol, 2.0 eq), 
EDC-HCl (664 mg, 3.46 mmol, 2.1 eq) and HOBt (39.02 mg, 0.288 mmol, 0.2 eq) were 
dissolved in DCM (30 mL) and stirred at room temperature for 10 min under an argon 
atmosphere. 6-Amino-4'-(benzyloxy)-[1,1'-biphenyl]-3-yl propionate (502 mg, 
1.44 mmol, 1.0 eq) was dissolved in DCM (10 mL) in a second dry Schlenk flask, and 
added to the clear reaction solution. The mixture was stirred at room temperature for 24 h 
and quenched with sat. aq. NaHCO3 solution (10 mL). The organic phase was washed 
with sat. aq. NaCl solution and dried over MgSO4. After evaporation and flash column 
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chromatography (n-hexane/EtOAc, 3:1), the product was isolated as a yellowish oil 
(500 mg, 0.87 mmol, 60%). 
TLC: Rf = 0.21 (n-hexane/EtOAc, 3:1) 
1H NMR (300 MHz, acetone) δ (ppm) 8.16 (dd, J = 8.8, 4.0 Hz, 1H, H-7), 7.98 – 7.83 
(m, 1H, H-NH), 7.54 – 7.24 (m, 9H, H-9, H-9’, H-4, H-14, H-14’, H-24, H-24’, H-15, H-
15’), 7.21 – 6.82 (m, 11H, H-16, H-6, H-26, H-10, H-10’,H-19, H-19’, H-20, H-20’, H-
25, H-25’), 5.14 (d, J = 17.3 Hz, 4H, H-12, H-22), 3.55 (s, 2H, H-17), 2.58 (q, J = 7.5 Hz, 
2H, H-28), 1.18 (t, J = 7.5 Hz, 3H, H-29). 
13C NMR (126 MHz, acetone) δ (ppm) 173.33 (1C, C-27), 170.00 (1C, C-1), 159.55 (1C, 
C-21), 159.05 (1C, C-11), 148.25 (1C, C-5), 138.4 (2C, C-23, C-13), 135.09 (1C, C-2), 
134.98  (2C, C-9, C-9’), 133.96 (1C, C-2),131.53 (2C, C-25, C-25’), 131.06 (2C, C-24, 
C-24’, 129.50 (4C, C-14, C-14’, C-19, C-19’), 128.85 (2C, C-15, C-15’), 128.60  (2C, C-
26, C-16), 128.31 (1C, C-7), 124.04 (1C, C-6), 121.64 (1C, C-4), 116.21 (4C, C-10, C-
10’, C-20, C-20’) (2C, C-12, C-22) 116.06, 114.29, 70.75 (1C, C-17), 28.24 (1C, C-28), 
9.60 (1C, C-29). 
MS (ESI+): 594.2 ([M+Na]+), 1165.4 ([2M+Na]+). 
HR-MS (ESI+): calc. for C37H33NO5 ([M+H]
+): 572.2431, found: 572.2431; calc. for 
C37H33NO5 ([M+Na]
+): 594.2251, found: 594.2248; calc. for C37H33NO5 ([M+K]
+): 
610.1990, found: 610.1981. 
FT-IR (Diamond-ATR): ν (cm-1) 3266.82, 2358.52, 1758.76, 1649.8, 1512.88, 1248.68, 
1141.65, 1007.62, 695.212. 
7.4.2.17 6-Amino-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl propionate (32) 
 
In a dry 250 mL Schlenk flask, under an argon atmosphere, 6-nitro-4'-(trifluoromethyl)-
[1,1'-biphenyl]-3-ol (819 mg, 2.89 mmol, 1.0 eq) was dissolved in anhydrous DCM 
(20 mL). To this solution propionic acid (0.430 mL, 5.78 mmol, 2.0 eq), and DMAP 
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(35.3 mg, 0.280 mmol, 0.1 eq) were added. The mixture was stirred for 15 min. In a 
second dry 50 mL schlenk flask under argon, EDC-HCl (555 mg, 2.89 mmol, 1.0 eq) was 
dissolved in anhydrous DCM (15 mL) and added to the reaction mixture. After complete 
addition of EDC-HCl, the flask was rinsed with an additional 10 mL of anhydrous DCM. 
The reaction mixture was stirred at ambient temperature for 12 h. The reaction mixture 
was washed with aq. HCl (1 M, 50 mL), water (50 mL), sat. aq. NaHCO3 solution 
(50 mL) and sat. aq. NaCl solution (50 mL). The organic phase was dried over MgSO4, 
filtered, and the solvent was removed in vacuo to give the compound as a yellow oil 
(922 mg, 2.71 mmol, 94%). That was used in the next step without further purification. 
In a pressure vessel, 6-nitro-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl propionate (900 mg, 
2.65 mmol, 1.0 eq) was dissolved in a mixture of EtOH (10 mL), EtOAc(5 mL), and 
acetic acid (8 mL). Pd/C (10%, 80 mg) was added to the reaction mixture, and it was 
stirred in a hydrogen atmosphere (3 bar) for 36 h. TLC analysis (n-hexane/EtOAc, 3:1) 
showed full conversion of the starting material. The reaction mixture was filtered over 
three fleeted filter papers, the filter cake was washed with EtOH and concentrated under 
reduced pressure. The title compound was isolated as yellowish-brown solid (491 mg, 
1.58 mmol, 60%) after purification by flash column chromatography (n-hexane/EtOAc, 
5:1 + 0.5% Et3N). 
TLC: Rf = 0.5 (n-hexane/EtOAc, 3:1) 
mp.: 66.3 °C 
1H NMR (300 MHz, cd2cl2) δ (ppm) 7.77 – 7.67 (m, 2H, H-9, H-9’), 7.67 – 7.56 (m, 2H, 
H-8, H-8’), 6.95 – 6.70 (m, 3H, H-2, H-3, H-6), 3.77 (s, 3H, 13), 2.55 (q, J = 7.5 Hz, 2H, 
16), 1.30 - 1.14 (m, 3H, 18). 
13C NMR (126 MHz, cd2cl2) δ (ppm) 173.54 (1C, C-12), 143.20 (1C, C-7), 142.86 (1C, 
C-4), 141.67  (1C, C-1), 129.66 (3C, C-10, C-8, C-8’), 126.48 - 125.98 (3C, C,-9, C-9’,C-
11), 123.45 (1C, C-5), 123.21 (1C, C-2), 122.48 (1C, C-6), 116.44 (1C, C-3), 27.92 (1C, 
C-13), 9.24 (1C, C-14). 
MS (ESI-): 308.1 ([M-H]-). 
HR-MS (ESI-): calc. for C16H14F3NO2 ([M-H]
-): 308.0904, found: 308.0898 
FT-IR (Diamond-ATR): ν (cm-1) 3492.45, 3383.5, 2359.48, 1747.19, 1626.66, 1495.53, 
1323.89, 1161.90, 1105.01. 
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7.4.2.18 6-(2-(4-((Tetrahydro-2H-pyran-2-yl)oxy)phenyl)acetamido)-4'-
(trifluoromethyl)-[1,1'-biphenyl]-3-yl propionate (33) 
 
In a dry Schlenk flask, 2-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)acetic acid (312 mg, 
1.32 mmol, 2.0 eq), EDC-HCl (305 mg, 1.58 mmol, 2.4 eq) and HOBt (17.6 mg, 
0.132 mmol, 0.2 eq) were dissolved in anhydrous DCM (10 mL) and stirred at room 
temperature for 10 min under an argon atmosphere. 6-Amino-4'-(trifluoromethyl)-[1,1'-
biphenyl]-3-yl propionate (204.5 mg, 0.66 mmol, 1.0 eq) was dissolved in DCM (10 mL) 
in a second dry Schlenk flask and added to the clear reaction solution. The mixture was 
stirred at room temperature for 24 h, quenched with sat. aq. NaHCO3 solution (10 mL) 
and extracted with DCM (2 x 50mL). The organic phase was washed with sat. aq. NaCl 
solution and dried over MgSO4. After evaporation and flash column chromatography 
(n-hexane/EtOAc, 3:1) the product was isolated as a yellowish solid (200 mg, 0.38 mmol, 
57%). 
TLC: Rf =0.18 (n-hexane/EtOAc, 3:1)  
mp.: 141.9 °C 
1H NMR (300 MHz, DMSO) δ 9.55 (s, 1H, NH), 7.66 (d, J = 8.1 Hz, 1H, H-7), 7.48 (dd, 
J = 8.2, 5.0 Hz, 3H, H-10, H-10’, H-4), 7.23 – 7.12 (m, 2H, H-18, H-18’), 7.12 – 7.02 (m, 
3H, H-9, H-9’, H-6), 7.00 – 6.87 (m, 2H, H-19, H-19’), 5.42 (t, J = 3.2 Hz, 1H, H-21), 
3.78 (m, 1H, H-25), 3.61 – 3.48 (m, 1H, H-25), 3.43 (s, 2H, H-16), 2.61 (q, J = 7.5 Hz, 
2H, H-14), 1.95 – 1.48 (m, 6H, H-22, H-23, H-24), 1.14 (t, J = 7.5 Hz, 3H, H-15). 
13C NMR (75 MHz, DMSO) δ 172.64 (1C, C-13), 169.65 (1C, C-1), 155.30 (1C, C-20), 
148.26 (1C, C-5), 142.18 (1C, C-8), 136.43 (1C, C-2), 129.95 (4C, C-18, C-18’, C-11, C-
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17), 129.37 (2C, C-9, C-9’), 128.50 (2C, C-10, C-10’), 125.13 (2C, C-12, C-3), 123.24 
(1C, C-7), 121.90 (1C, C-6),116.19 (3C, C-19, C-19’, C-4), 95.85 (1C, C-21), 61.49 (1C, 
C-22), 41.71 (1C, C-16), 29.91 (1C, C-22), 26.88 (1C, C-14), 24.73 (1C, C-24), 18.67 
(1C, C-23), 8.81 (1C, C-15). 
MS (ESI+): 528.2 ([M+H]+), 550.2 ([M+Na]+). 
HR-MS (ESI+): calc. for C29H28NO5F3 ([M+H]
+): 528.1992, found: 528.1996 calc. for 
C29H28NO5F3 ([M+Na]
+): 550.1812, found: 550.1822; calc. for C29H28NO5F3 
([M+NH4]
+): 545.2258, found: 545.2263. 
FT-IR (Diamond-ATR): ν (cm-1) 3219.58, 1761.65, 1654.62, 1509.03, 1322.93, 




In a one neck flask equipped with a reflux condenser, 6-(2-(4-
(benzyloxy)phenyl)acetamido)-[1,1'-biphenyl]-3-yl propionate (370 mg, 0.79 mmol, 
1.0 eq) and KOH (312 mg, 5.56 mmol, 7.0 eq) were dissolved in MeOH (30 mL). The 
reaction mixture was refluxed for 3 h, full conversion of the starting material was 
indicated by TLC analysis. The reaction mixture was concentrated in vacuo, the residue 
was dissolved in DCM (30 mL), filtered, washed with water (20 mL), sat. aq. NaCl 
solution (20 mL), dried over MgSO4 and concentrated under reduced pressure to obtain 
the title compound as off-yellow solid (320 mg, 0.78 mmol, 99%). 
TLC: Rf = 0.37 (n-hexane/EtOAc, 1:1) 
mp.: 128.2 °C 
1H NMR (300 MHz, CD3CN) δ (ppm) 7.56 (dd, J = 8.7, 4.4 Hz, 1H, H-7), 7.53 – 7.27 
(m, 8H, H-9, H-9’. H-10, H-10’, H-19, H-19’, H-20, H-20’), 7.26 – 7.14 (m, 2H, H-11, 
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H-21), 7.06 – 6.99 (m, 2H, H-14, H-14’), 6.88 – 6.81 (m, 2H, H-15, H-15’), 6.77 (dd, J = 
8.7, 2.9 Hz, 1H, H-6), 6.68 (d, J = 2.8 Hz, 1H, H-4), 5.08 (s, 2H, H-17), 3.40 (s, 2H, H-
12). 
13C NMR (126 MHz, CD3CN) δ (ppm)170.62 (1C, C-1), 158.48 (1C, C-16), 155.20 (1C, 
C-5), 139.22 (1C, C-8),138.30 (1C, C-18), 137.92 (1C, C-2), 131.21 (2C, C-14, C-14’), 
129.54, (2C, C-10, C-10), 129.38 (2C,C-20, C-20’), 128.71 (1C, C-11), 128.47 (2C, C-
19, C-19’), 128.29 (1C, C-13), 128.23 (2C, C-9, C-9’), 127.83 (1C, C-3), 127.11 (1C, C-
7), 117.28 (1C, C-6), 115.83 (2C, C-15, C-15’), 115.31 (1C, C-4), 70.5 (1C, C-17), 43.42 
(1C, C-12). 
MS (ESI-): 408.16 ([M-H]-), 817.33 ([2M-H]-) 
HR-MS (ESI-): calc. for C27H23NO3 ([M-H]
-): 408.1605, found: 408.1607 
HR-MS (ESI+): calc. for C27H23NO3 ([M+H]
+): 410.1751, found: 410.1743 calc. for 
C27H23NO3 ([M+Na]
+): 432.1570, found: 432.1566 





biphenyl]-3-yl propionate (155 mg, 0.28 mmol, 1.0 eq) was dissolved in 15 mL of MeOH, 
and stirred for 5 min. Then, KOH (177.4 mg, 2.56 mmol, 9.0 eq) was added. The reaction 
mixture was stirred for 2 h at ambient temperature. The solvent was removed under 
reduced pressure, the residue was dissolved in EtOAc (30 mL), washed with water 
(20 mL), and sat. aq. NaCl (30 mL) solution. The organic phase was dried over MgSO4 
and concentrated in vacuo. The title compound was obtained as yellowish solid (110 mg, 
0.230 mmol, 85%). 
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TLC: Rf = 0.32 (n-hexane/EtOAc, 3:1) 
mp.: 167.4 °C 
1H NMR (300 MHz, DMSO) δ 9.62 (s, 1H, NH), 9.30 (s, 1H, OH), 7.62 (d, J = 8.2 Hz, 
2H, H-9, H-9’), 7.43 (d, J = 8.1 Hz, 2H, H-10, H-10’), 7.15 (d, J = 8.6 Hz, 1H, H-7), 7.08 
– 6.97 (m, 2H, H-15, H-15’), 6.94 – 6.84 (m, 2H, H-16, H-16’), 6.79 (dd, J = 8.6, 2.8 Hz, 
1H, H-6), 6.72 (d, J = 2.8 Hz, 1H, H-4), 5.40 (t, J = 3.2 Hz, 1H, H-18), 3.77 (ddd, J = 
11.6, 8.3, 3.7 Hz, 1H, H-22'), 3.53 (dt, J = 11.3, 4.5 Hz, 1H, H-22'), 3.35 (s, 2H, H-12), 
1.95 – 1.49 (m, 6H, H-19, H-20, H-21). 
13C NMR (75 MHz, DMSO) δ 170.05 (1C, C-1), 156.00 (1C, C-5), 155.50  (1C, C-17), 
143.59 (1C, C-8), 137.68 (1C, C-2), 130.16 (3C, C-15, C-15’, C-11), 129.53 (3C, C-9, C-
9’, C-14), 129.09 (2C, C-10, C-10’), 126.27 - 125.21 (3C, C-3, C-12), 116.43 (4C, C-16, 
C-16’, C-6, C-7), 115.58 (1C, C-4), 96.14 (1C, C-18), 61.77 (1C, C-22), 41.91 (1C, C-
13), 30.20 (1C, C-19), 25.01 (1C, C-21), 18.97 (1C, C-20). 
HR-MS (ESI+): calc. for C26H24 F3NO4 ([M+H]
+): 472.1730, found: 472.1728; calc. for 
C26H24F3NO4 ([M+Na]
+): 494.1550, found: 494.1542. 
FT-IR (Diamond-ATR): ν (cm-1) 3232.11, 2971.76 1655.59, 1536.99, 1510.95, 
1321.96, 1166.72, 1107.9. 





In a dry 10 mL Schlenk flask and in an argon atmosphere, 2-(4-(benzyloxy)phenyl)-N-
(5-hydroxy-[1,1'-biphenyl]-2-yl)acetamide (50.0 mg, 0.120 mmol, 1.0 eq), 4-chloro-7-
nitro-1,2,3-benzoxadiazole (28.3 mg, 0.130 mmol, 1.1 eq), and trimethylamine (18.6 µL, 
0.134 mmol, 1.1 eq) were dissolved in anhydrous acetonitrile (3 mL). The orange 
reaction mixture was protected from light and stirred at ambient temperature for 24 h. 
The solvent was removed under reduced pressure, the residue was dissolved in DCM 
(20 mL) washed with water (20 mL), dried over anhydrous MgSO4, and concentrated in 
vacuo. The product was isolated as an orange solid (50.5 mg, 0.090 mmol, 73%) after 
purification by flash column chromatography. 
TLC: Rf = 0.23 (n-hexane/EtOAc, 2:1) 
1H NMR (500 MHz, Acetone) δ (ppm) 8.62 (d, J = 8.4 Hz, 1H, H-26), 8.33 (d, J = 8.9 
Hz, 1H, H-17), 7.53 – 7.47 (m, 2H, H-20, H-20’), 7.44 – 7.29 (m, 7H, H-5, H-5’, H-10, 
H-10’, H-9, H-9’,H-11), 7.28 – 7.21 (m, 3H, H-19, H-19’, H-21), 7.18 – 7.11 (m, 2H, H-
4, H-4’), 6.95 – 6.87 (m, 3H, H-16, H-17, H-27), 5.13 (s, 2H, H-7), 3.57 (s, 2H, H-2). 
13C NMR (126 MHz, Acetone) δ (ppm) 170.39 (1C, C-1), 158.98 (1C, C-6), 155.07 (1C, 
C-15), 150.26 (1C, C-22), 146.60 (1C, C-24), 145.55 (1C, C-18), 138.50 (1C, C-8), 
137.84 (1C, C-13), 136.65 (1C, C-23), 135.63 (1C, C-26), 134.94 (2C, C-3, C-12), 131.37 
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(2C, C-4, C-4’), 129.97 (2C, C-20, C-20’), 129.78 (2C, C-19, C-19’), 129.41 (2C, C-10, 
C-10’), 128.99 (1C, C-21), 128.73 (1C, C-11), 128.48 (2C, C-9, C-9’), 128.00 (1C, C-
25), 125.51(1C, C-17), 123.28 (1C, C-14), 121.10 (1C, C-16), 116.03 (2C, C-5, C-5’), 
110.07 (1C, C-27), 70.41 (1C, C-7), 44.04 (1C, C-2). 
HR-MS (ESI+): calc. for C33H24N4O6 ([M+H]
+): 573.1769, found: 573.1769 calc. for 
C33H24N4O6 ([M+Na]
+): 595.1588, found: 595.1588. calc. for C33H24N4O6 ([M+K]
+): 





In a dry one-neck flask, under an argon atmosphere, N-(5-hydroxy-4'-(trifluoromethyl)-
[1,1'-biphenyl]-2-yl)-2-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)acetamide (87.0 mg, 
0.180 mmol, 1.0 eq), 4-chloro-7-nitro-1,2,3-benzoxadiazole (36.1 mg, 0.180 mmol, 
1.1 eq) were dissolved in anhydrous acetonitrile (10 mL). The reaction mixture was 
stirred for 5 min. Then, triethylamine (28.13 µL, 0.200 mmol, 1.1 eq) was added, which 
resulted in an intense orange colour of the reaction solution. The reaction was protected 
from light and stirred at ambient temperature for 24 h. As TLC analysis showed no further 
consumption of the starting material, the reaction was stopped. The solvent was removed 
under reduced pressure, the residue was dissolved in DCM (50 mL) washed with water 
(40 mL), dried over anhydrous MgSO4, and concentrated in vacuo. The title compound 
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was isolated as a yellow-orange solid (56.5 mg, 0.080 mmol, 50%) after purification by 
flash column chromatography (n-hexane/EtOAc, 1:1). 
TLC: Rf = 0.5 (n-hexane/EtOAc, 1:1) 
mp.: 171.5 °C 
1H NMR (300 MHz, CD2Cl2) δ (ppm) 8.53-8.38 (m, 2H, H-22, H-NH), 7.66 – 7.55 (m, 
2H, H-14, H-14’), 7.39 – 7.22 (m, 3H, H-12, H-15, H-15’), 7.20 – 7.07 (m, 2H, H-9, H-
11), 7.06 – 6.96 (m, 2H, H-4, H-4’), 6.99 – 6.84 (m, 2H, H-5, H-5’), 6.64 (d, J = 8.3 Hz, 
1H, H-23), 5.38 (t, J = 3.3 Hz, 1H, H-24), 3.86 (ddd, J = 11.8, 9.0, 3.2 Hz, 1H, H-25), 
3.58 (s, 2H, H-2), 3.67 – 3.50 (m, 1H, H-25), 2.09 – 1.78 (m, 3H, H-27, H-28), 1.68-1.52 
(m, 3H, H-26, H-27). 
13C NMR (126 MHz, CD2Cl2) δ (ppm) 169.60 (1C, C-1), 156.91 (1C, C-6), 154.40 (1C, 
C-10), 149.03 (1C, C-18), 145.54 (1C, C-19), 144.58 (1C, C-20), 140.39 (1C, C-13), 
134.01 (1C, C-7), 130.81 (2C, C-4, C-4’), 129.65 (2C, C-15, C-15’), 126.76 (2C, C-16, 
C-17), 126.48 (2C, C-14, C-14’), 125.53 (1C, C-8), 123.97 (1C, C-22), 123.37 (1C, C-3), 
122.55 (2C, C-9, C-11), 121.46 (1C, C-12), 117.50 (2C, C-5, C-5’), 108.57 (1C, C-23), 
96.92 (1C, C-24), 62.52 (1C, C-25), 44.49 (1C, C-2), 30.71 (1C, C-28), 25.67 (1C, C-26), 
19.32 (1C, C-27). 
19F NMR (282 MHz, CD2Cl2) δ (ppm) -60.97. 
MS (ESI+): 635.2 ([M+H]+), 657.2 ([M+Na]+) 
HR-MS (ESI+): calc. for C32H25N4O7F3 ([M+H]
+): 635.1748, found: 635.1736; calc. for 
C32H25N4O7F3 ([M+Na]
+): 657.1568, found: 657.1561. 





In one-neck flask a mixture of N-(5-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)oxy)-4'-
(trifluoromethyl)-[1,1'-biphenyl]-2-yl)-2-(4-((tetrahydro-2H-pyran-2-
yl)oxy)phenyl)acetamide (34 mg, 0.050 mmol. 1.0 eq) and pyridinium p-toluenesulfonate 
(5.00 mg, 5.00 µmol, 0.1 eq) in MeOH (10 mL) was stirred at 50 °C for 24 h. The solvent 
was removed under reduced pressure, the residue was dissolved in EtOAc (15 mL) 
washed with water (10 mL), sat. aq. NaHCO3 (15 mL) solution. The organic layer was 
separated, dried over anhydrous MgSO4, and concentrated in vacuo. The title compound 
was obtained as a yellow-orange solid (21.0 mg, 0.040 mmol, 74%) after purification by 
flash column chromatography (DCM/MeOH, 100:1). 
TLC: Rf = 0.3 (n-hexane/EtOAc, 1:1) 
1H NMR (400 MHz, Acetone) δ (ppm) 8.64 (d, J = 8.4 Hz, 1H, H-22), 8.39 (s, 1H, H-
NH), 8.34 (s, 1H, H-OH), 8.23 (d, J = 8.6 Hz, 1H, H-12), 7.71 (d, J = 8.0 Hz, 2H, H-15, 
H-15’), 7.54 (d, J = 8.0 Hz, 2H, H-14, H-14’), 7.47 (d, J = 8.9 Hz, 1H, H-11), 7.40 (s, 
1H, H-9), 7.08 (d, J = 8.1 Hz, 2H, H-4, H-4’), 6.95 (d, J = 8.4 Hz, 1H, H-23), 6.77 (d, J 
= 8.2 Hz, 2H, H-5, H-5’), 3.55 (s, 2H, H-2). 
13C NMR (101 MHz, Acetone) δ (ppm) 169.66 (1C, C-1) , 156.57 (1C, C-6), 153.89  (1C, 
C-10), 149.98 (1C, C-18), 145.85 (1C, C-20), 144.50 (1C, C-13), 134.55 (1C, C-22), 
133.98 (1C, C-19), 130.37 (3C, C-7, C-4, C-4’), 129.68  (4C, C-14, C-14’, C-3, C-16), 
126.01, (1C, C-12), 125.63 (3C, C-15, C-15’, C-17), 122.39 (1C,  C-9), 120.87 (2C, C-8, 
C-11), 115.43  (3C, C-5, C-5’, C-21), 109.31  (1C, C-23), 42.84 (1C, C-2). 
 7.4 Synthesis of ligand molecules 
159 
19F NMR (377 MHz, Acetone) δ -62.97 (CF3). 
MS (ESI+): 573.1 ([M+Na]+). 
HR-MS (ESI+): calc. for C27H17F3N4O6 ([M+Na]
+): 573.0992, found: 573.0995 
FT-IR (Diamond-ATR): ν (cm-1) 2367.19,1735.62, 1653.66, 1615.09, 1540.85, 1509.03, 
1323.89, 1261.22. 
7.4.2.24 N-(5-Hydroxy-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)-2-(4-
hydroxyphenyl)acetamide (L9)  
 
In a pressure vessel 2-(4-(Benzyloxy)phenyl)-N-(5-hydroxy-4'-(trifluoromethyl)-[1,1'-
biphenyl]-2-yl)acetamide (85.0 mg, 0.160 mmol, 1.0 eq) was dissolved with EtOH 
(15 mL), and acetic acid (3 mL). Pd/C (30 mg) was added to the reaction mixture, which 
was stirred in a hydrogen atmosphere (3 bar) for 8 h. After this time, TLC analysis (n-
hexane/EtOAc, 1:1) showed complete consumption of the starting material. The reaction 
mixture was filtered over three fleeted filter papers, the filter cake was washed with EtOH 
and concentrated in vacuo. The title compound was isolated as an off-white solid 
(60.0 mg, 0.155 mmol, 97%.) after purification by flash column chromatography 
(n-hexane/EtOAc, 1:1). 
TLC: Rf = 0.21 (n-hexane/EtOAc, 1:1) 
mp.: 85 °C 
1H NMR (400 MHz, CD3CN) δ (ppm)7.64 – 7.55 (m, 3H, H-15, H-15’), 7.42 (d, J = 8.7 
Hz, 1H, H-12), 7.40 – 7.30 (m, 2H, H-14, H-14’), 6.97 – 6.89 (m, 2H, H-4, H-4’), 6.81 
(dd, J = 8.7, 2.9 Hz, 1H, H-11), 6.72 (d, J = 2.8 Hz, 1H, H-9), 6.69 – 6.63 (m, 2H, H-5, 
H-5’), 3.36 (s, 2H, H-2). 
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13C NMR (101 MHz, CD3CN) δ (ppm) 171.24 (1C, C-1), 156.89 (1C, C-6), 155.88 (1C, 
C-10), 143.79 (1C, C-13), 137.65 (1C, C-7), 131.37 (2C, C-14, C-14’), 130.40 (3C, C-4, 
C-4’, C-8), 128.56 (2C, C-15, C-15’), 127.77 (1C, C-3), 127.23 (1C, C-16), 126.09 (1C, 
C-17), 117.35 (1C, C-11), 116.25 (3C, C-5, C-5’, C-9), 43.32 (1C,C-2). 
19F NMR (376 MHz, CD3CN) δ (ppm)-62.84 (CF3). 
MS (ESI+): 410.1([M+Na]+), 388.2 ([M+H]+) 
HR-MS (ESI+): calc. for C21H16NO3F3 ([M+H]
+): 388.1155, found: 388.1155 calc. for 
C21H16NO3F3 ([M+Na]
+): 410.0974, found: 410.0978 





To a solution of 4'-(benzyloxy)-6-(2-(4-(benzyloxy)phenyl)acetamido)-[1,1'-biphenyl]-
3-yl propionate (469 mg, 0.820 mmol, 1.0 eq) in EtOAc (45 mL), EtOH (50 mL), and 
acetic acid (5 mL), in a small pressure reactor vessel, Pd/C (10%, 60 mg) was added. The 
reaction mixture was stirred in a hydrogen atmosphere (3 bar) at ambient temperature for 
12 h. Afterwards, TLC analysis (n-hexane/EtOAc, 2:1) showed complete consumption of 
the starting material. The mixture was filtered through three pleated filters and washed 
with EtOH. The filtrate was concentrated in vacuo to give a colourless oil (345 mg) which 
was used without further purification in the next step. 
The oil was dissolved in MeOH (15 mL), and KOH (449 mg, 0.880 mmol, 7.0 eq) was 
added under stirring. The reaction was monitored by TLC analysis (DCM/MeOH, 19:1). 
As starting material was still observed after stirring 3 h under reflux, further KOH 
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(234 mg, 0.440 mmol) was added and the reaction was left to equilibrate under reflux 
overnight. After 20 h, no further product formation was observed. Hence, the solvent was 
removed under reduced pressure, the residue was dissolved in DCM (30 mL), filtered, 
and washed with acidified water pH (4-5). The title compound was purified by flash 
column chromatography (DCM/MeOH 19:1) and isolated as an off-white solid (213 mg, 
0.64 mmol, 78%). 
TLC: Rf = 0.14 (DCM/MeOH, 19:1) 
mp.: 92.5 °C 
1H NMR (500 MHz, Acetone) δ (ppm) 7.93 (s, 1H, H-NH), 7.72 (d, J = 7.0 Hz, 1H, H-
12), 7.06 – 7.01 (m, 4H, H-14, H-14’, H-4, H-4’), 6.83 – 6.80 (m, 2H, H-15, H-15’), 6.76 
– 6.72 (m, 3H, H-11, H-5, H-5’), 6.67 (d, J = 2.9 Hz, 1H, H-9), 3.46 (s, 2H, H-2). 
13C NMR (126 MHz, Acetone) δ (ppm) 170.43 (1C, C-1), 157.86 (1C, C-16), 157.32 
(1C, C-6), 155.37 (1C, C-10), 136.91 (1C, C-7), 131.25 (2C, C-4, C-4’), 130.91 (2C, C-
14, C-14’), 130.47 (1C, C-3), 128.20 (1C, C-13), 127.08 (1C, C-8), 126.28 (1C, C-12), 
117.29 (1C, C-9), 116.42 (2C, C-15, C-15’), 116.32 (2C, C-5, C-5’), 114.75 (1C, C-11), 
43.77 (1C, C-2). 
MS (ESI+): 336.1 ([M+H]+), 358.1([M+Na]+). 
HR-MS (ESI+): calc. for C20H17NO4 ([M+H]
+): 336.1230, found: 336.1234; calc. for 
C20H17NO4 ([M+Na]
+): 358.1050, found: 358.1046. 
FT-IR (Diamond-ATR): ν (cm-1) 3285.14, 1611.23, 1513.85, 1444.42, 1230.36, 
821.527. 





In a reactor pressure vessel 2-(4-(Benzyloxy)phenyl)-N-(5-hydroxy-[1,1'-biphenyl]-2-
yl)acetamide (115 mg, 0.280 mmol, 1.0 eq) was dissolved in a mixture of EtOAc 
(10 mL), EtOH (15 mL) and acetic acid (5 mL), and Pd/C (10%, 50 mg) was added. The 
reaction was stirred at room temperature in a hydrogen atmosphere (2 bar) for 24 h, after 
which full consumption of starting material was indicated by TLC analysis 
(n-hexane/EtOAc, 1:1). The reaction mixture was filtered over three fleeted filter papers, 
and the filter cake was washed thoroughly with EtOH and concentrated in vacuo. The 
title compound was isolated as an off-white solid (85.0 mg, 0.280 mmol, quant.) after 
purification by flash column chromatography (n-hexane/EtOAc 1:1). 
TLC: Rf = 0.20 (n-hexane/EtOAc, 1:1) 
mp.: 94 °C 
1H NMR (300 MHz, dmso) δ (ppm) 9.48 (s, 1H, NH), 9.22 (s, 1H, OH), 9.04 (s, 1H, OH), 
7.41 – 7.24 (m, 4H, H-7, H-11, H-10, H-10’), 7.24 – 7.12 (m, 2H, H-9, H-9’), 6.99 – 6.88 
(m, 2H, H-14, H-14’), 6.77 – 6.68 (m, 2H, H-6, H-4), 6.68 – 6.59 (m, 2H, H-15, H-15’), 
3.31 (s, 2H, H-12). 
13C NMR (126 MHz, dmso) δ (ppm) 169.84 (1C, C-1), 155.67 (1C, C-16), 155.16 (1C, 
C-5), 138.76 (C, C-2), 138.13 (1C, C-8), 129.79 (2C, C-14, C-14’), 128.70 (2C, C-10, C-
10’), 128.40 (1C, C-3), 128.02 (3C, C-9, C-9’, C-11), 126.87 (1C, C-13), 125.89 (1C, C-
7), 116.12 (1C, C-6), 114.85 (2C, C-15, C-15’), 114.30 (1C, C-4), 41.65 (1C, C-12). 
FT-IR (Diamond-ATR): ν (cm-1) 3345.89, 2321.87, 1735.62, 1541.81, 1232.29, 
1204.33. 
MS (ESI+): 320.1 ([M+H]+), 342.1 ([M+Na]+), 661.3 ([2M+Na]+). 
 7.4 Synthesis of ligand molecules 
163 
HR-MS (ESI+): calc. for C20H17NO3 ([M+H]
+): 320.1281, found: 320.1278 calc. for 
C28H22NO3F3 ([M+Na]
+): 342.1101, found: 342.1095. 
7.4.2.27 2-Bromo-1-(4-(tert-butoxy)phenyl)ethan-1-one (40) 
 
In a two-neck flask, which was equipped with a reflux condenser, CuBr2 (1.78 g, 
7.98 mmol, 2.0 eq) and 1-(4-(tert-butoxy)phenyl)ethan-1-one were dissolved in EtOAc 
(40 mL) and refluxed for 36 h. The reaction mixture was cooled down to room 
temperature, filtered over celite, and the solvent was concentrated under reduced pressure. 
TLC analysis showed consumption of starting material, the crude mixture was obtained 





In a Schlenk flask, and under an argon atmosphere, 3,4-dihydro-2H-pyran (1.91 mL, 
0.020 mmol, 1.5 eq) and pyridinium p-toluenesulfonate (175 mg, 0.700  mmol, 0.1 eq) 
were added to the suspension of 2-bromo-1-(4-hydroxyphenyl)ethan-1-one (3.00 g, 
14 mmol, 1.0 eq) in anhydrous DCM (28 mL). The reaction mixture was stirred for 72 h 
at room temperature while monitoring by TLC (n-hexane/EtOAc, 7:1). The black reaction 
mixture was diluted with sat. aq. NaHCO3 (40 mL), the layers were separated, and the 
aqueous layer was extracted with DCM (3 x 30 mL). The combined organic layers were 
washed with sat. aq. NaCl (50 mL), dried over MgSO4 and concentrated in vacuo. The 
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title compound was obtained as a brownish solid (2.50 g, 8.36 mmol, 60%), after 
purification by flash column chromatography (n-hexane/EtOAc, 7:1). 
TLC: Rf = 0.23 (n-hexane/EtOAc, 7:1) 
1H NMR (600 MHz, cd2cl2) δ (ppm)7.97 – 7.87 (m, 2H, H-4, H-4’), 7.13 – 7.07 (m, 2H, 
H-5, H-5’), 5.52 (t, J = 3.2 Hz, 1H, H-7), 4.43 (s, 2H, H-2), 3.81 (ddd, J = 11.3, 9.9, 3.0 
Hz, 1H, H-11''), 3.59 (dtd, J = 11.4, 4.1, 1.5 Hz, 1H, H-11'), 2.03 – 1.93 (m, 1H, H-10''), 
1.92 – 1.79 (m, 2H, H-8), 1.74 – 1.63 (m, 2H, H-9'', H-10'), 1.62 – 1.55 (m, 1H, H-9'). 
13C NMR (126 MHz, dmso) δ (ppm)189.92 (1C, C-1), 160.64 (1C, C-6), 130.76 (2C, C-
4, C-4’), 127.27 (1C, C-3), 116.01 (2C, C-5, C-5’), 95.45 (1C, C-7), 61.55 (1C, C-11), 
30.07 (1C, C-2), 24.46 (1C, C-10), 18.28 (1C, C-9). 
MS (ESI+): 321.0 [M+Na+] 
HR-MS (ESI+): calc. for C13H15BrO3 ([M+Na]
+): 321.0097, found: 321.0101 calc. for 
C13H15BrO3 ([M+Na]
+): 323.0077, found: 323.0082 
FT-IR (Diamond-ATR): ν (cm-1) 3267.79, 2941.88, 1597.73 
7.4.2.29 6-((2-Oxo-2-phenylethyl)amino)-[1,1'-biphenyl]-3-yl propionate (44) 
 
In a two-neck flask, equipped with reflux condenser, 6-amino-[1,1'-biphenyl]-3-yl 
propionate (161 mg, 0.670 mmol, 1.0 eq) was dissolved in MeCN (20 mL). Then K2CO3 
(184 mg, 1.32 mmol, 2.0 eq) and 2-bromo-1-phenylethan-1-one (132 mg, 0.670 mmol, 
1.0 eq) were added. While reflux for 48 h, and monitoring by TLC analysis 
(n-hexane/EtOAc, 4:1), there was no observed change on the TLC plate. Mass analysis 
of the crude reaction mixture didn’t show any product formation. 





In a two-neck flask, under an argon atmosphere, 6-amino-[1,1'-biphenyl]-3-yl propionate 
(237 mg, 0.980 mmol, 1.1 eq) was dissolved in anhydrous DCM, followed by addition of 
pyridine (0.1 mL,0.980 mmol, 1.1 eq). In a second one-neck flask, and under argon, 4-
nitrobenzenesulfonyl chloride (218 mg, 0.890 mmol, 1.0 eq) was dissolved in anhydrous 
DCM (15 mL) and added to the reaction mixture. The reaction mixture was stirred for 
12 h at room temperature and afterwards refluxed for an additional 12 h. Brown solid 
reaction mixture was dissolved in DCM (15 mL), washed with 1 M HCl (20 mL). The 
organic phase was separated, and the aqueous phase was extracted with DCM (3x10 mL). 
The combined organic layers were washed with sat. aq. NaCl, dried over Na2SO4 and 
concentrated in vacuo. After purification by flash column chromatography (n-
hexane/EtOAc, 6:1) 6-((4-nitrophenyl)sulfonamido)-[1,1'-biphenyl]-3-yl propionate 46 
was obtained as a brownish oil (223 mg, 58%). The oil (190 mg, 0.450 mmol, 1.0 eq) was 
dissolved in MeCN (10 mL). Then K2CO3 (124 mg, 0.890 mmol, 2.0 eq), and 2-bromo-
1-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)ethan-1-one (147 mg, 0.490 mmol, 1.1 eq) 
were added. The yellow reaction mixture was stirred at room temperature for 24 h. TLC 
analysis monitoring did not show the formation of the product; hence the reaction mixture 
was refluxed for 4 h. The solvent was concentrated in vacuo, and the residue was 
dissolved in water (70 mL) extracted with EtOAc (3x40 mL). The organic layers were 
washed with sat. aq. NaCl solution (50 mL), dried over MgSO4 and concentrated in vacuo 
to obtain a yellow oil. Mass analysis of the crude yellow oil did not show any traces of 
product formation. 
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7.4.2.31 4-Aminophenyl benzoate (56) 
 
In a 250 mL hydrogen pressure vessel 4-nitrophenyl benzoate (1.56 g, 6.41 mmol, 1.0 eq) 
was dissolved in EtOH (20 mL) and EtOAc (15 mL), Pd/C (156 mg, 10%) was added to 
the stirring solution. The vessel was purged three times with nitrogen, followed by 
hydrogen. The reaction was stirred at room temperature for 3.5 h, at 2.5 bar. After 2 h 
pressure dropped to 1 bar, the reaction was stirred for an additional 1.5 h, there was no 
additional change in pressure observed. The TLC plate control (n-hexane/EtOAc, 2:1) 
showed complete consumption of the starting material. The reaction mixture was filtered 
over three pleated filter papers, washed thoroughly with EtOAc and dried in vacuum. 
Product was obtained as an off-white solid (1.29 g, 6.05 mmol, 95%). 
TLC: Rf = 0.28 (n-hexane/EtOAc 2:1) 
mp.: 156.1 °C 
1H NMR (300 MHz, CD2Cl2) δ (ppm) 8.17 (d, J = 7.7 Hz, 2H, H-3, H-3’), 7.65 (d, J = 
14.8 Hz, 1H, H-5), 7.56 – 7.48 (m, 2H, H-4, H-4’), 6.98 (d, J = 8.8 Hz, 2H, H-7, H-7’), 
6.71 (d, J = 8.8 Hz, 2H, H-8, H-8’), 3.75 (s, 2H, H-NH2). 
13C NMR (75 MHz, CD2Cl2): δ (ppm) 165.63 (1C, C-1), 144.73 (1C, C-9), 142.86 (1C, 
C-6), 133.36 (1C, C-5), 129.90 (2C, C-3, C-3’), 128.52 (2C, C-4, C-4’), 122.24 (2C, C-
7, C-7’) 115.27 (2C, C-8, C-8’). 
HR-MS (ESI+): calc. for C13H11NO2 ([M+H]
+): 214.0863, found: 214.0867; calc. for 
C13H11NO2 ([M+Na]
+): 236.0682, found: 236.0687 
FT-IR (Diamond-ATR): ν (cm-1) 3449.06, 3370.96, 2361.41, 1715.37, 1508.06, 1273.75, 
1191.79. 
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7.4.2.32 4-Amino-3-bromophenyl benzoate (57) 
 
In one neck flask in an argon atmosphere, 4-aminophenyl benzoate (630 mg, 2.97 mmol, 
1.0 eq) was dissolved in anhydrous DCM (18 mL). After stirring for five minutes NBS 
(529 mg, 2.97 mmol, 1.0 eq) was added. The reaction was monitored by TLC plate (n-
hexane/EtOAc 2:1) for 6h. The reaction was stopped after 20h, a dark purple solution was 
washed with water (3x 25 mL), aq. NaCl (50 mL), dried over MgSO4 and concentrated in 
vacuum. The product was purified by flash column chromatography and obtained as a 
dark red solid (683 mg, 2.33 mmol, 78%). 
TLC: Rf = 0.50 (n-hexane/EtOAc, 2:1) 
mp.: 56.3 °C 
1H NMR (300 MHz, CD2Cl2) δ (ppm) 8.24 – 8.14 (m, 2H, H-3, H-3’), 7.75 – 7.63 (m, 
1H, H-5), 7.56 (t, J = 7.7 Hz, 2H, H-4, H-4’), 7.35 (d, J = 2.6 Hz, 1H, H-7), 7.04 (dd, J = 
8.7, 2.6 Hz, 1H, H-11), 6.86 (d, J = 8.7 Hz, 1H, H-10), 4.18 (s, 2H, H-NH2). 
13C NMR (75 MHz, CD2Cl2) δ 165.32 (1C, C-1), 142.46 (1C, C-9), 133.56 (1C, C-5), 
129.95 (3C, C-3, C-3’, C-2), 129.48, 128.57 (2C, C-4, C-4’), 125.50 (1C, C-7), 121.82  
(1C, C-11), 115.39 (1C, C-10), 108.10 (1C, C-8). 
HR-MS (ESI+): calc. for C13H10BrNO2 ([M+H]
+): 291.9968, found: 291.9970 calc. for 
C13H10BrNO2 ([M+Na]
+): 313.9787, found: 313.9788 
FT-IR (Diamond-ATR): ν (cm-1) 3466.41, 3376.74, 1728.87, 1487.81, 1253.50, 702.96. 
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7.4.2.33 4-(((Benzyloxy)carbonyl)amino)-3-bromophenyl benzoate (58) 
 
In one neck flask, 4-amino-3-bromophenyl benzoate (5.08 g, 17.3 mmol, 1.0 eq) was 
dissolved in EtOAc (60 mL) and pyridine (1.62 mL, 20.07 mmol, 1.3 eq) was added. The 
reaction mixture was cooled down while dropwise addition of CBz-Cl (4.86 mL, 
34.7 mmol, 2.0 eq). Shortly after addition, white suspension occurred. The reaction was 
monitored by TLC plate (n-hexane/EtOAc, 3:1), and it was stopped after 1 h. The reaction 
mixture was washed with water and the aqueous phase was extracted with EtOAc (3 x 
40 mL). The combined organic phases were washed with (2 x 40 mL), sat. aq. NaHCO3 
solution sat. aq. NaCl solution (50 mL), dried over MgSO4 and the solvent was removed 
under reduced pressure. The obtained crude product was recrystallized from 
(n-hexane/EtOAc, 10:1) 370 mL, and the product was obtained as a light orange needle 
(6.48 g, 15.2 mmol, 87%). 
TLC: Rf = 0.77 (n-hexane/EtOAc, 2:1) 
mp.: 99.4 °C 
1H NMR (300 MHz, Acetone) δ (ppm) 8.22 – 8.13 (m, 2H, H-3, H-3’), 8.09 – 8.00 (m, 
1H, H-5), 7.80 – 7.68 (m, 1H, H-7), 7.68 – 7.54 (m, 3H, H-4, H-4’, H-10), 7.52 – 7.29 
(m, 6H, H-15, H-15’, H-16, H-16’, H-17, H-11), 5.23 (s, 2H, H-13). 
13C-NMR (75 MHz, Acetone) δ (ppm) 165.35 (1C, C-1), 158.93 (1C, C-12), 154.40 (1C, 
C-14), 148.26 (1C, C-6), 137.51(1C, C-2), 135.17 (1C, C-9), 134.75 (1C, C-5), 130.82 
(2C, C-3, C-3´), 130.15 (1C, C-8), 129.66 (2C, C-4, C-4´), 129.32 (2C, C-16, C-16´), 
128.98 (2C, C-15, C-15´), 126.89 (1C, C-17), 124.37 (1C, C-11), 122.67 (1C, C-10), 
100.87 (1C, C-7),67.52 (C-13). 
HR-MS (ESI+): calc. for C21H16BrNO4 ([M+H]
+): 426.0335, found: 426.0331. 
FT-IR (Diamond-ATR): ν (cm-1) 3300.05, 3029.15, 2958.98, 1751.93, 1689.76, 
1527.22, 753.62, 699.43. 
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7.4.2.34 Benzyl (2-bromo-4-hydroxyphenyl) carbamate (59) 
 
In a one neck flask, 4-amino-3-bromophenyl benzoate (428 mg, 1.47 mmol, 1.0 eq) was 
dissolved in 10 mL of EtOAc. Pyridine (153.7 µL, 1.90 mmol, 1.3 eq) was added and the 
reaction mixture was stirred for 5 min. The reaction mixture was cooled down while 
dropwise addition of CBz-Cl (420 µL, 2.93 mmol, 2.0 eq). Shortly after addition reaction 
mixture became a white suspension.  The reaction was monitored by TLC 
(n-hexane/EtOAc, 2:1), and it was stopped after 1.5 h. The reaction mixture was washed 
with water (25 mL), sat. aq. NaHCO3 solution (30 mL), sat. aq. NaCl solution (50 mL), 
dried over MgSO4 and the solvent was removed under vacuum. The quantitatively 
obtained product was used further in the second step without additional purification. It 
was dissolved in MeOH (50 mL), stirred for 20 min, until the reaction mixture was 
homogenous, K2CO3 (261.4 mg, 1.89 mmol, 2.6 eq) was added and the reaction was 
stirred on room temperature for 30 min. TLC (n-hexane/EtOAc, 3:1) analysis confirmed 
completion of the reaction, as no educt was observed on the TLC plate. MeOH was 
removed under vacuum, the reaction mixture was dissolved in EtOAc (20 mL), washed 
with water (30 mL), sat. aq. NaHCO3 solution (30 mL), sat. aq. NaCl solution (30 mL), 
dried over MgSO4 and the solvent was removed under vacuum. The product was isolated 
as a white solid (388 mg, 1.20 mmol, 81%) after purification by flash column 
chromatography. 
TLC: Rf = 0.16 (n-hexane/EtOAc, 5:1) 
mp.: 150.3 °C 
1H NMR (300 MHz, Acetone) δ 8.67 (s, 1H, H-OH), 7.79 (s, 1H, H-NH), 7.58 (d, J = 8.8 
Hz, 2H, H-6), 7.48 – 7.25 (m, 5H, H-10, H-10’, H-11, H-11’, H-12), 7.10 (dd, J = 2.8, 
0.8 Hz, 1H, H-4), 6.86 (dd, J = 8.8, 2.7 Hz, 1H, H-6), 5.17 (s, 2H, H-8). 
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13C NMR (75 MHz, Acetone) δ, 155.19 (1C, C-1), 154.12 (1C, C-5), 137.00 (1C, C-9), 
128.47 (1C, C-2) 128.38 (3C, C-11, C-11’, C-12), 127.92 (3C, C-10, C-10’, C-7), 118.81 
(1C, C-4), 115.07 (1C, C-6), 66.24 (1C, C-8). 
HR-MS (ESI+): calc. for C14H12BrNO3 ([M+Na]
+): 343.9893, found: 343.9906. 
FT-IR (Diamond-ATR): ν (cm-1) 3291.89, 3031.55, 2317.05, 2116.49, 1662.34,1528.31, 
1340.28, 1216.86, 1070.3, 867.81, 757.88. 
7.4.2.35 Benzyl (5-hydroxy-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-
biphenyl]-2-yl)carbamate (60)  
 
In a 10 mL microwave vial, benzyl (2-bromo-4-hydroxyphenyl)carbamate (58.0 mg, 
0.16 mmol, 1.0 eq), (4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)boronic acid (37.9 mg, 
0.170 mmol, 1.1 eq), Na2CO3 (32.85 mg, 0.310 mmol, 2.0 eq) and Pd(PPh3)4 (9.00 mg, 
0.078 mmol, 5 mol%) were dissolved in 3 mL (DME/H2O, 3:1) solvent; previously 
degassed under an argon stream for 30 min. Upon addition, a light yellow solution 
occurred; the reaction mixture was placed into a microwave, stirred for 10 min at 110 °C, 
and maximal pressure was 12 psi. TLC plate control (n-hexane/EtOAc, 2:1) showed 
completion of the reaction, consecutively, the solvent was removed under reduced 
pressure. The reaction mixture was dissolved in EtOAc and washed with water (2 x 
10 mL). The aqueous phase was extracted with EtOAc (2 x 15 mL). Afterwards, the 
combined organic phases were washed with sat. aq. NaHCO3 solution (20 mL), sat. aq. 
NaCl solution (20 mL), dried over MgSO4 and concentrated in vacuum resulting as crude 
orange-yellow oil. The pure product was obtained as a white solid (45.0 mg, 0.110 mmol, 
68%) after flash column chromatography with (n-hexane/EtOAc, 3:1). 
TLC: Rf = 0.22 (n-hexane/EtOAc, 3:1) 
mp.: 46.3 °C 
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1H NMR (300 MHz, CD2Cl2) δ7.70 (d, J = 8.6 Hz, 1H, -OH), 7.34 (m, 5H, H-19, H-19’, 
H-20, H-20’, H-21), 7.26 – 7.18 (m, 2H, H-9, H-9’), 7.13 – 7.03 (m, 2H, H-10, H-10’), 
6.76 – 6.65 (m, 2H, H-4, H-6), 6.49 (s, 1H, H-7), 5.79 (s, 1H, -NH), 5.45 (t, J = 3.4 Hz, 
1H, H-12), 5.12 (s, 2H, H-17, H-17’), 3.92 (ddd, J = 11.8, 8.9, 3.2 Hz, 1H, H-13), 3.65 – 
3.56 (m, 1H, H-13’), 2.07 – 1.80 (m, 3H, H-16, H-16’, H-15), 1.66 (tdd, J = 17.6, 8.7, 4.5 
Hz, 3H, H-14, H-14’, H-15). 
13C NMR (75 MHz, CD2Cl2) δ 157.36 (C-11), 154.81 (C-5), 153.25 (C-1), 137.03 (C-
18), 131.69 (C-8), 130.67 (C-9, C-9´), 129.02 (C-20, C-20´), 128.67 (C-21), 128.58 (C-
19, C-19´), 128.00 (C-3), 117.44 (C-2), 117.36 (C-6, C-10, C-10´), 115.18 (C-4, C-7), 
97.09 (C-12), 67.38 (C-17), 62.85(C-13), 30.92 (C-16), 25.76 (C-14), 19.47 (C-15). 
HR-MS (ESI-): calc. for C25H25NO5 ([M-H]
-): 418.1660, found: 418.1655 
FT-IR (Diamond-ATR): ν (cm-1) 3315.15, 3052.25, 2935.89, 2881.71, 1712.85, 1612.49, 
1512.12, 1434.85, 1194.15, 1116.88, 1031.61, 954.34, 923.25, 822.88, 753.61, 706.53.  
7.4.2.36 6-(((Benzyloxy)carbonyl)amino)-4'-((tetrahydro-2H-pyran-2-
yl)oxy)-[1,1'-biphenyl]-3-yl benzoate (61) 
 
In a dry 100 mL Schlenk flask, benzoic acid (1.25 g, 10.2 mmol, 2.0 eq), 4-
(dimethylamino)-pyridine (63.0 mg, 0.512 mmol, 0.1 eq) and EDC-HCl (1.47 g, 
7.68 mmol, 1.5 eq) were dissolved in anhydrous chloroform (30 mL). Benzyl (5-hydroxy-
4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-2-yl)carbamate (2.09 g, 4.99 mmol, 
1.0 eq) was dissolved in anhydrous chloroform (40 mL) and added to the reaction 
mixture. It was stirred overnight at room temperature. After monitoring the reaction by 
TLC (n-hexane/EtOAc, 4:1), the reaction was stopped as it was observed the complete 
consumption of the starting material. The solvent was removed under reduced pressure, 
and the reaction mixture was diluted in EtOAc (40 mL), washed with water (50 mL). The 
aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic phase was 
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washed with 1 M HCl, sat. aq. NaHCO3 solution, sat. aq. NaCl solution dried over MgSO4 
and concentrated in vacuum. Product was isolated as a brown solid (2.21 g, 4.22 mmol, 
83%) after purification by flash column chromatography (n-hexane/EtOAc, 4:1). 
TLC: Rf = 0.66 (n-hexane/EtOAc 4:1) 
mp.: 97 °C 
1H NMR (300 MHz, CD2Cl2) δ (ppm) 8.25 – 8.14 (m, 3H,  H-3, H-3’, H-10), 7.64 – 7.44 
(m, 3H, H-5, H-4, H-4’), 7.43 – 7.26 (m, 6H, H-16, H-16’, H-17, H-17’, H-18, H-11), 
7.26 – 7.07 (m, 4H, H-20, H-20’, H-21, H-21), 6.80 (s, 1H, H-12), 5.46 (t, J = 3.3 Hz, 
1H, H-23), 5.17 (s, 2H, H-14), 3.94- 3.87 (m, 1H, H-24), 3.68 – 3.54 (m, 1H, H-24'), 2.10 
– 1.77 (m, 3H, H-26, H-27), 1.77 – 1.50 (m, 3H, H-25, H-26). 
13C NMR (75 MHz, CD2Cl2) δ (ppm) 165.61 (1C, C-1), 157.61 (1C, C-22), 153.86 (1C, 
C-13), 146.96 (1C, C-6), 136.76 (1C, C-15), 133.22 (2C, C-5, C-8), 130.65 (5C, C-16, C-
16’, C-17, C-17’, C-18), 130.00 (2, C-19, C-2), 129.01 (4C, C-20, C-20’, C-4, C-4’), 
128.90 (3C, C-9, C-3, C-3’), 123.72 (1C, C-10), 121.50 (1C, C-11), 117.44 (3C, C-21, C-
21’, C-7), 96.90 (1C, C- 23), 67.32 (1C, C-14), 62.60 (1C, C-24), 30.74 (1C, C-27), 25.60 
(1C, C-25), 19.27 (1C, C-27). 
FT-IR (Diamond-ATR): ν (cm-1) 3285.1433, 3028.6572, 1642.0896, 1611.234, 
1512.8823, 1306.5364, 1230.3619, 1103.0831, 899.6298, 705.33. 
MS (ESI+): 546.2 ([M+Na]+). 
HR-MS (ESI+): calc. for C32H29NO6 ([M+Na]




In a 250 mL pressure vessel 6-(((benzyloxy)carbonyl)amino)-4'-((tetrahydro-2H-pyran-
2-yl)oxy)-[1,1'-biphenyl]-3-yl benzoate (2.15 g, 4.10 mmol, 1.0 eq) was dissolved in 
EtOH (25 mL) and EtOAc (30 mL), Pd/C (200 mg, 1.88 mmol, 50 mol%) was added and 
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stirred under hydrogen pressure at 4 bar for 5 h. TLC control (n-hexane/EtOAc, 4:1) 
confirmed complete consumption of the starting material. The reaction mixture was 
filtrated, the solvent was removed under reduced pressure. After purification by flash 
column chromatography (n-hexane/EtOAc, 4:1), the product was obtained as a white 
solid (1.55 g, 3.98 mmol, 94%). 
TLC: Rf = 0.23 (n-hexane/EtOAc, 4:1) 
mp.: 49 °C 
1H NMR (300 MHz, CD2Cl2) δ (ppm) 8.21 – 8.14 (m, 2H, H-3, H-3’), 7.64 (dd, J = 7.6, 
0.5 Hz, 1H, H-5), 7.57 – 7.48 (m, 2H, H-4, H-4’), 7.40 (m, 2H, H-14, H-14’), 7.16 – 7.10 
(m, 2H, H-15, H-15’), 7.01 – 6.94 (m, 2H, H-11, H-7), 6.81 – 6.76 (m, 1H, H-10), 5.45 
(t, J = 3.4 Hz, 1H, H-17), 3.98 – 3.54 (m, 2H, H-18). 1.90 – 1.54 (m, 6H, H-21, H-20, H-
19). 
13C NMR (75 MHz, CD2Cl2) δ (ppm) 166.03 (1C, C-1), 156.95 (1C, C-16), 143.30 (1C, 
C-9), 142.27 (1C, C-6), 133.76 (1C, C-5), 132.20 (1C, C-13), 130.35(2C, C-14, C-14’), 
130.32 (2C, C-3, C-3’), 128.93 (2C, C-4, C-4’), 128.16 (1C, C-8), 123.52 (1C, C-7), 
121.56 (1C, C-11), 117.23 (2C, C-15, C-15’), 116.14 (1C, C-10), 96.93 (1C, C-17), 62.59 
(1C, C-18), 30.78 (1C, C-19), 25.64 (1C, C-20), 19.33 (1C, C-17). 
MS (ESI+): 390.2 ([M+H]+), 412.2 ([M+Na]+). 
HR-MS (ESI+): calc. for C24H23NO4 ([M+H]
+): 390.1700, found: 390.1702; calc. for 
C24H23NO4 ([M+Na]
+): 412.1519, found: 412.1520 
FT-IR (Diamond-ATR): ν (cm-1) 3372.40, 2941.39, 1725.01, 1485.88, 1229.39, 1167.68. 
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7.4.2.38 6-(2-(3,5-Dimethoxyphenyl)acetamido)-4'-((tetrahydro-2H-pyran-2-
yl)oxy)-[1,1'-biphenyl]-3-yl benzoate (63) 
 
In a dry 100 mL two neck round bottom flask equipped with a reflux condenser (3,5-
dimethoxyphenyl)acetic acid (250 mg, 1.30 mmol, 2.0 eq), EDC-HCl (390 mg, 
1.90 mmol, 3.0 eq), 1-Hydroxybenzotriazole (26 mg, 0.19 mmol, 0.3 eq) and anhydrous 
toluene (20 mL) were added and stirred at 100°C for 10 minutes under an argon 
atmosphere.6-amino-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-3-yl benzoate 
(250 mg, 0.640 mmol, 1.0 eq) was dissolved in anhydrous toluene (5 mL) and added to 
the flask. The reaction mixture was refluxed at 120°C for 6 h and stirred overnight at 
room temperature. Reaction monitoring using TLC showed completion, water (50 mL) 
was added, and extracted with toluene. The organic phase was washed with 1 M HCl 
(50 mL) sat. aq. NaHCO3 solution (50 mL), sat. aq. NaCl solution (50 mL), dried over 
MgSO4 and concentrated in vacuum. After the purification by flash column 
chromatography (n-hexane/EtOAc, 1.5:1), the product was obtained as a brown solid 
(350 mg, 0.61 mmol, 95%). 
TLC: Rf = 0.47 (n-hexane/EtOAc, 1.5:1) 
mp.: 106 °C 
1H NMR (300 MHz, CD2Cl2) δ (ppm) 8.44 (d, J = 8.9 Hz, 1H, H-10), 8.22 – 8.12 (m, 
2H, H-3, H-3’), 7.71 – 7.59 (m, 1H, H-5), 7.52 (ddt, J = 8.3, 7.0, 1.1 Hz, 2H, H-4, H-4’), 
7.37 (s, 1H, H-12), 7.17 (dd, J = 8.9, 2.8 Hz, 1H, H-11), 7.09 – 6.89 (m, 5H, H-7, H-16, 
H-16’, H-22, H-22’), 6.33 (t, J = 2.3 Hz, 1H, H-18), 6.26 (d, J = 2.3 Hz, 2H, H-16, H-
16’), 5.46 (t, J = 3.2 Hz, 1H, H-24), 4.00 – 3.86 (m, 1H, H-25), 3.73 (s, 6H, H-19, H-19’), 
3.70 – 3.58 (m, 1H, H-25), 3.56 (s, 2H, H-14), 1.97 – 1.83 (m, 2H, H-28), 1.80 – 1.59 (m, 
4H, H-26, H-27). 
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13C NMR (75 MHz, CD2Cl2) δ (ppm) 168.89 (1C, C-13), 165.55 (1C, C-1), 161.69 (1C, 
C-15), 157.36 (1C,  C-23), 147.14 (1C, C-6), 136.41, 133.98 (1C, C-5), 133.39 (1C, C-
2), 133.20 (1C, C-9), 130.39 (2C, C-3, C-3’), 129.98 (2C, C-21, C-21’), 128.99 (2C, C-
4, C-4’), 123.60 (1C, C-7), 121.61 (1C, C-10), 121.29 (1C, C-11), 120.9 (1C, C-8), 117.20 
(2C, C-22, C-22’), 107.59 (2C, C-16, C-16’),100.21 (1C, C-18), 96.97 (1C, C-24), 62.63 
(1C, C-25), 60.63, 55.63 (2C, C-19, C-19’), 45.69 (1C, C-14),, 30.91(1C, C-26), 30.11, 
25.65 (1C, C-27),19.41 (1C, C-28). 
MS (ESI+): 590.2 ([M+Na]+), 568.3 ([M+H]+). 
HR-MS (ESI+): calc. for C34H33NO7 ([M+Na]
+): 590.2149, found: 590.2149; calc. for 
C34H33NO7 ([M+H]
+): 568.2330 found: 568.2338. 
FT-IR (Diamond-ATR): ν (cm-1) 3265.37, 2952.48, 2922.10, 1735.13, 1510.47, 1238.07, 
1148.40, 816.70, 704.85. 
7.4.2.39 6-(2-(2,5-Dimethoxyphenyl)acetamido)-4'-((tetrahydro-2H-pyran-2-
yl)oxy)- [1,1'-biphenyl]-3-yl benzoate (64) 
 
In a two neck flask, 6-amino-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-3-yl 
benzoate (304.4 mg, 0.782 mmol, 1.0 eq.) was dissolved in anhydrous toluene with 2-
(2,5- dimethoxyphenyl)acetic acid (307 mg, 1.56 mmol, 2.0 eq.), EDC-HCl (450 mg, 
2.34 mmol, 3.0 eq) and HOBt (28.7 mg, 0.212 mmol, 0.3 eq) and refluxed for 27 h under 
an argon atmosphere. The reaction was controlled by TLC (n-hexane/EtOAc, 3:1) till the 
full conversion of the educt. The mixture was washed with water, and the aqueous phase 
was extracted with toluene (4 x 40 mL), the combined organic phases were washed with 
sat. aq. NaHCO3 solution (2 x 40 mL) and sat. aq. NaCl solution (40 mL). The organic 
phase was dried over MgSO4 and the solvent was removed under vacuum. The product 
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was purified with a n-hexane wash and was obtained as a light green-yellow milky oil 
(337 g, 0.594 mmol, 76%). 
TLC: Rf = 0.3 (n-hexane/EtOAc, 3:1) 
1H-NMR (300 MHz, CD2Cl2) δ (ppm) 8.38 (d, J = 8.9 Hz, 1H, H-7), 8.21 – 8.13 (m, 2H, 
H-3, H-3’), 7.73 (s, 1H, -NH), 7.68 – 7.60 (m, 1H, H-5), 7.56 – 7.46 (m, 2H, H-4, H-4’), 
7.19 – 7.06 (m, 3H, H-11, H-13, H-13’), 7.04 – 6.95 (m, 3H, H-10, H-14, H-14’), 6.81 – 
6.71 (m, 3H, H-25, H-26-H, H-28), 5.47 (t, J = 3.3 Hz, 1H, H-16), 3.94 (ddd, J = 11.8, 
9.0, 3.2 Hz, 1H, H-17), 3.74 (s, 3H, H-30), 3.69 – 3.60 (m, 1H, H-17), 3.57 (d, J = 2.2 
Hz, 2H, H-22), 3.47 (s, 3H, H-29), 2.10 – 1.84 (m, 3H, H-19, H-20), 1.76 – 1.58 (m, 3H, 
H-18, H-19). 
13C-NMR (75 MHz, CD2Cl2) δ (ppm) 169.47 (1C, C-21), 165.74 (1C, C-1), 157.41 (1C, 
C-15), 154.31 (1C, C-23), 151.50 (1C, C-27), 147.19 (1C, C-24), 134.12 (1C, C-5), 
133.76 (1C, C-6), 133.54 (1C, C-9), 130.67 (1C, C-12), 130.54 (2C, C-13, C- 13´), 130.45 
(2C, C-3, C-3´), 130.16 (1C, C-8), 129.14 (2C, C-4, C-4´), 124.16 (1C, C-2), 123.83 (1C, 
C-10), 122.32 (1C, C- 7), 121.35 (1C, C-11), 117.46 (2C, C-14, C14´), 117.15 (1C, C-
28), 114.05 (1C, C-26), 112.42 (1C, C-25), 97.04 (1C, C- 16), 62.81 (1C, C-17), 55.62 
(2C, C-29, C-30), 40.30 (1C, C-22), 30.30 (1C, C-20), 25.82 (1C, C-18), 19.05 (1C, C-
19). 
HR-MS (ESI+): calc. for C34H33NO7 ([M+H]+): 568.2330, found: 568.2337.  
7.4.2.40 4'-((Tetrahydro-2H-pyran-2-yl)oxy)-6-(2-(o-tolyloxy)acetamido)-
[1,1'-biphenyl]- 3-yl benzoate (65) 
 
In a two neck flask 6-amino-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-3-yl 
benzoate (249 mg, 0.640 mmol, 1.0 eq.) was dissolved in anhydrous chloroform with 2-
(o-tolyloxy)acetic acid (213 mg, 1.28 mmol, 2.0 eq), EDC-HCl (369 mg, 1.93 mmol, 
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3.0 eq) and HOBt (26.0 mg, 0.192 mmol, 0.3 eq) and refluxed for 22 h under argon 
atmosphere. The reaction was frequently controlled via TLC (n-hexane/EtOAc, 2:1) till 
the full conversion of the educt. After that the mixture was washed with water and the 
aqueous phase was extracted with chloroform (4 x 40 mL), the combined organic phases 
were washed with sat. aq. NaHCO3 solution (2 x 40 mL) and sat. aq. NaCl solution 
(40 mL). The organic phase was dried over MgSO4 and the solvent was removed under 
vacuum. The product was obtained as an off-yellow solid (310 mg, 0.576 mmol, 90%) 
after washing with n-hexane. 
TLC: Rf = 0.7 (n-hexane/EtOAc, 2:1) 
mp.: 151.6 °C 
1H-NMR (300 MHz, CD2Cl2) δ (ppm) 8.55 (d, J = 8.9 Hz, 1H, H-10), 8.47 (s, 1H, -NH), 
8.22 – 8.15 (m, 2H, H-3, H-3’), 7.73 – 7.66 (m, 1H, H-5), 7.60 – 7.53 (m, 2H, H-4-H, H-
4’), 7.23 (dd, J = 8.7, 3.6 Hz, 3H, H-7, H-13, H-13’), 7.18 – 7.08 (m, 3H, H-26, H-25, H-
27), 7.07 – 7.00 (m, 2H, H-14, H-14’), 6.91 (td, J = 7.4, 1.0 Hz, 1H, H-11), 6.76 (d, J = 
8.1 Hz, 1H, H-28), 5.41 (t, J = 3.3 Hz, 1H, H-16), 4.55 (s, 2H, H-22), 3.89 (ddd, J = 12.2, 
9.4, 3.2 Hz, 1H, H-17), 3.63 – 3.54 (m, 1H, H-17), 2.05 – 1.84 (m, 3H, H-19, H-20), 1.80 
(s, 3H, H-29), 1.74 – 1.57 (m, 3H, H-18, H-19). 
13C-NMR (75 MHz, CD2Cl2) δ (ppm) 166.86 (1C, C-21), 165.71 (1C, C-1), 157.90 (1C, 
C-15), 155.73 (1C, C-23), 147.61 (1C, C-6), 134.18 (1C, C-5), 133.97 (C-9), 132.84 (C-
12), 131.42 (C-25), 130.79 (2C, C-13, C-13’), 130.67 (2C, C-3, C-3’), 130.25 (1C, C-2), 
130.11 (1C, C-8), 129.11 (2C, C-4, C-4’), 127.54 (1C, C-27), 127.26 (1C, C-24), 124.07 
(1C, C-26), 122.29 (1C, C-11), 122.08 (1C, C-10), 121.61 (1C, C-7), 117.53 (2C, C-14, 
C-14’), 111.70 (1C, C-28), 96.94 (1C, C-16), 68.19 (1C, C-22), 62.64 (1C, C-17), 30.93 
(1C, C-20), 25.79 (1C, C-18), 19.37 (1C, C-19), 16.11 (1C, C-29). 
HR-MS (ESI+): calc. for C33H31NO6 ([M+H]
+): 538.2224, found: 538.2224 





In a dry 100 mL two neck round bottom flask thymine-1-acetic acid (240 mg, 1.20 mmol, 
2.0 eq), EDC-HCl (390 mg, 1.90 mmol, 3.0 eq.) and 1-hydroxybenzotriazole (26.0 mg, 
0.190 mmol, 0.30 eq.) were dissolved in anhydrous toluene (20 mL) and stirred at 100 °C 
under an argon atmosphere. In a second flask 6-amino-4'-((tetrahydro-2H-pyran-2-
yl)oxy)-[1,1'-biphenyl]-3-yl benzoate (250 mg, 0.640 mmol, 1.0 eq) was dissolved in 
anhydrous toluene (5 mL) and added to the flask. The reaction mixture was refluxed at 
120 °C for 18 h. Reaction monitoring by TLC (DCM/EtOAc, 50:1) showed incompletion. 
The toluene was evaporated, and the reaction mixture was diluted with 
dimethylformamide. It was stirred for 6 h at 162 °C and room temperature for 2 days. The 
reaction was monitored by TLC and no educts were observed. EtOAc (10 mL) and water 
(10 mL) were added into the reaction mixture, the aqueous phase was extracted with 
EtOAc (3 x 20 mL). The combined organic phase was washed with water (20 mL), 1 M 
HCl (20 mL), sat. aq. NaHCO3 solution (20 mL), sat. aq. NaCl solution (20 mL) dried 
over MgSO4 and concentrated in vacuum. The raw product was obtained as a brown solid 
(127 mg, 0.35 mmol, 30%). Before biophysical studies sample was purified by 
preparative HPLC.  
TLC: Rf = 0.19 (DCM/EtOAc, 50:1) 
HPLC (preparative, 20 → 100% MeCN in 35 min): tR = 13.5 min. 
mp.: 50 °C (decomposition) 
1H NMR (400 MHz, DMSO) δ (ppm)11.27 (s, 1H, H-4), 9.56 – 9.39 (m, 2H, H-15, H-
20), 9.26 (s, 1H, H-NH), 7.35 (d, J = 1.5 Hz, 1H, H-13), 7.29 – 7.01 (m, 3H, H-11, H-17, 
H-17’), 6.85 – 6.62 (m, 4H, H-13, H-14, H-18, H-18’), 4.31 (s, 2H, H-2), 1.75 (s, 3H, H-
8).  
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13C NMR (101 MHz, DMSO) δ (ppm) 167.01 (1C, C-1), 164.94 (1C, C-5), 155.98 (1C, 
C-12), 151.49 (1C, C-3), 138.62 (1C, C-10), 130.28 (3C, C-9, C-17, C-17’), 129.79 (1C, 
C-16), 125.63 (1C, C-11), 116.60 (1C, C-13), 115.65 (2C, C-18, C-18’), 108.40 (1C, C-
6), 49.99 (1C, C-2), 12.38 (1C, C-8). 
FT-IR (Diamond-ATR): ν (cm-1) 3736.4, 3525.24, 2969.84, 2361.41, 1964.14, 1742.37, 
1363.43, 1216.86. 
MS (ESI+): 390.1 ([M+Na]+), 368.1 ([M+H]+). 
HR-MS (ESI+): calc. for C19H17N3O5 ([M+H]
+): 368.1241, found: 368.1243 calc. for 
C19H17N3O5 ([M+Na]
+): 390.1060, found: 390.1058. 
7.4.2.42 6-(3-Methylbutanamido)-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-
biphenyl]-3-yl benzoate (68) 
 
In a two neck flask, 6-amino-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-3-yl 
benzoate (246 mg, 0.632 mmol, 1.0 eq.) was dissolved in anhydrous chloroform with 
isovaleric acid (132 mg, 1.29 mmol, 2.0 q.), EDC-HCl (364 mg, 1.90 mmol, 2.0 eq.) and 
HOBt (26.0 mg, 0.192 mmol, 0.3 eq.) and refluxed for 36 h under an argon atmosphere. 
The reaction was frequently controlled by TLC (n-hexane/EtOAc, 2:1) until the full 
conversion of the educt. After that the mixture was washed with water, then the aqueous 
phase was extracted with chloroform (4 x 40 mL) and the combined organic phases were 
washed with sat. aq. NaHCO3 solution (2 x 40 mL) and sat. aq. NaCl solution (40 mL). 
The organic phase was dried over MgSO4 and the solvent was removed under vacuum. 
The product was obtained as a white solid (279 mg, 0.589 mmol, 93%) after washing with 
n-hexane. 
TLC: Rf = 0.63 (n-hexane/EtOAc, 2:1) 
mp.: 129.9 °C  
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1H-NMR (300 MHz, CD2Cl2) δ (ppm) 8.30 (d, J = 8.9 Hz, 1H, H-7), 8.22 – 8.15 (m, 2H, 
H-3, H-3’), 7.70 – 7.61 (m, 1H, H-5), 7.60 - 7.52 (m, 2H, H-4, H-4’), 7.36 – 7.30 (m, 2H, 
H-13, H-13’), 7.22 – 7.11 (m, 4H, H-10, H-11, H-14, H-14’), 5.47 (t, J = 3.3 Hz, 1H, H-
16), 3.91 (ddd, J = 11.9, 9.0, 3.2 Hz, 1H, H-17), 3.66 – 3.58 (m, 1H, H-17), 2.07 (q, J = 
2.4 Hz, 3H, H-22-H, H-23), 2.04 – 1.81 (m, 3H, H-20, H-19), 1.76 – 1.58 (m, 3H, H-18, 
H-19), 0.97 – 0.89 (m, 6H, H-24, H-24’). 
13C-NMR (75 MHz, CD2Cl2) δ (ppm) 171.31 (1C, C-21), 166.23 (1C, C-1), 158.02 (1C, 
C-15), 148.22 (1C, C-6), 134.37 (1C, C-5), 134.02 (1C, C-8), 133.46 (1C, C-9), 130.93 
(2C, C-13, C-13’), 130.79 (1C, C-12), 131.24 (2C, C-3, C-3’), 130.93 (1C, C-2), 129.37 
(2C, C-4, C-4’), 124.05 (1C, C-10), 123.08 (1C, C-7), 121.48 (1C, C-11), 117.03 (2C, C-
14, C-14’), 97.49 (1C, C-16), 63.11 (1C, C-17), 47.79 (1C, C-22), 31.23 (1C, C-20), 26.68 
(1C, C-23), 26.23 (1C, C-18), 23.10 (2C, C-24, C-24’), 19.66 (1C, C-19).  
HR-MS (ESI+): calc. for C29H31NO5 [M+H]
+: 474.2275, found: 474.2276.  
7.4.2.43 6-Isobutyramido-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-
biphenyl]-3-yl benzoate (69) 
 
In a two neck flask, 6-amino-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-3-yl 
benzoate (247 mg, 0.635 mmol, 1.0 eq.) was dissolved in anhydrous chloroform with 
isobutyric acid (113 mg, 1.28 mmol, 2.0 eq), EDC-HCl (368 mg, 1.92 mmol, 3.0 eq) and 
HOBt (28.0 mg, 0.229 mmol, 0.3 eq) and refluxed for 40 h under an argon atmosphere. 
The reaction was frequently controlled by TLC (n-hexane/EtOAc, 2:1) till the full 
conversion of the educt. Afterwards, the reaction mixture was washed with water and the 
aqueous phase was extracted with chloroform (4 x 40 mL). The combined organic phases 
were washed with sat. aq. NaHCO3 solution (2 x 40 mL), sat. aq. NaCl solution (40 mL), 
dried over MgSO4 and the solvent was removed under vacuum. The product was purified 
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with an n-hexane wash and a white solid was obtained. Residual isobutyric acid was 
removed by washing with sat. aq. NaHCO3 solution, and the product was obtained as a 
white solid (242.1 mg, 0.53 mmol, 83 %).  
TLC: Rf: 0.3 (n-hexane/EtOAc, 2:1) 
mp.: 122.4 °C 
1H-NMR (300 MHz, CD2Cl2) δ (ppm) 8.30 (d, J = 8.7 Hz, 1H, H-10), 8.23 – 8.14 (m, 
2H, H-3, H-3’), 7.71 – 7.61 (m, 1H, H-5), 7.59 – 7.48 (m, 2H, H-4, H-4’), 7.34 (dd, J = 
8.6, 4.6 Hz, 2H, H-13, H-13’), 7.23 (s, 1H, H-NH), 7.21 – 7.10 (m, 4H, H-7, H-11, H-14, 
H-14’), 5.47 (t, J = 3.2 Hz, 1H, H-16), 3.90 (dtd, J = 8.6, 3.3, 2.9 Hz, 1H, H-17), 3.66 – 
3.56 (m, 1H, H-17), 2.42 – 2.29 (m, 1H, H-22), 2.08 – 1.82 (m, 3H, H-20, H-19), 1.77 – 
1.57 (m, 3H, H-18, H-19), 1.12 (d, J = 8.9 Hz, 6H, H-23, H-23’). 
13C-NMR (75 MHz, CD2Cl2) δ (ppm) 174.74 (1C, C-21), 165.35 (1C, C-1), 157.14 (1C, 
C-15), 146.98 (1C, C-6), 133.97 (1C, C-5), 133.35 (1C, C-12), 130.31 (2C, C-13, C-13’), 
130.15 (1C, C-2), 129.97 (2C, C-3, C-3’), 128.44 (2C, C-4, C-4’), 123.13 (1C, C-11), 
122.28 (1C, C-10), 120.94 (1C, C-7), 116.87 (2C, C-14, C-14’), 96.56 (1C, C-16), 62.18 
(1C, C-17), 36.55 (1C, C-22), 30.30 (1C, C-20), 25.30 (1C, C-18), 19.20 (1C, C-19), 
18.87 (2C, C-23, C-23’).  
FT-IR (Diamond-ATR): ν (cm-1) 3266.97, 2943.89, 2874.61, 1728.85, 1659.67, 1597.39, 
1519.23, 1364.68, 1241.22, 1163.06, 1078.68, 1016.51, 954.35, 799.79. 
HR-MS (ESI+): calc. for C28H29NO5 [M+H]
+: 460.2118, found: 460.2118  
7.4.2.44 N-(4',5-Dihydroxy-[1,1'-biphenyl]-2-yl)-2-methoxyacetamide (70)  
 
In a dry 100 mL two-neck round bottom flask 6-amino-4'-((tetrahydro-2H-pyran-2-
yl)oxy)-[1,1'-biphenyl]-3-yl benzoate (250 mg, 0.640 mmol, 1.0 eq), EDC-HCl (390 mg, 
1.90 mmol, 3.0 eq) and 1-hydroxybenzotriazole (26.0 mg, 0.190 mmol, 0.30 eq) were 
added and dissolved in anhydrous DMF (15 mL) under argon atmosphere. Methoxyacetic 
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acid (95.0 µL, 1.20 mmol, 2.0 eq) was slowly added to the flask and the reaction mixture 
was stirred at 160 °C overnight. Reaction monitoring by TLC (DCM/MeOH, 10:1) 
showed complete conversion of the starting material. The reaction mixture was diluted 
with EtOAc (20 mL) and water (20 mL), the aqueous phase was extracted with EtOAc 
(3 x 15 mL), combined organic phases were washed thoroughly with water, 1 M HCl 
(20 mL), sat. aq. NaHCO3 solution (20 mL), sat. aq. NaCl (20 mL), dried over MgSO4 
and concentrated in vacuum. After purification by flash column chromatography 
(DCM/MeOH 10:1) product was isolated as a light orange solid (77.0 mg, 0.280 mmol, 
44%), and a brown oil (57.0 mg, 0.210 mmol, 38%) as a mixture of protected and 
unprotected product. 
TLC: Rf = 0.62 (DCM/MeOH, 10:1) 
mp.: 76.7 °C 
1H NMR (400 MHz, MeOD) δ (ppm) 7.60 (m, 1H, H-10), 7.2 -7.03 (m, 2H, H-13, H-
13), 7.03 -6.62 (m, 4H, H-7, H-9, H-14, H-14’), 3.83 (m, 2H, H-2), 3.27 (m, 3H, H-3). 
13C NMR (101 MHz, MeOD) δ (ppm) 170.87 (1C, C-1), 158.27 (1C, C-15), 156.48 (1C, 
C-8), 138.76 (1C, C-7), 131.16 (2C, C-13, C-13’), 130.94 (1C, C-12), 126.75 (1C, C-5), 
117.78 (1C, C-10), 116.41 (1C, C-6), 116.37 (2C, C-14, C-14’), 115.19 (1C, C-9), 71.28 
(1C, C-2), 59.67 (1C, C-3). 
MS (ESI+): 296.1 ([M+Na]+), 274.1 ([M+H]+), 596.2 ([2M+Na]+). 
HR-MS (ESI+): calc. for C15H15NO4 ([M+H]
+): 274.1074, found: 274.1073 calc. for 
C15H15NO4 ([M+Na]
+): 296.0893, found: 296.0893. 
7.4.2.45 3-Bromo-4-(2-(2,5-dimethoxyphenyl)acetamido)phenyl benzoate 
(71) 
 
In a dry 250 mL two neck round bottom flask (2,5-dimethoxyphenyl)acetic acid (2.52 g, 
13.7 mmol, 2.0 eq), EDC-HCl (3.95 g, 21.0 mmol, 3.0 eq) and 1-Hydroxybenzotriazole 
(270 mg, 2.00 mmol, 0.3 eq) were dissolved in anhydrous chloroform (10 mL) and stirred 
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for 15 min under an argon atmosphere. 4-amino-3-bromophenyl benzoate (2.0 g, 6.8 
mmol, 1.0 eq) was dissolved in anhydrous chloroform (40 mL) and added to the flask. 
The reaction mixture was stirred at room temperature overnight. Monitoring of the 
reaction by TLC (n-hexane/EtOAc, 2:1) showed incompletion, therefore additional EDC-
HCl (520 mg, 0.37 eq) and HOBt (170 mg, 0.18 eq) were added. It was stirred 
additionally at 65 °C for 6 h and afterwards for 12 h at room temperature. After 
completion, the reaction mixture was washed with water, sat. aq. NaHCO3 solution 
(50 mL), sat. aq. NaCl solution (50 mL) dried over MgSO4 and concentrated in vacuum. 
The title compound was obtained after purification by flash column chromatography 
(n-hexane/MTBE, 2:1) as a brown solid (1.85 g, 3.93 mmol, 57%). 
TLC: Rf = 0.38 (n-hexane/EtOAc, 2:1) 
mp.: 117 °C 
1H NMR (300 MHz, CD2Cl2) δ (ppm) 8.38 (d, J = 9.1 Hz, 1H, H-10), 8.21 – 8.10 (m, 
3H, H-12, H-3, H-3’), 7.72 – 7.60 (m, 1H, H-5), 7.59 – 7.46 (m, 2H, H-4, H-4’), 7.42 (d, 
J = 2.6 Hz, 1H, H-7), 7.22 – 7.11 (m, 1H, H-11), 6.97 – 6.87 (m, 2H H-20, H-17), 6.85 
(m, 1H, H-18), 3.89 (s, 3H, H-22), 3.75 (s, 3H, H-21), 3.72 (s, 2H, H-14). 
13C NMR (75 MHz, CD2Cl2) δ (ppm) 169.28 (1C, C-13), 154.03 (1C, C-19), 151.30 (1C, 
C-16), 134.5 (1C, C-6), 133.78 (1C, C-5), 130.03 (2C, C-3, C-3’), 128.6 (2C, C-4, C-4’), 
125.4 (1C, C-7), 123.7 (1C, C-20), 121.7 (1C, C-10), 121.47 (1C, C-11), 117.05 (1C, C-
5), 113.57 (1C, C-17), 111.72 (1C, C-9), 56.08 (1C, C-20), 55.68 (1C, C-21), 40.28 (1C, 
C-14). 
MS (ESI+): 470.1 ([M+H]+) 390.1 ([M+Na]+), 
HR-MS (ESI+): calc. for C23H20NO5Br ([M+H]
+): 470.0598, found: 470.0601. 
FT-IR (Diamond-ATR): ν (cm-1) 3287.55, 2933.19, 1736.58, 1683.06, 1499.38, 1233.73, 
1187.45, 1060.17, 706.30. 
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7.4.2.46 2-(2,5-Dimethoxyphenyl)-N-(5-hydroxy-4'-(trifluoromethyl)-[1,1'-
biphenyl]-2-yl)acetamide (72)  
 
In a microwave vessel 3-bromo-4-(2-(2,5-dimethoxyphenyl)acetamido)phenyl benzoate 
(150 mg, 0.320 mmol, 1.0 eq), Pd(PPh3)4 (18.0 mg, 0.016 mmol, 5 mol%), Na2CO3 
(67.0 mg, 0.640 mol, 2.0 eq) and 4-(trifluoromethyl)phenylboronic acid (66.0 mg, 
0.350 mmol, 1.1 eq) were added and dissolved in 5 mL of the solvent mixture (DME/H2O 
3:1) previously degassed for 30 min. The reaction mixture was placed into a microwave 
and stirred at 100 °C for 10 min. After cooling down, monitoring by TLC 
(n-hexane/EtOAc, 2:1) showed complete consumption of the starting material. The DME 
was evaporated and the reaction mixture was dissolved in EtOAc. The organic phase was 
washed with water (20 mL), sat. aq. NaHCO3 solution (20 mL), sat. aq. NaCl solution 
(20 mL), dried over MgSO4 and concentrated in vacuum. After purification by flash 
column chromatography (n-hexane/EtOAc, 1:1), the product was obtained as a light-
brown solid (124 mg, 0.280 mmol, 83%). 
TLC: Rf = 0.39 (n-hexane/EtOAc 2:1) 
mp.: 112 °C 
1H NMR (300 MHz, DMSO) δ (ppm) 9.60 (s, 1H, H-9), 9.00 (s, 1H, H-2), 7.67 (d, J = 
8.1 Hz, 2H, H-21, H-21’), 7.49 (d, J = 8.0 Hz, 2H, H-20, H-20’), 7.26 (d, J = 8.6 Hz, 1H, 
H-8), 6.90 – 6.66 (m, 5H, H-14, H-13, H-5, H-7, H-16), 3.65 (s, 3H, H-18), 3.63 (s, 3H, 
H-17), 3.40 (s, 2H, H-10). 
13C NMR (75 MHz, DMSO) δ (ppm) 169.33 (1C, C-1), 155.48 (1C, C-6), 152.90 (1C, 
C-15), 151.25 (1C, C-12), 143.26 (1C, C-19), 136.77 (1C, C-4), 129.26 (2C, C-20, C-
20’), 128.77 (1C, C-8), 127.73 (1C, C-22), 127.31 (1C, C-3), 126.23 (1C, C-11), 125.64 
(2C, C-21, C-21’), 125.00 (1C, C-23), 117.07 (1C, C-16), 115.32 (1C, C-13), 111.90 (2C, 
C-5, C-7), 111.67(1C, C-14), 55.83(1C, C-17), 55.23 (1C, C-18), 37.02 (1C, C-10). 
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19F NMR (282 MHz, DMSO) δ (ppm) -60.94 (-CF3). 
MS (ESI+): 432.2 ([M+H]+), 863.3 ([2M+H]+). 
HR-MS (ESI+): calc. for C23H20F3NO4 ([M+H]
+): 432.1417, found: 432.1418 





In a microwave vessel 3-bromo-4-(2-(2,5-dimethoxyphenyl) acetamido) phenyl benzoate 
(150 mg, 0.320 mmol, 1.0 eq), Pd(PPh3)4 (18.0 mg, 0.016 mmol, 5 mol%), Na2CO3 
(67.0 mg, 0.640 mmol, 2.0 eq) and 4-nitrophenylboronic acid (58.0 mg, 0.350 mmol, 
1.1 eq) were added and dissolved in previously degassed (DME/H2O, 3:1) solvent 
mixture (5 mL). The reaction mixture was placed into the microwave and stirred at 110 °C 
for 10 min. The reaction mixture was cooled down to room temperature and checked by 
TLC (n-hexane/EtOAc, 1:1) which showed complete consumption of the starting 
material. DME was evaporated and EtOAc was added, the organic phase was washed 
with water (10 mL), sat. aq. NaHCO3 (10 mL), sat. aq. NaCl (10 mL), dried over MgSO4 
and concentrated in vacuum. After purification by flash column chromatography 
(n-hexane/EtOAc, 1:2) product was obtained as yellow solid (102 mg, 0.250 mmol, 
79%). 
TLC: Rf = 0.22 (n-hexane/EtOAc 1:1) 
mp.: 146 °C 
1H NMR (400 MHz, DMSO) δ (ppm) 9.69 (s, 1H, H-9), 9.13 (s, 1H, H-2), 8.13 (d, J = 
8.0 Hz, 2H, H-21, H-21’), 7.51 (d, J = 8.8 Hz, 2H, H-20, H-20’), 7.22 (d, J = 8.6 Hz, 1H, 
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H-8), 6.87 – 6.79 (m, 2H, H-7, H-13,), 6.76 – 6.68 (m, 2H, H-5, H-14), 6.55 (d, J = 3.1 
Hz, 1H, H-16), 3.63 (d, J = 10.2 Hz, 6H, H-17, H-18), 3.38 (s, 2H, H-10). 
13C NMR (101 MHz, DMSO) δ (ppm) 169.67(1C, C-1),, 156.08 (1C, C-6), 153.26 (1C, 
C-15), 151.66 (1C, C-12), 146.74 (1C, C-22), 146.64 (1C, C-19), 137.12 (1C, C-4), 
130.09 (2C, C-20, C-20’), 129.33 (1C, C-8), 126.66 (1C, C-3), 125.38 (1C, C-11), 123.70 
(2C, C-21, C-21’), 117.38 (1C, C-16), 116.49 (1C, C-5), 116.22 (1C, C-13), 112.06 (1C, 
C-14), 112.03 (1C, C-7), 56.35 (1C, C-17), 55.61 (1C, C-18), 37.24 (1C, C-10). 
MS (ESI+): 409.2 ([M+H]+) 
HR-MS (ESI+): calc. for C22H20N2O6 ([M+H]
+): 409.1394, found: 409.1396 





In a one neck flask 6-(2-(3,5-dimethoxyphenyl)acetamido)-4'-((tetrahydro-2H-pyran-2-
yl)oxy)-[1,1'-biphenyl]-3-yl benzoate (300 mg, 0.5 mmol, 1.0 eq), K2CO3 (180 mg, 
1.30 mmol, 2.5 eq) were dissolved in MeOH (44 mL) and stirred at room temperature 
overnight. The reaction was monitored by TLC (n-hexane/EtOAc, 1.5:1), upon 
completion, the solvent was removed, the reaction residue was diluted with EtOAc 
(20 mL) and washed with water (30 mL), sat. aq. NaHCO3 solution (30 mL), sat. aq. NaCl 
solution (30 mL), dried over MgSO4 and concentrated in vacuum. The product was 
obtained as off-white solid (230 mg, 0.490 mmol, 99.6%) which was used further in the 
final deprotection step. In a one neck flask 2-(3,5-dimethoxyphenyl)-N-(5-hydroxy-4'-
((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-2-yl)acetamide (150 mg, 0.320 mmol, 
1.0 eq) was dissolved in MeOH (12 mL) and 1 M HCl (2 mL) was added. The reaction 
mixture was refluxed at 70 °C for 2 h. Reaction monitoring by TLC (n-hexane/EtOAc, 
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1:2) showed complete conversion of the starting material. Afterwards, the solvent was 
evaporated, and the reaction mixture was dissolved in EtOAc (2 mL), water (5 mL) was 
added and the aqueous phase was extracted with EtOAc (3 x 5 mL). The organic phase 
was washed with sat. aq. NaHCO3 solution (5 mL), sat. aq. NaCl solution (5 mL), dried 
over MgSO4 and concentrated in vacuum. Purification by flash column chromatography 
(n-hexane/EtOAc, 1:2) resulted in isolated product (110 mg, 0.290 mmol, 96 %) as a 
white solid. Before biophysical studies sample was purified by preparative HPLC. 
TLC: Rf = 0.36 (n-hexane/EtOAc, 1:2) 
HPLC (preparative, 20 → 100% MeCN in 45 min): tR = 23.0 min. 
mp.: 196 °C 
1H NMR (300 MHz, MeOD) δ (ppm) 7.41 (d, J = 8.6 Hz, 1H, H-8), 7.03 – 6.93 (m, 2H, 
H-17, H-17’), 6.77 – 6.63 (m, 4H, H-7, H-18, H-18’, H-5), 6.42 -6.33 (m, 3H, H-12, H-
12’, H-14), 3.74 (s, 6H, H-15, H-15’), 3.47 (s, 2H, H-10). 
13C NMR (75 MHz, MeOD) δ (ppm) 172.40 (1C, C-1), 162.21 (2C, C-13, C-13’), 157.71 
(1C, C-19), 156.38 (1C, C-6), 139.17 (1C, C-4), 137.76 (1C, C-11), 130.68 (1C, C-16), 
130.61 (2C, C-17, C-17’), 127.76 (1C, C-8), 126.96 (1C, C-3), 117.44 (1C, C-5), 115.98 
(2C, C-8, C-18’), 114.79 (1C, C-7), 108.03 (2C, C-2, C-12’), 99.94 (1C, C-14), 55.43 
(2C, C-15, C-15’), 44.35 (1C, C-10). 
MS (ESI+): 380.2 ([M+H]+), 402.1 ([M+Na]+). 
HR-MS (ESI+): calc. for C22H21NO5 ([M+H]
+): 380.1492, found: 380.1495 calc. for 
C22H21NO5 ([M+Na]
+): 402.1312, found: 402.1315. 
FT-IR (Diamond-ATR): ν (cm-1) 3359.38, 3330.94, 3164.61, 2954.89, 1647.87, 1588.57, 
1429.47, 1158.52, 1063.06, 813.33. 
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7.4.2.49 N-(4',5-Dihydroxy-[1,1'-biphenyl]-2-yl)-2-(o-tolyloxy)acetamide (75)  
 
In a one neck flask 4'-((tetrahydro-2H-pyran-2-yl)oxy)-6-(2-(o-tolyloxy)acetamido)-
[1,1'-biphenyl]-3-yl benzoate (268 mg, 0.500 mmol, 1.0 eq) was dissolved in MeOH 
(20 mL) and 1 M aq. HCl solution (1 mL) was added. The mixture was stirred at room 
temperature for 1 h and after TLC control (n-hexane/EtOAc, 2:1) showed complete 
conversion of the starting material, the reaction was stopped. The solvent was removed 
under vacuum and the residue was dissolved in EtOAc. The organic phase was washed 
with water and the resulting aqueous phase was extracted with EtOAc (4 x 40 mL). The 
organic phase was washed with sat. aq. NaHCO3 and Na2CO3 solution (3 x 40 mL, pH 10) 
and the solvent was removed under vacuum. In the following step the residue was 
dissolved in MeOH and K2CO3 (172 mg, 1.25 mmol, 2.5 eq) was added and the mixture 
was stirred for 1 h. The reaction was monitored by TLC plate (n-hexane/EtOAc, 1:1) and 
afterwards the solvent was removed under vacuum. The reaction mixture residue was 
dissolved in EtOAc and washed with water. The aqueous phase was extracted with EtOAc 
(4 x 30 mL) and the combined organic phases were washed with sat. aq. NaCl solution 
(50 mL), dried over MgSO4 and concentrated in vacuum. The product was obtained as a 
light orange-brown solid (153 mg, 0.440 mmol, 88%). Before biophysical studies 
compound was purified by preparative HPLC. 
TLC: Rf = 0.4 (n-hexane/EtOAc, 1:1) 
HPLC (preparative, 20 → 100% MeCN in 30 min): tR = 14.0 min. 
mp.: 195.3 °C 
1H NMR (300 MHz, DMSO) δ (ppm) 9.51 (s, 2H, H-OH), 8.79 (s, 1H, H-NH), 7.61 (d, 
J = 8.7 Hz, 1H, H-7), 7.18 – 7.06 (m, 4H, H-4, H-9, H-9’, H-17), 6.92 – 6.66 (m, 5H, H-
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14, H-15, H-16, H-10, H-10’), 6.63 (d, J = 2.8 Hz, 1H, 7), 4.53 (s, 2H, H-12), 1.96 (s, 3H, 
H-19). 
13C NMR (75 MHz, DMSO) δ (ppm) 166.41 (1C, C-1), 157.01 (1C, C-13), 155.42 (1C, 
C-11), 154.80 (1C, C-5), 136.54 (1C, C-8), 130.55 (1C, C-2), 129.82 (2C, C-9, C-9’), 
128.74 (1C, C-18), 126.90 (1C, C-15), 125.91 (1C, C-3), 121.04 (1C, C-16), 115.43 (2C, 
C-10, C-10’), 113.96 (1C, C-6), 111.47 (1C, C-14), 67.08 (1C, C-12), 15.68 (1C, C-19). 
MS (ESI+): 350.1 ([M+H]+), 699.3 ([2M+H]+), 372.1 ([M+Na]+). 
HR-MS (ESI+): calc. for C21H19NO4 ([M+H]
+): 350.1387, found: 350.1391 calc. for 
C21H19NO4 ([M+Na]
+): 372.1206, found: 372.1206. 





In a one neck flask 6-(2-(2,5-dimethoxyphenyl)acetamido)-4'-((tetrahydro-2H-pyran-2-
yl)oxy)-[1,1'-biphenyl]-3-yl benzoate (304 mg, 0.540 mmol, 1.0 eq) was dissolved in 
MeOH and K2CO3 (185 mg, 1.34 mmol, 2.5 eq) was added. The mixture was stirred at 
room temperature for 1 h. Monitoring by TLC plate (n-hexane/EtOAc, 2:1) confirmed 
complete consumption of the starting material. The solvent was evaporated, and the 
reaction mixture residue was dissolved in EtOAc and washed with water. The aqueous 
phase was extracted with EtOAc (4 x 30 mL) and the solvent was removed under vacuum. 
In the next step, the residue was dissolved in MeOH and 1 M aq. HCl solution (1 mL) 
was added. The mixture was stirred at room temperature for 1 h and controlled by TLC 
(n-hexane/EtOAc, 1:1). The solvent was removed under vacuum and the residue was 
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dissolved in EtOAc. The organic phases were washed with water and the resulting 
aqueous phase was extracted with EtOAc (4 x 40 mL). The combined organic phase was 
washed with sat. aq. NaCl solution (50 mL), dried over MgSO4 and the solvent was 
removed in vacuum. The product was obtained as an orange-brown oil (173 mg, 
0.450 mmol, 84%). Before the biophysical studies sample was purified by semi-
preparative HPLC. 
TLC: Rf = 0.2 (n-hexane/EtOAc, 1:1) 
HPLC (semi-preparative, 20 → 100% MeCN in 45 min): tR = 23.0 min. 
1H NMR (300 MHz, CD3CN) δ (ppm) 7.74 (d, J = 8.8 Hz, 1H, H-7) 7.54 (s, 1H, H-NH), 
7.04 – 6.92 (m, 2H, H-9, H-9’), 6.84 – 6.67 (m, 6H, H-5, H-15, H-16, H-18, H-10, H-
10’), 6.61 (d, J = 2.9 Hz, 1H, H-4), 3.73 (s, 3H, H-19), 3.61 (s, 3H, H-20), 3.49 (s, 2H, 
H-12). 
13C NMR (75 MHz, CD3CN) δ (ppm) 170.30 (1C, C-1), 157.40 (1C, C-11), 154.80 (1C, 
C-5), 154.60 (1C, C-17), 152.32 (1C, C-14), 135.63 (1C, C-2), 129.80 (2C, C-9, C-9’) 
128.40, 125.60 (1C, C-7), 124.12 (1C, C-3), 123.92 (1C, C-7), 116.43 (1C, C-4), 115.41 
(1C, C-18), 114.97 (2C, C10, C-10’), 113.98 (1C, C-16), 113.94 (1C, C-6) 112.98 (1C, 
C-15), 55.52 (1C, C-20), 55.18 (1C, C-19), 39.83 (1C, C-12).  
MS (ESI-): 378.1 ([M-H]-). 
HR-MS (ESI-): calc. for C22H21NO5 ([M-H]
-): 378.1347, found: 378.1342  
FT-IR (Diamond-ATR): ν (cm-1) 3268.97, 2928.79, 2843.52, 1643.57, 1597.39, 1512.12,   
1441.95, 1302.51, 714.52, 1108.88, 1031.61, 830.88. 
7.4.2.51 N-(4',5-Dihydroxy-[1,1'-biphenyl]-2-yl)-3-methylbutanamide (77)  
 
In a one neck flask, 6-(3-methylbutanamido)-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-
biphenyl]-3-yl benzoate (296.5 mg, 0.626 mmol, 1.0 eq) was dissolved in MeOH (10 mL) 
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and 6 M aq. HCl (4 mL) solution was added. The mixture was stirred at room temperature 
for 30 min and afterwards, TLC (n-hexane/EtOAc, 2:1) showed complete conversion of 
the starting material, the reaction was stopped. Two possible product spots were observed, 
one was a side product where the amide group was removed, which possibly formed 
because of the usage of 6 M aq. HCl solution. The solvent was removed under vacuum 
and the residue was dissolved in EtOAc. The organic phase was washed with water and 
the aqueous phase was extracted with EtOAc (4 x 40 mL). The organic phase was washed 
with sat. aq. NaHCO3 and Na2CO3 solution (3 x 40mL, pH = 10) and the solvent was 
removed under reduced pressure. In the following step the residue was dissolved in 
MeOH (10 mL) and K2CO3 (216 mg, 1.57 mmol, 2.5 eq) was added and the mixture was 
stirred for 1 h. Afterwards, TLC plate control (DCM/MeOH, 9:1) confirmed complete 
consumption of the starting material. The solvent was removed under reduced pressure, 
and the reaction residue was dissolved in EtOAc and washed with water. The aqueous 
phase was extracted with EtOAc (4 x 30 mL) and the combined organic phases were 
washed with sat. aq. NaCl solution (50 mL). The organic phase was dried over MgSO4 
and concentrated in vacuum. The product was obtained as a brown solid (105 mg, 
0.368 mmol, 58%). Prior to biophysical studies, the compound was purified by 
preparative HPLC. 
TLC: Rf = 0.5 (DCM/MeOH, 9:1) 
HPLC (preparative, 20 → 100% MeCN in 45 min): tR = 21.5 min. 
mp.: 105 °C 
1H NMR (300 MHz, DMSO) δ (ppm) 9.44 (s, 1H, C-11, H-OH ), 9.39 (s, 1H, C-5, H-
OH), 8.87 (s, 1H, H-NH), 7.19 – 7.02 (m, 3H, H-4, H-9, H-9’), 6.82 – 6.61 (m, 4H, H-6, 
H-7, H-10, H-10’), 2.04 – 1.88 (m, 3H, H-12, H-13), 0.84 (d, J = 6.3 Hz, 6H, H-14, H-
15). 
13C NMR (75 MHz, DMSO) δ (ppm) 171.16 (1C, C-1), 156.63 (1C, C-11), 155.36 (1C, 
C-5), 138.91 (1C, C-2), 129.41 (2C, C-9, C-9’), 126.14 (1C, C-3), 116.09 (1C, C-7), 
114.91 (2C, C-10, C-10’), 113.76 (1C, C-4), 44.80 (1C, C-12), 25.43 (1C, C-13), 22.34 
(2C, C-14, C-15). 
FT-IR (Diamond-ATR): ν (cm-1) 3254.28, 2951.51,1614.12, 1521.56, 1190.82. 
MS (ESI-): 284.11 ([M-H]-), 569.1 ([2M-H]-). 
HR-MS (ESI-): calc. for C17H19NO3 ([M-H]
-): 284.1292, found: 284.1296. 
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7.4.2.52 N-(4',5-Dihydroxy-[1,1'-biphenyl]-2-yl)isobutyramide (78) 
 
In a one neck flask 6-isobutyramido-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-
3-yl benzoate (209 mg, 0.460 mmol, 1.0 eq) was dissolved in MeOH and K2CO3 (158 mg, 
1.14 mmol, 2.5 eq) was added. The mixture was stirred at room temperature for 1 h and 
after TLC (n-hexane/EtOAc, 2:1) showed complete conversion of the starting material, 
the reaction was stopped, and the solvent was evaporated. The residue was dissolved in 
EtOAc and washed with water. The aqueous phase was extracted with EtOAc (4 x 30 mL) 
and the solvent removed under vacuum. In the next step, the residue was dissolved in 
MeOH and 1 M aq. HCl solution (1 mL) was added. It was stirred at room temperature 
for 40 min and monitored by TLC (n-hexane/EtOAc, 1:1). Afterwards, the solvent was 
removed under vacuum and the residue was dissolved in EtOAc. The organic phase was 
washed with water and the resulting aqueous phase was extracted with EtOAc (4 x 
40 mL). The combined organic phase was washed with sat. aq. NaCl (50 mL), dried over 
MgSO4 and the solvent was removed under vacuum. Product was obtained as light brown 
oil (114 mg, 0.420 mmol, 91%). Before biophysical studies compound was purified by 
preparative HPLC. 
TLC: Rf = 0.24 (n-hexane/EtOAc, 1:1) 
HPLC (preparative, 20 → 100% MeCN in 45 min): tR = 18.6 min. 
1H NMR (300 MHz, CD3CN) δ (ppm) 7.53 (s, 1H, H-NH), 7.38 (d, J = 8.4 Hz, 1H, H-
7), 7.22 – 7.11 (m, 3H, H-9, H-9’, H-4), 6.88 – 6.78 (m, 2H, H-10, H-10’), 6.78 – 6.66 
(m, 1H, H-6), 2.35 (hept, J = 7.3 Hz, 1H, H-12), 1.03 (d, J = 6.9 Hz, 6H, H-13, H-14). 
13C NMR (75 MHz, CD3CN) δ (ppm) 175.91 (1C, C-1), 156.36 (1C, C-11), 154.80 (1C, 
C-2), 138.01 (1C, C-8), 137.99 (1C, C-3), 130.31 (2C, C-9, C-9’), 128.49, 127.50 (1C, 
C-7), 116.56 (2C, C-4, C-6), 115.01 (2C, C-10, C-10’), 35.30 (1C, C-12), 18.74 (2C, C-
13, C-14). 
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MS (ESI+): 272.1 ([M+H]+), 294.1 ([M+Na]+). 
HR-MS (ESI+): calc. for C16H17NO3 ([M+H]
+): 272.1281, found: 272.1284 calc. for 
C16H17NO3 ([M+Na]
+): 294.1101, found: 294.1101. 
FT-IR (Diamond-ATR): ν (cm-1) 3252.35, 2924.52, 2857.02, 1606.41, 1519.63, 1202.14. 
7.4.2.53 4'-((Tetrahydro-2H-pyran-2-yl)oxy)-6-(2-(4-((tetrahydro-2H-pyran-
2-yl)oxy)phenyl)acetamido)-[1,1'-biphenyl]-3-yl benzoate (81)  
 
In a 10 mL microwave vial, benzyl (3-bromo-4-(2-(4-((tetrahydro-2H-pyran-2-
yl)oxy)phenyl)acetamido)phenyl benzoate (213 mg, 0.420 mmol, 1.0 eq), (4-
((tetrahydro-2H-pyran-2-yl)oxy)phenyl)boronic acid (102 mg, 0.460 mmol, 1.1 eq), 
Na2CO3 (88.3 mg, 0.840 mmol, 2.0 eq) and Pd(PPh3)4 (24.1 mg, 0.021 mmol, 5 mol%) 
were dissolved in DME/H2O, 3:1 solvent mixture (5 mL); previously degassed under an 
argon stream for 30 min. Upon addition, a light yellow solution occurred; the reaction 
mixture was placed into a microwave, stirred for 10 min at 110 °C, and maximal pressure 
was 12 psi. Monitoring by TLC plate (n-hexane/EtOAc, 3:1) showed completion of the 
reaction, consecutively, the solvent was removed under reduced pressure. The reaction 
mixture residue was dissolved in EtOAc and washed with water (2 x 20 mL). The aqueous 
phase was extracted with EtOAc (2x30 mL). Afterwards, the combined organic phases 
were washed with sat. aq. NaHCO3 solution (50 mL), sat. aq. NaCl solution (50 mL), 
dried over MgSO4 and concentrated in vacuum. The product was obtained as an off-white 
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solid (189 mg, 0.310 mmol, 75%) after purification by flash column chromatography 
with (n-hexane/EtOAc, 3:1). 
TLC: Rf = 0.20 (n-hexane/EtOAc, 4:1) 
mp.: 70 °C (decomposition) 
1H NMR (300 MHz, CD2Cl2) δ (ppm) 8.35 (d, J = 8.9 Hz, 1H-7), 8.22 – 8.10 (m, 2H, H-
29, H-29’), 7.72 – 7.59 (m, 1H, H-31), 7.57 – 7.47 (m, 2H, H-30, H-30’), 7.25 – 7.10 (m, 
1H, H-4), 7.08-6.90 (m, 9H, H-9, H-9’, H-10, H-10’, H-19, H-19’, H-20, H-20’, H-4), 
5.51 - 5.41 (m, 2H, H-12, H-22), 3.91 -3.56 (m, 4H, H-16, H-23), 3.54 (s, 2H, H-17), 2.10 
– 1.51 (m, 12H, H-13, H-14, H-15, H-24, H-25, H-26). 
13C NMR (75 MHz, CD2Cl2) δ (ppm) 169.12 (1C, C-1), 165.14 (1C, C-27), 156.91 (2C, 
C-11, C-21), 146.84 (1C, C-5), 133.57 (1C, C-2), 133.29 (1C, C-31), 132.89 (1C, C-9), 
130.37 (2C, C-29, C-29’) 129.98 (2C, C-19, C-19’), 129.57 (2C, C-9, C-9’), 128.58 (2C, 
C-30, C-30’), 123.15 (1C, C-7), 121.76 (1C, C-6), 120.86 (1C, C-4), 116.97 (4C, C-20, 
C-20, C-10, C-10’), 96.43 (2C, C-12, C-22), 62.12 (2C, C-16, C-23), 44.07 (1C, C-11), 
30.40 (2C, C-13, C-26), 25.23 (2C, C-15, C-24), 18.95 (2C, C-14, C-25). 
MS (ESI+): 630.2 ([M+Na]+), 608.3 ([M+H]+). 
HR-MS (ESI+): calc. for C37H37NO7 ([M+H]
+): 608.2643, found: 608.2625 calc. for 
C37H37NO7 ([M+Na]
+): 630.2462, found: 630.2453 






In a one neck flask N-(5-hydroxy-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-biphenyl]-2-
yl)-2-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenyl)acetamide (241 mg, 0.480 mmol, 
1.0 eq) and NBD-Cl (96.0 mg, 0.480 mmol, 1.0 eq) were dissolved in anhydrous 
acetonitrile (12 mL). To a light orange solution, Et3N (73.0 µL, 0.530 mmol, 1.1 eq) was 
added, the reaction mixture was turning gradually to a darker orange colour. The reaction 
was monitored by TLC (n-hexane/EtOAc, 1:1), and stopped after 7 h, as no starting 
material was observed. The solvent was removed under vacuum, reaction residual was 
dissolved in DCM (30 mL), washed with water (20 mL), sat. aq. NaHCO3 solution 
(20 mL), sat aq. NaCl solution (30 mL) dried over MgSO4 and concentrated in vacuum. 
The product was isolated as a yellow solid (221 mg, 0.330 mmol, 70%) after gradient 
purification (n-hexane/EtOAc, 3:1 → 2:1 → 1:1) by flash column chromatography. 
TLC: Rf = 0.5 (n-hexane/EtOAc, 1:1) 
mp.: 103 °C (decomposition) 
1H NMR (300 MHz, Acetone) δ (ppm) 8.64 (d, J = 8.4 Hz, 1H, H-31), 8.34 (dd, J = 8.9, 
3.9 Hz, 1H, H-7), 8.20 (s,1H, H-NH), 7.37 (dd, J = 8.9, 2.9 Hz, 1H, H-6), 7.28 – 7.14 (m, 
5H, H-9, H-9’, H-19, H-19’, H-4), 7.09 – 6.96 (m, 4H,  H-10, H-10’, H-20, H-20’), 6.90 
(d, J = 8.4 Hz, 1H, H-32), 5.57 – 5.43 (m, 2H, H-22, H-12), 3.88 (td, J = 11.4, 5.6 Hz, 
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2H, H-23, H-16), 3.69 – 3.50 (m, 4H, H-23, H-12, H-16), 1.97 – 1.52 (m, 12H, H-13, H-
14, H-15, H-23, H-25, H-26). 
13C NMR (75 MHz, Acetone) δ (ppm) 154.03(C-27), 144.65 (1C, C-29), 130.85 (1C, C-
31), 124.70 (1C, C-7), 122.96 (1C, C-6), 120.62 (1C, C-4), 117.76 (4C, C-10, C-10’, C-
20, C-20’), 109.07 (1C, C-32) 96.98 (2C, C-22, C-12), 61.56 (2C, C-16, C-23), 43.12 
(1C, C-17), 31.14 (2C, C-13, C-26), 25.96 (2C,  C-15, C-24), 19.59 (2C, C-14, C-25). 
MS (ESI+): 689.3 ([M+Na]+), 667.3 ([M+H]+). 
HR-MS (ESI+): calc. for C36H34N4O9 ([M+H]
+): 667.2399, found: 667.2388 calc. for 
C36H34N4O9 ([M+Na]
+): 689.2218, found: 689.2212. 
FT-IR (Diamond-ATR): ν (cm-1) 2927.41, 2851.24, 1683.55, 1609.31, 1539.88, 1510.95, 
1331.61, 1238.08, 1180.22, 1035.59, 962.305, 919.879, 812.849. 
7.4.2.55 N-(4'-Hydroxy-5-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)oxy)-[1,1'-
biphenyl]-2-yl)-2-(4-hydroxyphenyl)acetamide (83) LS A1 
 
In a one neck flask compound, 82 (181 mg, 0.270 mmol, 1.0 eq) was dissolved in MeOH 
(20 mL) at 50 °C, 1 M HCl (1 mL) was added, and the reaction mixture was stirred at 
60 °C. The reaction was monitored by TLC (n-hexane/EtOAc, 1:1), after 1 h complete 
conversion of the educt was confirmed, and the reaction was stopped. The solvent was 
removed under reduced pressure, the reaction residual was dissolved in EtOAc (5 mL) 
and water (15 mL) was added. The aqueous phase was extracted with EtOAc (3 x 15 mL), 
combined organic phases were washed with sat. aq. NaHCO3 solution (10 mL), sat aq. 
NaCl solution (15 mL), dried over MgSO4 and concentrated under vacuum. Product was 
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isolated as a yellow solid (60.0 mg, 0.110 mmol, 44%) after purification by flash column 
chromatography (n-hexane/EtOAc, 1:1). 
TLC: Rf = 0.2 (n-hexane/EtOAc, 1:1) 
mp.: 103 °C 
1H NMR (300 MHz, Acetone) δ (ppm) 8.62 (d, J = 8.4 Hz, 1H, H-26), 8.33 (d, J = 8.8 
Hz, 1H, H-7), 8.18 (s, 1H, H-NH), 7.33 (d, J = 9.0 Hz, 1H, H-6), 7.24 (d, J = 3.4 Hz, 1H, 
H-4), 7.17 – 7.04 (m, 4H, H-9, H-9’, H-19, H-19’), 6.93 – 6.82 (m, 3H, H-10, H-10’, H-
27), 6.77 (d, J = 8.6 Hz, 2H, H-20, H-20’), 3.57 (s, 2H, H-17). 
13C NMR (75 MHz, Acetone) δ (ppm) 170.48 (1C, C-1), 158.32 (1C, C-11), 157.42 (1C, 
C-5), 157.16 (1C, C-21), 155.12 (1C, C-22), 150.01 (1C, C-24), 135.66 (C-2), 135.05 
(1C, C-8), 134.39 (1C, C-26), 130.32 (4C, C-9, C-9’, C-19, C-19’), 125.88 (1C, C-18) 
124.39 (1C, C-7), 122.20 (1C, C-4), 119.38 (1C, C-6), 116.00 (1C, C-27), 115.95 (2C, C-
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 Expression and purification data of hSOD1 
 
Figure 9.1 Growth rate with induction. Expression of hSOD1 in E. coli BL21 Star™. 
 
 
Figure 9.2 Chromatogram of hSOD1 purification on TMAE column. 
 Manual Run 9:10_UV  Manual Run 9:10_Cond  Manual Run 9:10_Conc  Manual Run 9:10_Fractions
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Figure 9.3 SDS-page gels from the purification of hSOD1wt 
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 Free binding energies of the lead structures 
Filename Mode Affinity[kcal/mol] RMSD l.b. [Å] RMSD u.b. [Å] 
LS A 1 -9.0 0 0 
LS A 2 -8.6 3.732 6.075 
LS A 3 -8.5 3.63 5.26 
LS A 4 -8.4 3.21 8.085 
LS A 5 -8.2 1.885 3.83 
LS A 6 -8.2 3.434 4.443 
LS A 7 -8.2 3.143 8.024 
LS A 8 -8.1 3.515 8.5 
LS A 9 -8.1 2.238 3.552 
 
Filename Mode Affinity[kcal/mol] RMSD l.b. [Å] RMSD u.b. [Å] 
LS B 1 -9.1 0 0 
LS B 2 -9.0 4.081 6.019 
LS B 3 -9.0 4.323 6.498 
LS B 4 -8.8 1.812 3.619 
LS B 5 -8.8 2.396 4.402 
LS B 6 -8.5 1.598 1.767 
LS B 7 -8.5 1.256 1.904 
LS B 8 -8.5 1.348 2.285 
LS B 9 -8.3 3.539 6.33 
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Filename Mode Affinity[kcal/mol] RMSD l.b. [Å] RMSD u.b. [Å] 
LS C 1 -8.5 0 0 
LS C 2 -8.4 3.149 6.935 
LS C 3 -8.4 1.977 5.918 
LS C 4 -8.3 3.234 8.725 
LS C 5 -8.3 3.888 5.529 
LS C 6 -8.0 3.424 5.811 
LS C 7 -7.9 4.625 9.928 
LS C 8 -7.9 2.216 2.675 
LS C 9 -7.9 2.435 5.442 
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 Biophysical and protein studies 
 
Figure 9.4 Activity assay with ligand L1 in Hepes buffer (Experiment performed and data 
obtained by Lisa-Marie Funk) 
 





















Figure 9.5 Size exclusion chromatography (SEC) Biorad standard curve 
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 Binding affinity assay development 
































 Monomer (0.03 µg/mL)
 Dimer (0.03 µg/mL)
 
Figure 9.6 Data of NHS-ester labelled hSOD1wt protein for MST binding studies. SEC 
chromatogram (top) and activity assay of the isolated labelled hSOD1 protein, monomer 




Figure 9.7 Raw data of the ITC run with L1. Titration of L1 into Hepes buffer with 20% 
DMSO 
 
Figure 9.8 MST binding assay data. Aggregation is observed in thermophoretic signals of 
the complex (ligand L1 and Atto 647 labelled hSOD1wt protein target) as well as the labelled 
protein target only. 
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Figure 9.10 MST data of ligand L2. Fluorescence capillary scan (top), thermophoretic signal 
with 1.5 s MST-on time (middle), binding affinity curve of the ligand (bottom). 
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Figure 9.11 MST data of ligand L14 thermophoretic traces.  
 
 
Figure 9.12 SDS denaturation test (SD test) and confirmation of fluorescent dependent 
binding of ligand L7. as visible from the equal fluorescence in bound and unbound state 
(right), compared to the binding assay before denaturation (left). 
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 Aggregation assay data 





















  - ctrl
 hSOD1 A4V apo
 hSOD1 wt holo
 A4V apo + L14
 A4V apo + L3
 A4V apo + L5
 
Figure 9.13 Aggregation assay in DMSO with PROTEOSTAT dye. Assay was conducted in 
50 mM sodium phosphate buffer pH 7.4 and 20% DMSO, incubated at 50 °C for 24 h with 
final concentrations of 20 µM and 1 mM for the protein and ligands, respectively. 
Monomeric lysozyme was used as a negative assay control, final concentration of 15 µM. 





















  - ctrl
 hSOD1 A4V apo
 hSOD1 wt holo
 A4V apo + L3
 A4V apo + L4
 A4V apo + L1
 A4V apo + L14
 
Figure 9.14 Aggregation assay in DMSO with ThT dye. Assay was conducted in 50 mM 
sodium phosphate buffer pH 7.4 and 20% DMSO, incubated at 50 °C for 24 h with final 
concentrations of 20 µM and 1 mM for the protein and ligands, respectively. Lysozyme 
protein as (+) and (-) assay control; final concentration (15 µM). 
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 Analytics 





9.6.2 Tert-butyl(3-iodo-4-nitrophenoxy)diphenylsilane (2)  
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9.6.4  (4-(Tert-butoxy)phenyl)boronic acid (5)  
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9.6.6 6-Nitro-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-ol (19)  
 







9.6.7 6-nitro-[1,1'-biphenyl]-3-ol (21)  
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9.6.9 6-Amino-[1,1'-biphenyl]-3-yl propionate (23)  
 
 
 9 Appendices 
235 
 

















9.6.11 2-(4-((Tetrahydro-2H-pyran-2-yl)oxy)phenyl)acetic acid (27) 
 















9.6.13 4'-(Benzyloxy)-6-nitro-[1,1'-biphenyl]-3-yl propionate (29) 
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9.6.14 6-Amino-4'-(benzyloxy)-[1,1'-biphenyl]-3-yl propionate (30) 
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9.6.15 4'-(Benzyloxy)-6-(2-(4-phenoxyphenyl)acetamido)-[1,1'-biphenyl]-




















9.6.16 6-Amino-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl propionate (32) 
 
 





















(trifluoromethyl)-[1,1'-biphenyl]-3-yl propionate (33) 
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hydroxyphenyl)acetamide (L9)  
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9.6.25 2-(4-Hydroxyphenyl)-N-(5-((7-nitrobenzo [c][1,2,5] oxadiazol-4-
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9.6.29 4-(((Benzyloxy)carbonyl)amino)-3-bromophenyl benzoate (58) 
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9.6.30 Benzyl (2-bromo-4-hydroxyphenyl)carbamate (59) 
 
 9 Appendices 
267 
 

















 9 Appendices 
269 
 

















yl)oxy)-[1,1'-biphenyl]-3-yl benzoate (61) 
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9.6.34 6-(2-(3,5-Dimethoxyphenyl)acetamido)-4'-((tetrahydro-2H-pyran-2-
yl)oxy)-[1,1'-biphenyl]-3-yl benzoate (63) 
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[1,1'-biphenyl]- 3-yl benzoate (64) 
 












dihydropyrimidin-1(2H)-yl)acetamide  (67) 
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9.6.39 6-Isobutyramido-4'-((tetrahydro-2H-pyran-2-yl)oxy)-[1,1'-
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9.6.47 N-(4',5-Dihydroxy-[1,1'-biphenyl]-2-yl)-3-methylbutanamide (77) 
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biphenyl]-2-yl)-2-(4-hydroxyphenyl)acetamide (83) LS A1 
 















9.6.52 Proof of concept reaction 



























 R-450 nm18.5 
 
Figure 9.15 HPLC chromatograms of LS A (100 µM) with 85 (100 µM) in DMSO, as a 
proof of concept reaction after 2h incubation at 25 °C, (analytical C-18; 20 → 100% 
MeCN in 35 min). 
 
